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Abstract
The widely expressed bromodomain and extraterminal motif (BET) proteins bromodomain-containing
protein 2 (BRD2), BRD3, and BRD4 are multifunctional transcriptional regulators that bind acetylated
chromatin via their conserved tandem bromodomains. Small molecules that target BET bromodomains
are being tested for various diseases, but typically do not discern between BET family members. Genomic
distributions and protein partners of BET proteins have been described, but the basis for differences in
BET protein function within a given lineage remains unclear. By establishing a gene knockout–rescue
system in a Brd2-null erythroblast cell line, we compared a series of mutant and chimeric BET proteins for
their ability to modulate cell growth, differentiation and gene expression. We found that the BET Nterminal halves bearing the bromodomains convey marked differences in protein stability, but do not
account for specificity in BET protein function. Instead, when BET proteins were expressed at comparable
levels, their specificity was largely determined by the C-terminal half. Remarkably, a chimeric BET protein
comprised of the N-terminal half of the structurally similar short BRD4 isoform (BRD4S) and the Cterminal half of BRD2 functioned similarly to intact BRD2. We traced part of the BRD2-specific activity to a
previously uncharacterized short segment predicted to harbor a coiled coil (CC) domain. Deleting the CC
segment impaired BRD2’s ability to restore growth and differentiation, and the CC region functioned in
conjunction with the adjacent ET domain (ETCC) to impart BRD2-like activity onto BRD4S. We found that
despite having different functions, BET proteins share similar genome-wide chromatin binding profiles.
Neither exchanging the bromodomain-containing N-terminal nor the ETCC-bearing C-terminal regions of
BET proteins alters their distribution. Rather, BRD2-specific function may in part be mediated by ETCC
interactions with the RNA polymerase II associated factor and casein kinase II complexes. In summary,
our results identify distinct BET protein domains that regulate protein turnover and biological activities.
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ABSTRACT
STRUCTURE-FUNCTION ANALYSIS OF BET PROTEINS IN TRANSCRIPTION

Michael T. Werner
Gerd A. Blobel

The widely expressed bromodomain and extraterminal motif (BET) proteins
bromodomain-containing protein 2 (BRD2), BRD3, and BRD4 are multifunctional
transcriptional regulators that bind acetylated chromatin via their conserved tandem
bromodomains. Small molecules that target BET bromodomains are being tested for
various diseases, but typically do not discern between BET family members. Genomic
distributions and protein partners of BET proteins have been described, but the basis for
differences in BET protein function within a given lineage remains unclear. By establishing
a gene knockout–rescue system in a Brd2-null erythroblast cell line, we compared a series
of mutant and chimeric BET proteins for their ability to modulate cell growth, differentiation
and gene expression. We found that the BET N-terminal halves bearing the
bromodomains convey marked differences in protein stability, but do not account for
specificity in BET protein function. Instead, when BET proteins were expressed at
comparable levels, their specificity was largely determined by the C-terminal half.
Remarkably, a chimeric BET protein comprised of the N-terminal half of the structurally
similar short BRD4 isoform (BRD4S) and the C-terminal half of BRD2 functioned similarly
to intact BRD2. We traced part of the BRD2-specific activity to a previously
uncharacterized short segment predicted to harbor a coiled coil (CC) domain. Deleting the
CC segment impaired BRD2’s ability to restore growth and differentiation, and the CC
region functioned in conjunction with the adjacent ET domain (ETCC) to impart BRD2-like
iii

activity onto BRD4S. We found that despite having different functions, BET proteins

share similar genome-wide chromatin binding profiles. Neither exchanging the
bromodomain-containing N-terminal nor the ETCC-bearing C-terminal regions of
BET proteins alters their distribution. Rather, BRD2-specific function may in part
be mediated by ETCC interactions with the RNA polymerase II associated factor and
casein kinase II complexes. In summary, our results identify distinct BET protein domains
that regulate protein turnover and biological activities.
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PREFACE

A large fraction of the work I present in this dissertation is published (Werner
et al)1. The remainder of this work will form the basis of future studies.
The first chapter of this dissertation is a broad introduction to serve as
backdrop for the biological questions that I address about BET proteins. The
second chapter includes detailed materials and methods used in these studies.
The third and fourth chapters serve as result sections for my two major lines of
investigation: 1) isolating the critical element that distinguishes BET proteins from
each other and 2) characterizing this domain. These chapters contain focused
introductions, experimental results, and tailored discussions. The final chapter
draws on these findings to make broader conclusions and to discuss the
implications, limitations, and future directions of this work.

1

CHAPTER 1: INTRODUCTION

Gene transcription is regulated to ensure that cell-appropriate genes are
expressed at adequate levels. For example, red blood cells must express globin
genes in order to produce oxygen-carrying hemoglobin. They do this while
simultaneously preventing the expression of unnecessary genes. Such cell-type
specific gene expression allows each cell and tissue to take on specialized
functions – whether carrying oxygen throughout the body or conveying electrical
impulses across long distances in the nervous system. A breakdown in
transcriptional regulation can result in disease by interfering with these biological
processes. Elaborate regulatory mechanisms to control gene expression have
thus evolved. In ancestral organisms such as bacteria, these mechanisms can be
thought of as relatively simple transcriptional circuits. A classic example is the lac
operon, which turns on lactose metabolism genes only when bacteria are in the
presence of lactose but not glucose. In multicellular eukaryotes, the regulatory
mechanisms are more complicated but achieve the same goal: finely tuned
expression of genes in the right cell and at the right time.
The goal of the work I present here is to describe one layer of eukaryotic
transcriptional regulation. This layer falls within the realm of epigenetics, a broad
field of study that describes changes in phenotypes that are unrelated to changes
in the basic genetic code. Though the term was originally used to describe
inheritance patterns that could not be explained by typical genetic mechanisms,

2

the term is now applied more broadly to the study of transcriptional regulation and
chromatin biology.

Figure 1.1. Electron micrograph of chromatin. Imaged was produced by Olins
and Olins who first published the finding in 19742. The image depicts the “beads
on a string” model of chromatin structure. DNA wraps around regularly spaced
histones. Each DNA-histone core is a nucleosome, the fundamental unit of
chromatin and a major regulator of gene expression.
Chromatin is the dense meshwork of DNA and protein found within the
nucleus. In its most compact form, chromatin is organized into ~30µm width
structures called chromosomes. Packaging of DNA into chromosomes is critical
for the physical delivery of the genome to daughter cells during mitosis and
meiosis. When cells are not dividing (interphase), chromatin is more loosely
organized into smaller structures. High resolution imaging of interphase chromatin
reveals a “beads on a string” pattern (Figure 1.1). This corresponds to the periodic
wrapping of DNA (the string) around core histone proteins (the beads). A
significant amount of biochemical and functional characterization has revealed that
the structure and chemical modification of chromatin at this level is critical to the
regulation of transcription3. Thus, whereas the term genetics can be applied to the
3

study of elements and diseases hard coded into the sequence of DNA itself and
inherited through cell division, the term epigenetics can be thought of as the study
of how the structure of chromatin controls the expression of genes and how
dysregulation manifests as disease.
In the remainder of this chapter, I will introduce a family of proteins,
bromodomain and extraterminal motif (BET) proteins, that are broadly considered
to be “epigenetic reader” proteins. This terminology is based on the finding that
these proteins possess specialized domains that recognize signatures of
chemically modified chromatin. BET proteins thus “read” the epigenome by
translating these chemical signals into transcriptional output.
BET proteins: linking chromatin acetylation to transcription

Common

post-translational

modifications

of

proteins

include

phosphorylation, acetylation and methylation, which are all well known to affect
protein function. Histones, in fact, were the first proteins identified to be altered by
acetylation and methylation, and even in these initial studies the functional
consequence of acetylation and methylation on RNA synthesis was appreciated4.
This early work provided the first evidence that post-translational modifications of
chromatin may influence transcription.
Chromatin acetylation is associated with active transcription

Early characterization of histone acetylation revealed that the small
molecule sodium butyrate could increase histone acetylation and induce cancer
cell differentiation, providing an additional link between histone acetylation and
gene expression5. Subsequent studies realized sodium butyrate targeted histone
4

deacetylase activity found in nuclear protein fractions and that in addition to
increasing histone acetylation levels it also altered chromatin accessibility6,7. A
direct link between the acetylation of histone tails at lysine residues and
transcription was not tested until several decades later when antibodies raised
against acetylated histone isoforms were used to immunoprecipitated chromatin
containing active but not inactive genes8. Immunofluorescent staining revealed
non-uniform distribution of acetylated histone isoforms into distinct domains
associated with different levels of transcriptional activity on polytene chromosomes
of Drosophila salivary glands9. Together, these studies linked histone acetylation
and chromatin decondensation (based on imaging of the polytene chromosomes)
with transcriptional activity. Purification of the first histone acetyltransferases
(KAT2A/GCN5)

and

deacetylases

(HDAC1/RPD3),

known

transcriptional

activators and repressors in yeast respectively, further cemented the notion that
the directed modification of chromatin by acetylation was directly linked to
transcription10,11.
The bromodomain is a specialized domain that binds to acetylated residues

How does chromatin acetylation activate transcription? It was first proposed
that acetylation of lysines may neutralize the net positive charge of histones12. It
was thought that the negative charge of the acetyl group would relax the interaction
between positively charged histones and negatively charged DNA, leading to local
decondensation of chromatin and access of the underlying DNA to various
transcription factors. However, in addition to any biochemical affect acetylation
may have on the structure of chromatin, a common ~110 amino acid sequence
5

possessed by many chromatin binding proteins was identified as an acetyl-lysine
recognition domain. This domain was termed the bromodomain. A solution
structure of the bromodomain from the acetyltransferase PCAF/KAT2B revealed
the molecular interface of the acetyl-lysine recognition cleft of this domain with
acetylated lysine13. Despite a considerable amount of diversity in the sequences
of various bromodomains, this acetyl-lysine recognition pocket is strikingly
conserved across each bromodomains14. Bromodomains are found in a multitude
of

chromatin-associated

proteins,

including

histone

acetyltransferases,

methyltransferases, chromatin remodeling proteins, nuclear scaffolds and
helicases15. These transcriptional regulators can be classified as epigenetic writers
(histone acetyltransferases), erasers (histone deacetylases), or readers (histone
acetylation binding proteins) based on their ability to add, remove, or bind to these
chemical modifications on chromatin (Figure 1.2). Thus, the prevailing hypothesis
as to how acetylation of chromatin affects transcription is that in addition to any
electrostatic changes that acetyl groups may convey, acetyl groups also recruit a
network of acetylation-dependent transcriptional regulatory proteins onto
chromatin16.
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mammalian BET protein identified. It was initially characterized as a nuclear kinase
associated with cell proliferation25. However, it had sequence similarity to the
Drosophila embryonic development regulator FS(1)H, which when mutated resulted in
embryonic lethality26,27. It also resembled another mammalian paralog, later identified

as BRD4, which associated with the Mediator transcriptional complex28. Subsequent
characterization of BRD2 revealed that like BRD4, it associated with a vast network of
chromatin regulators and transcriptional cofactors29–31, suggesting that BET proteins

were integrated into the transcriptional machinery. The molecular nature and
functional significance of many of these interactions will be detailed in later sections.

Imaging studies confirmed that BRD2 and BRD4 both localize to chromatin in an
acetylation- and bromodomain-dependent manner32–34. Their association with
chromatin is also mediated at least in part by protein dimerization and/or association
with other protein complexes in a bromodomain-independent manner35,36.
The above studies suggest that BET proteins bind chromatin predominantly via

their bromodomains, associate with transcriptional regulators, and are required for
proper embryonic development, but what is the evidence that BET proteins directly
contribute to transcription? An early piece of evidence suggesting their direct role in

transcription was the observation that yeast strains deficient in the BET paralogue
BDF137 shared phenotypes strongly reminiscent of strains defective in general
transcription cofactors38. In addition, a gain-of-function reporter system was used to

study the Drosophila paralog FS(1)H39. In this assay, overexpression of FS(1)H
increased reporter activity only when the reporter’s promoter was intact. Gel-shifts
assays demonstrated direct binding of FS(1)H to the promoter sequence,
9

indicating that FS(1)H activated the reporter through direct binding to this
promoter. More definitive evidence for a role of BET proteins in transcription was
obtained using in vitro transcriptional elongation assays. These experiments
demonstrated that 1) BRD2, BRD3 and BRD4 were each capable of facilitating
transcriptional elongation through chromatin templates, 2) that this activity only
occurred on acetylated nucleosome substrates, and 3) intact bromodomains were
required40,41. In summary, multiple studies provided evidence that BET proteins
directly facilitate transcription in an acetylation- and bromodomain-dependent
manner.
BET protein structure-function

BET proteins are classified as a family based on the shared and modular
domain structure for which they are named. These eponymous domains include
the two tandem N-terminal bromodomains (BD1 and BD2) and a C-terminal
domain called the extraterminal motif (ET)18. The bromodomains associate with
acetylated histones on chromatin and other acetylated proteins. The ET domain is
a protein-protein interaction module. This stereotypical domain structure (Figure
1.4) thereby allows BET proteins to function as molecular scaffolds onto which
multiple transcriptional regulators bind acetylated chromatin. Disruption of this
scaffold is the basis for anti-BET therapeutics, as discussed later. In addition to the
bromodomains and ET domain, many other conserved features have been
identified (Figure 1.4, Table 1.1). The remainder of this section will discuss the
structure-function relationship of BET protein domains in greater detail.
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Figure 1.4. Conserved protein domains and other features across the BET
family. BET proteins share two tandem bromodomains, BD1 and BD2, which bind
to acetylated proteins, as well as the ET protein interaction domain. Additional
domains include motif A (uncharacterized) and motif B (a dimerization domain).
Two protein isoforms of BRD4 are depicted, a short (BRD4S) and long (BRD4L).
The long isoform contains the CTM domain. Known phosphorylated sites are
indicated (NPS and CPS). Together, the NPS and BID comprise a phospho-switch.
Putative atypical kinase domains are highlighted in orange and the kinase catalytic
site is marked with a purple arrow. The putative acetyl-coA binding sites (depicted
in teal) and a putative histone acetyl transferase domain (HAT) specific to BRD4L
are indicated.
Domain Name
Bromodomain 1
Motif A
Bromodomain 2
Motif B
Extraterminal motif
Histone acetyltransferase domain
C-terminal motif
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
Atypica kinase domain
N-terminal phosphorylation site
Basic domain
C-terminal phosphorylation site
N-terminal acetyl coA binding site
C-terminal acetyl coA binding site
Kinase Catalytic Site

Abbreviation
BD1
mA
BD2
mB
ET
HAT
CTM
VIA
VIB
IX
VIA (2)
VIB (2)
VIII
IX
I-II
III
NPS
BID
CPS
-

BRD2
73-184
270-289
344-456
509-554
630-708
80-94
112-122
154-169
352-363
385-395
407-413
427-437
598-619
641-648
479-510
530-591
774-794
572

BRD3
33-144
233-252
306-418
453-498
563-641
40-54
72-82
114-129
314-325
347-357
369-375
389-399
547-552
574-581
441-454
474-539
705-724
521

BRD4S
58-169
281-300
350-462
503-548
601-679
65-79
97-107
139-154
358-369
391-401
413-419
433-443
584-590
612-619
485-504
524-580
699-717
175-180
563

BRD4L
58-169
281-300
350-462
503-548
601-679
1157-1197
1365-1400
65-79
97-107
139-154
358-369
391-401
413-419
433-443
584-590
612-619
175-180
1097-1102
563

Table 1.1. Amino acid sequences of mouse BET protein domains and
features. Sequences are depicted in Figure 1.4.
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Evolution and conservation of BET proteins

As noted above, BET proteins share a stereotypical and modular domain
structure. Clustering based on bromodomain homology suggests that the BRDT
bromodomains are the most ancestral, followed by BRD4 and then BRD2 and
BRD3 (Figure 1.3). Clustering of the full-length proteins supports this conclusion
by showing that BRDT is the most closely related to FS(1)H/FSH in Drosophila.
BRDT then gave rise to BRD4, followed by BRD2 and BRD3 (Figure 1.5).
Interestingly, the Brd2 gene is located within the major histocompatibility complex
(MHC) II locus, which is a cluster of genes associated with immune function. The
Brd3 gene is located in a region with MHC-like genes, indicating that it likely
spawned from Brd2 via a gene duplication event42,43.

Figure 1.5. Sequence comparison of full-length BET proteins from human,
mouse, fish (DANRE), Drosophila (DROME) and yeast. F1QQP6 and Q1LWX7
are the longest isoforms of BRD3 and BRD2 in DANRE, respectively. The
dendrogram is the result of sequencing alignment of the indicated proteins in
UniProt.
The bromodomains

The BET bromodomains, as with bromodomains in other proteins, are the
acetyl-recognition domains13,44. Deletion of these domains, or point mutations in
their acetyl-lysine recognition pocket, dramatically reduces the ability of BET
proteins to associate with chromatin32–36. The BET bromodomains are the targets
of small molecule inhibitors being tested in various preclinical and clinical
settings45. The details of these inhibitors are described in more detail below. The
12

amino acid sequences of the BD1 and BD2 bromodomains across the BET family
are ~75% identical, whereas the sequences of BD1 and BD2 within a given protein
are only ~44% identical, indicating that BD1 and BD2 are more evolutionarily
distinct than the proteins (Figure 1.3)46. Nevertheless, the structures of the BET
bromodomains reveal remarkable similarity overall44,46–52. The bromodomains
generally consist of four alpha helixes (aZ, aA, aB, aC) and two interconnecting
loops (ZA and BC)45. The four helices form a left-handed bundle around a
hydrophobic core with a deep acetyl-recognition cleft formed by juxtaposition of
the two intervening ZA and BC loops. The structural elements of the helical bundle
bear strong resemblance across the bromodomains. In contrast, the ZA and BC
loops comprising the acetyl-lysine binding pocket are more structurally distinct.
Though the residues in the ZA and BC loops that make contact with the acetyllysine are highly conserved47,53, sequence divergence among the adjacent
residues is thought to contribute to the specificity of each bromodomain for given
acetylated substrates.
BET proteins have been shown in many contexts to bind preferentially to
multi-acetylated peptides. Because the initial structural characterization of BET
bromodomains—in particular those of BRD246,49,51,52 and BRD447,53—was
performed in the context of mono-acetylated peptides (H4K12ac for BRD2 and
H3K14ac for BRD4), it was hypothesized that preference for multi-acetylated
substrates was due to the tandem BET bromodomains binding synchronously to
individual acetylated lysines of a di-acetylated peptide. However, the co-crystal
13

structure of BRDT-BD1 with a di-acetylated H4K5ac/8ac peptide revealed an
alternative explanation for multi-acetylated substrate binding48. The acetyl-binding
pocket of BRDT-BD1 can actually accommodate both acetylated lysine residues
on its own. The first acetyl-lysine engages with BD1 using the canonical binding
cleft described above. The second acetyl-lysine contacts hydrophobic residues on
the outside surface of the primary binding pocket. The negative charge imparted
by the second acetyl group forms a hydrogen bond with a water molecule that
bridges with the first acetyl group, creating a favorable binding surface. Thus,
BRDT-BD1 binds preferentially to di-acetylated peptides. Unlike BD1, BD2 only
engages with one acetylated lysine due to amino acid differences within BC loop
which prevent BD2 from interacting with the second acetylated lysine. Peptide
binding assays confirm the distinct binding modalities of BD1 and BD2. BD1
requires at least two acetylated lysines on histone tail peptides for binding to take
place, whereas BD2 recognized mono-acetylated peptides with the same affinity
as multi-acetylated peptides48. Structural homology between BET proteins
suggests that these BD1 and BD2-specific binding modalities are likely to be
shared across the BET family. Indeed, subsequent solution structures of the
BRD3-BD1 in complex with a di-acetylated GATA1 peptide and BRD4-BD1 with
various di-acetylated histone tail peptide isoforms (H4K5ac/8ac, H4K12ac/16ac,
and H4K12ac/20ac) confirmed this di-acetyl binding mechanism44,50.
Interestingly, comparison of BRDT bromodomain binding to in vitro
reconstituted acetylated nucleosomes versus histone peptides revealed that BD1
binds 6-fold more strongly to acetylated nucleosomes than to acetylated histone
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tail peptides54. This enhanced affinity for nucleosomes is due to a positively
charged patch in close proximity to DNA on the first alpha helix of BD1 (aZ) which
binds to DNA directly. This additional bivalent binding modality further diversifies
the in vivo substrate binding preferences of the individual BET bromodomains. For
example, the DNA binding patch is absent on BRDT-BD2 and though present on
BRD3-BD1 and BRD4-BD1, does not appear to bind DNA in those cases54.
Recognition of diacetyl H4K8ac/12ac is a special case both for BRD4-BD1
and BRD2-BD1. Though BRD4-BD1 binds simultaneously to both of the acetyl
groups of many diacetylated peptides, for di-acetylated H4K8ac/12ac, it only
recognizes one acetyl at a time, indicating that the exact context of the diacetylated
substrate dictates the binding modality used by the bromodomain44. BRD2-BD1
also behaves differently in terms of H4K8ac/12ac recognition. Like BRD4-BD1,
BRD2-BD1 does not recognize the di-acetylated surface of this particular substrate
and instead only associates with one of the acetyl groups. However, unlike BRD4BD1, which can interact with either of the acetyl groups, BRD2-BD1 only
recognizes H4K12ac. In fact, acetylation of H4K8ac interferes with the binding of
BRD2-BD1 to H4K12ac. The mechanism for this inhibition is that H4K8ac
interferes with the BRD2-BD1 dimerization, which is important for BRD2-BD1
recognition of H4K12ac46,51. Dimerization does not appear to occur for any of the
other BET bromodomains, making this feature unique to BRD2-BD1. Thus, the
sequence context of an acetylated substrate affects whether the acetyl-lysine is
recognized by different individual BET bromodomains and the modality by which it
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is recognized (mono- versus di-acetyl binding). A large-scale study of this
phenomenon revealed that recognition of acetylated histone peptide substrates is
influenced not only by the acetyl groups on adjacent residues, but also by methyland phospho-marks on these flanking residues and by the length and sequence of
the linker region between any two modifications44.
How do these structural considerations relate to substrate binding
preferences of the full-length BET proteins? Histone marks enriched in vivo by
each full length BET protein include various combinations of di-, tri-, and tetraacetylated H4K5/8/12/16 preferentially over monoacetylated H455. Of the diacetylated H4 peptides, H4K8ac/16ac and H4K5ac/8ac were the most strongly
enriched. This was true even in the case of BRD2, which was originally thought to
prefer mono-acetylated residues – specifically H4K12ac – based on early but
limited histone interaction studies32 and subsequent structural evaluation of its
bromodomains46,49,51,52. The direct binding of full-length BET proteins with multiacetylated histones is supported biochemically by the bromodomain structures
described above as well as various histone peptide and nucleosomal binding
studies, the latter of which suggest that some BET proteins may associate more
tightly with chromatin in vivo via bivalent DNA-histone nucleosomal interactions54.
Indeed, genome-wide chromatin distributions of BRD2 in vivo correlate better with
di-acetylated H4K5ac/8ac, a direct substrate, than with either H3K27ac or
H3K4me3, which are histone marks associated with transcription but not predicted
to directly bind to BET proteins56. Nevertheless, it is likely BET proteins affiliate
with large multi-unit complexes which may influence to some extent where BET
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proteins are found on chromatin and the chemical makeup of this chromatin. Thus,
the specificity and selectivity of BET proteins for substrates in vivo may be
determined not simply by the structures of the acetyl-recognition pocket in the
bromodomains, but also by protein-protein complex formation that may anchor
BET proteins to regions not necessarily enriched for preferred bromodomain
substrates. An example of this is the observation that H2A.Z-containing
nucleosomes preferentially enrich BRD2 over BRD3 and BRD457–59 despite no
preference of the BRD2 bromodomains for binding acetylated H2A peptides44. A
comprehensive comparison of histone binding preferences and chromatin
occupancy is needed to better understand to what extent the bromodomains drive
genome-wide binding of each BET protein.
BET proteins also interact with acetylated transcription factors. BRD3-BD1
binds to diacetylated GATA1 using a mechanism strikingly similar to acetylated
histone recognition (two acetyl-lysines spaced three residues apart)50. A similar
binding mechanism also occurs between BRD4-BD2 but not BRD4-BD1 and
diacetylated TWIST60, which is interesting because the opposite would be
expected based on recognition of diacetylated histone peptides44,48. Nevertheless,
this arrangement allows BRD4-BD2 to bind acetylated TWIST and BRD4-BD1 to
bind acetylated H4, which may be a general mechanism by which BET proteins
anchor acetylated transcription factors to chromatin. BRD4 also binds to diacetylated ERG61, mono-acetylated RELA (a component of the NF-kB transcription
factor complex)62 and to the acetylated androgen receptor63. The binding
mechanisms for these interactions have been investigated to varying detail, but
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more generally it also remains unclear whether any of the above transcription
factor interactions are specific for particular BET proteins. Nevertheless, the ability
of BET proteins to recognize acetylated transcription factors may be as functionally
significant as their ability to bind to acetylated histones.
The ET domain

The bromodomains are largely responsible for acetyl-lysine recognition and
the association of BET proteins with chromatin. However, the ET domain is also
critical for BET protein function, and like the bromodomains, is strongly conserved
across the BET family. The ET domain has been shown to mediate protein
interactions with several transcriptional co-activators including JMJD6, ATAD5,
GLTSCR1, CHD4, and NSD3 (WHSC1L1)31,64–66. The interaction between BRD4
and JMJD6 was shown to promote enhancer-mediated promoter-proximal pauserelease of RNA polymerase II (POL)267, and the interaction with NSD3 was shown
to promote leukemic gene expression and cell growth through CHD865. The ET
domain also functions as the binding site for IN (from murine leukemia virus)68 and
LANA (from Kaposi’s sarcoma-associated herpesvirus)69 to promote viral
integration and latency, respectively, and it maintains HIV latency through an
association with endogenous BRG1 in HIV-infected cells70. The ET domain also
associates with CHD4, a component of the NuRD complex which functions in both
transcriptional activation and repression71. Structural characterization of the ET
domain in complex with many of these substrates reveals a common binding motif
recognized by the ET domain31,64,66,68,71,72. More recently, the association between
BRD4 and the cohesin-loading factor NIPBL was shown through yeast two-hybrid
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screening assays to be mediated by the ET domain, though it is unclear if NIPBL
contains the same ET-binding motif73,74. Interestingly, mutations in BRD4 and
NIPBL are both associated with Cornelia de Lange syndrome (CdLS), suggesting
a causal link. It is possible that the BRD4 mutations disrupt a functional interaction
between BRD4 and NIPBL as several of the BRD4 mutations are located in the
bromodomains or ET domain74,75. This highlights the role of BET proteins as
molecular scaffolds onto which additional factors bind to acetylated chromatin.
Mutations in any of the critical regions of BRD4 may generate hypomorphic BRD4
alleles unable to effectively recruit transcriptional regulators to chromatin. This
same biology is the basis for therapeutic BET bromodomain-disrupting drugs that
inhibit disease-promoting pathways by dislodging transcriptional regulators from
chromatin. Of note, there is no indication that ET-mediated interactions are specific
for one particular BET protein. Thus, as with the bromodomains, it is unclear if the
ET domains contribute to BET protein specific functions.
The BRD4L-specific C-terminal tail and the short isoform of BRD4

The Brd4 gene encodes both a short (BRD4S) and long (BRD4L) isoform.
BRD4L is structurally distinct from BRD2, BRD3, and BRD4S in that it possesses
an extended tail with a protein-interaction domain located at the C-terminus (Figure
1.4). This C-terminal motif (CTM) binds to polymerase elongation factor beta
(PTEFb)76. PTEFb is a dimer composed of CCNT1 and CDK9, the latter of which
phosphorylates POL2. Recruitment of PTEFb and phosphorylation of POL2 is a
key molecular switch that transitions POL2 from its paused configuration to its
elongation mode77. The CTM of BRD4 is thus thought to recruit PTEFb to gene
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promoters to facilitate transcriptional elongation78. BRD4L also contains a putative
histone acetyltransferase catalytic (HAT) domain and acetyl-CoA binding sites that
enable BRD4L to directly acetylate H3K122, which destabilizes nucleosomes and
de-compacts chromatin (Figure 1.4)79. A screen of mutations that disrupt BRD4
activity validates that in addition to the bromodomains and the ET domain both the
CTM and the HAT of BRD4L also contribute to its overall function80.
BRD4S lacks the extended C-terminal tail of BRD4L due to the presence of
a stop codon in an alternatively spliced exon. BRD4S therefore lacks the HAT and
CTM domains and more closely resembles BRD2 and BRD318. The regulation of
this alternative splicing event has not been studied, and the functional significance
of the ratio of BRD4S and BRD4L protein isoforms has not been directly tested,
though it may drive certain phenotypes such as tumor growth and metastasis in
cancer cells81. BRD4S localizes to the nuclear periphery where it interacts with
different protein partners in comparison to BRD4L82. Importantly these changes in
nuclear compartmentalization occur despite BRD4S and BRD4L containing the
same acetyl-binding bromodomains, indicating that additional protein interaction
domains can drive BET protein localization. BRD4S also functions to maintain HIV
latency in infected T cells by recruiting repressive BRG1, a component of a
chromatin remodeling complex70, and like BRD2 and BRD3, can recruit the viral
latency protein LANA1 in KSHV-infected cells69. However, its expression and
function in most cell types remains poorly characterized.
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Additional conserved features

In addition to the domains described above, BET proteins also possess a
conserved regions motif A and motif B (Figure 1.4). Whereas no function has been
ascribed to motif A, limited analysis of motif B indicates that it facilitates homo- and
hetero-dimerization of BET proteins and their association with chromatin35. Motif B
also interacts with LYAR, which contributes to BET occupancy on chromatin and
promotes transcription, particularly of ribosomal genes83,84.
BET proteins possess shared serine-rich patches in the N- and C-terminal
regions termed the NPS and CPS respectively (Figure 1.4). Phosphorylation of the
NPS induces a conformation change that affects chromatin occupancy85. This
phospho-switch mechanism was proposed for BRD4, but based on conservation
of the relevant residues, may also apply to the other BET proteins. In the
unphosphorylated state, BD2 forms an intra-molecular interaction with NPS that
prevents BD2 from engaging chromatin. Phosphorylation of the NPS releases BD2
in favor of a basic region termed the BID, allowing BD2 to bind freely to acetylated
chromatin. The degree of phosphorylation may thus determine the substrates to
which BET proteins bind. Interestingly, hyperphosphorylation of BET proteins may
result in bromodomain-independent occupancy on chromatin through gained
interactions with the Mediator complex, though it is unclear if this is related to the
phospho-switch mechanism above86. Thus, the binding of BET proteins to
acetylated substrates is not only determined by the residues in contact between
the bromodomains and the acetylated peptide substrates, but also by tertiary
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folding of the full length BET proteins, which is subject to regulation through posttranslational processes such as phosphorylation.
Perturbing BET protein function

BET proteins have received considerable attention as therapeutic targets.
This is due in part to their direct involvement in a rare cancer called NUT midline
carcinoma (NMC) and their indirect role in more common cancers such as acute
myeloid leukemia (AML) among others87. However, the large majority of data
implicating BET proteins in disease is based on the exploratory use of BET
inhibitors in various disease models. It is important to note that BET proteins are
critical transcriptional regulators. Thus, any therapeutic benefit derived from BET
inhibition may be limited by unwanted effects on normal transcription. For example,
it has been shown that global reduction of BRD4 in the adult mouse results in
multiple deficits including weight loss, epidermal hyperplasia, and stem cell
depletion within the small intestine88. Depletion of BRD2 can result in bone marrow
failure89. This section will therefore summarize the initial observations that drove
the development of BET inhibitors. It will then discuss subsequent studies
exploring their role in other diseases. And it will conclude with the transcriptional
effects associated with BET inhibition. The goal is to provide a lens through which
the mechanism of action of these drugs and their potential side effects can be
understood.
Role of BET proteins in disease

NUT midline carcinoma is a rare but aggressive squamous cell carcinoma
characterized by chromosomal translocations directly involving BRD3 or BRD490.
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Translocations involving BRD2 have not been described. The translocations result
in chimeric proteins comprised of the intact chromatin-binding domains of BRD3/4
and the transcriptional activation domain of the NUT protein. The BRD3/4-NUT
fusion protein recruits the histone acetyl transferase EP300 leading to a cycle of
hyperacetylation

that

extends

across

large

swaths

of

DNA91,92.

This

hyperacetylation in turn leads to aberrant expression of the underlying genes and
ultimately cancer93. It is unclear why this malignancy only occurs at midline
anatomic structures of the head, neck, and mediastinum but in addition to the onset
of disease in young adults, this anatomic pattern suggests an embryonic origin. In
addition to being direct mediators of NMC, BET proteins were also identified in
global candidate screens that looked for susceptibility genes in AML80,94.
Mechanistically, the dependency of AML cells on BET proteins for cell growth is
based on BET proteins driving oncogenic Myc expression.
Inhibition using small molecules

Based on this clinical need, a new class of drugs targeting BET proteins
was developed. Evolution of candidate compounds and chemical screening
approaches converged on thienodiazepine chemistry to target the BET
bromodomains95,96. Due to the structural similarity of the BET bromodomains,
these inhibitors typically do not discriminate between individual BET proteins. The
first proof-of-principle use of these pre-clinical compounds was in NMC, where the
inhibitor directly targets the translocated BRD3/4-NUT oncogene product95.
Treatment with the BET inhibitor JQ1 significantly displaced BRD4 and BRD4-NUT
from chromatin, induced growth arrest, and differentiated the malignant cells into
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a more benign, squamous state. Gene expression analysis indicated that submicromolar doses of JQ1 did not simply suppress all genes, but rather selectively
turned off the oncogenic program driven by BRD4-NUT95. A second
thienodiazepine-based BET-specific inhibitor, I-BET, was shown to displace BRD4
from tetra-acetylated H4 peptide, indicating that bromodomains inhibitors
outcompete the natural ligands of BET proteins96. Strikingly, I-BET prevented LPSinduced inflammatory gene expression in macrophages, which had previously
shown to require BRD497, while minimally affecting non-inducible genes.
BET inhibitors have been shown to disrupt cell growth in a number of
hematological and solid malignancies. An incomplete list of these studies include
diffuse large B cell lymphoma98, multiple myeloma99, triple negative breast
cancer100,

castration-resistance

prostate

cancer63,

melanoma58,

Ewing

sarcoma101, liposarcoma102, and glioblastoma103. BET inhibitors have been used
in other disease settings as well. In cultured pancreatic islet cells, inhibition of BET
proteins may protect against the development of insulin resistance104. In hepatic
cells, targeting BET proteins protects against fibrosis by blocking multiple
profibrotic transcriptional pathways105. And under cardiac stress conditions,
targeting BET proteins prevents cardiomyocyte hypertrophy and cardiac
remodeling106. Thus, the exploratory use of BET inhibitors has demonstrated that
in addition to treating many solid and hematological malignancies, these drugs
may have additional use in inflammatory, metabolic, and cardiac disorders.
Based on these promising preliminary findings, several generations of BET
inhibitors have since been developed and are at various stages of preclinical and
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clinical testing45,107. For example, bivalent BET inhibitors using linkers demonstrate
stronger anti-leukemic efficacy than molar equivalents of their monovalent
counterparts. This enhanced avidity may be due to the ability of individual
bromodomains to interact with multiple acetylated lysine residues simultaneously
or to the ability of BET proteins to engage two substrates using their tandem
bromodomains. Inhibitors that discriminate between the first and second
bromodomains (BD1 and BD2) have also been developed108–110. Comparison of
BD1- and BD2-specific transcriptional effects largely corroborate structural studies
indicating that BD1 is the more critical bromodomain for substrate binding.
However, the less drastic transcriptional impact caused by BD2 inhibition can be
leveraged therapeutically to target more aggressive cancers with better
specificity109 or to prevent particular phenotypes, such as inflammatory gene
expression, without altering baseline genes110. Interestingly, BD1 inhibition largely
recapitulates BD1+BD2 inhibition in terms of antiproliferative effect, whereas BD2
inhibition more directly targets inducible gene expression during inflammation110.
In summary, BET bromodomain inhibitors block BET protein activity by
competitively occupying their acetyl-lysine binding pocket, which displaces the
natural acetylated peptide ligands and forces the disassociation of BET proteins
from chromatin30,95,96. These drugs may have widespread clinical use, but a better
understanding of BET protein function is required. Therefore, the transcriptional
consequences of removing BET proteins from chromatin will be discussed below.
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Transcriptional mechanisms revealed by BET inhibition

There is striking consistency across experimental approaches that
perturbing BET protein function reduces transcriptional elongation41,67,106,111,112.
This is consistent with several lines of evidence implicating BET proteins in
promoting POL2 pause-release and/or functioning as histone chaperones to allow
POL2 processivity through nucleosomes. BET proteins can complex with PTEFb30,
a known transcriptional elongation factor that releases POL2 from its paused state
into its elongating state77. BET proteins found at enhancers may contribute to
POL2 pause-release by recruiting JMJD6 to enhancers which then form enhancerpromoter contacts that allow JMJD6 to release PTEFb from its inhibitory
complex67. In support of this model, some studies suggest that degree of BET
protein enrichment at enhancers correlates with BET inhibitor sensitivity98,99.
However, these PTEFb-related mechanisms may not be as functional as originally
thought, given that BET proteins can affect elongation independent of PTEFb
occupancy111. In addition to pause-release, assays using highly purified
components have shown that BET proteins can each individually stimulate
transcriptional elongation independent of the PTEFb-interacting CTM domain
when added to in vitro transcription reactions and that this activity is sensitive to
bromodomain inhibition40,41. It was therefore proposed that BET proteins are
histone chaperones that assemble and disassemble nucleosomes from acetylated
histones to allow the passage of POL2. Though the biochemical basis for this
hypothesis remains unexplored, this model is supported by the fact that the amount
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of BET protein enriched on gene bodies correlates better with transcriptional
activity than the amount enriched at gene promoters41.
In addition to pause-release and elongation, BET proteins also function in
transcriptional initiation through their interactions with acetylated transcription
factors. Displacement of BET proteins from chromatin via BET bromodomain
inhibition has been shown to decrease transcription factor binding resulting in
concomitant changes in gene expression61–63,96,113. Our lab has shown that in the
case of GATA1, BET proteins may play a role not only in GATA1 recruitment and
thus transcriptional initiation, but also in downstream transcriptional events that
take place after GATA1 binding has been established113. The role of BET proteins
in establish transcription factor occupancy may be key to the observation that
“inducible” genes tend to be the most sensitive to BET inhibition96. This indicates
that lineage- or state-dependent transcriptional programs – whether oncogenic,
inflammatory, or stress-induced – may be more easily targeted by therapeutic BET
inhibitors.
Predicting genes that are vulnerable to BET inhibition remains a challenge.
No single chromatin attribute, including proximity to enhancers or degree of BET
enrichment, adequately predicts a gene’s primary responsiveness to BET
inhibition112. Moreover, comparison of JQ1-sensitive and JQ1-insensitive AML cell
lines have shown that a core set of genes – including oncogenic Myc – are
hypersensitive to BET inhibition regardless of the resultant effect on cell growth,
indicating that even if a gene’s sensitivity could be predicted, the ultimate effect on
cell phenotype cannot be predicted112. This suggests that for some transcriptional
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programs, the cellular response to BET inhibition does not depend on the primary
transcriptional response but instead on secondary cell-specific attributes. Plasticity
within these transcriptional pathways may also be at fault for the development of
resistance to BET inhibitors over time86,114–116. Therefore, a better understanding
of the exact role BET proteins play in transcription is needed to guide the
development of more dependable anti-BET therapeutic strategies.
In scenarios where BET inhibition has a favorable outcome, the therapeutic
efficacy is often attributed to BRD4 inhibition. This is in part due to the proposed
BRD4-PTEFb molecular mechanism considered to be important for transcriptional
pause-release and elongation77. Though many studies do not investigate the
independent roles of BRD2/3/4, in the case of AML, depletion of BRD2 or BRD3
does not affect cell proliferation or POL2 phosphorylation whereas depletion of
BRD4 does80,94,112. However, in other cases, BRD2 and BRD3 do in fact contribute,
which will be discussed below. Thus, though BRD4 certainly contributes to
transcription, it is important to remember that BET bromodomain inhibitors typically
used in these studies do not discriminate between individual BET proteins. Their
therapeutic effect is thus the aggregate result of inhibiting the entire BET family.
Identifying the individual roles of BET proteins in transcription is critical to
understanding the mechanism of action of BET inhibitors.
Evidence for distinct BET protein functions

BET proteins are epigenetic reader proteins – adaptor proteins with
specialized domains that bind to acetylated chromatin and recruit multi-protein
complexes. However, it remains unclear whether individual BET proteins function
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distinctly or redundantly. Identifying distinct functions for individual BET proteins is
complicated by their propensity to dimerize with one another35, to associate with
similar multi-protein complexes30,31,64, and to co-localize on chromatin63,102,117,118.
Given these findings, one can imagine models where BET proteins function
interdependently within multi-unit complexes. The purpose of this section is to
synthesize the evidence that individual BET proteins function non-redundantly and
thus possess specialized functional niches on chromatin.
Insights revealed by genetic studies

The phenotypes of genetic knockout mice provide the strongest evidence
that BET proteins function non-redundantly. For example, both BRD2 and BRD4
are independently required for embryonic development, and the phenotypes of
these mice are distinct. BRD4-defects manifest earlier during development
resulting in early post-implantation defects, whereas BRD2-defects occur later
during development resulting in impaired neural tube closure21–23. Interestingly,
mice with hypomorphic Brd2 alleles (resulting in global reduction of BRD2 protein
across tissues) are viable but display metabolic irregularities, indicating that even
the levels of BRD2 are critical119. BRD3 knockout mice have not been reported.
The requirement for individual BET proteins can also be identified through
targeted depletion strategies. For example, depletion of BRD2, BRD3 or BRD4
each reduces proliferation of castration-resistant prostate cancer cells and diffuse
large B cell lymphoma cells63,98. Likewise, depletion of all three BET proteins
effects cell growth in Ewing sarcoma cells101,120,121. Both BRD2 and BRD4 are
individually required for the differentiation of CD4+ Th17 cells122, and all three BET
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proteins contribute to LPS-induced stimulation of cytokine expression in
macrophages123. These studies indicate that like BRD4, BRD2 and BRD3 are also
required for many biological processes.
Global transcriptional signatures and phenotypes are also different
depending on whether BRD2, BRD3 or BRD4 are depleted. For example, in
pancreatic beta cells, depletion of either BRD2 or BRD4 enhances transcription of
insulin, whereas inhibition of BRD2 but not BRD4 enhances fatty acid oxidation104.
A global analysis of gene expression changes in these cells revealed that depletion
of BRD2, BRD3 and BRD4 each yielded different signatures, indicating that
individual BET proteins are involved in both shared and discrete transcriptional
pathways104. A similar gene expression analysis performed in breast cancer cells
revealed distinct effects on a panel of epithelial-to-mesenchymal transition (EMT)
genes upon depletion of BRD2, BRD3 or BRD4. Phenotypically, BRD2 appeared
to promote EMT whereas BRD3 and BRD4 repressed EMT124. Likewise, in skeletal
myogenesis, depletion of BRD3 and BRD4 have opposing effects on myogenic
differentiation with BRD4 appearing to promote differentiation and BRD3
appearing to inhibit it (BRD2 depletion was not achieved so was not examined
further)125. In embryonic stem cell differentiation into myoblasts, Nodal gene
expression is mediated first by BRD4 and then by BRD2 with a concomitant switch
in the BET protein predominantly found at cis-regulatory elements near the Nodal
gene126. This indicates that BRD2 and BRD4 promote Nodal gene expression
independently. In blocking interferon-induced gene expression, targeted BRD4depletion was not as effective as pan-BET bromodomain inhibition, supporting
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contributory or perhaps independent roles for BRD2 and BRD3 in transcription110.
BRD2 and BRD4 also have unique roles in the DNA damage response with BRD2
directly contributing to DNA repair at double-strand breaks127 and BRD4
functioning as a more general insulator of acetylated chromatin128. Collectively,
these studies strongly suggest that BRD2, BRD3 and BRD4 function within distinct
niches during transcription and other nuclear processes.
Insights revealed by chromatin occupancy studies

The distribution of individual BET proteins on chromatin are largely similar
but with some distinctions. A list of studies that perform chromatin
immunoprecipitation coupled to high-throughput sequencing (ChIPseq) for two or
more BET proteins in parallel is presented as Table 1.2.
Study

Cells/tissue

PMID

BET proteins

Main findings

Nicodeme et al, Nature (2010)

Mouse bone marrow derived
macrophages

PMID: 21068722

BRD2/3/4

Gene tracks show similarities and distinctions.

LeRoy et al, Genome Biol
(2012)

Human 293T cells

PMID: 22897906

BRD2/3/4 (Flagtagged)
Similar metaprofiles across genes

Asangani et al, Nature (2014)

Human prostate cancer cells

PMID: 24759320

BRD2/3/4

Colocalization at many regions as well as
independent peaks.

Anders et al, Nature Biotech
(2014)

Human MM1.S multiple
myeloma cells

PMID: 24336317

BRD2/3/4

Strong colocalization of BRD2/3/4 at promoters
with BRD2/4 but little BRD3 at enhancers

Di Micco et al ,Cell Reports
(2014)

Human ESC

PMID: 25263550

BRD2/3/4

No comparative analysis

Fong et al, Nature (2015)

Mouse MLL–AF9 AML cells

PMID: 26367796

BRD2/3/4

No comparative analysis

Ding et al, PNAS (2015)

Human LX-2 cells (hepatic
stellate cells)

PMID: 26644586

BRD2/3/4

No comparative analysis

Keck et al, J Biol Chem (2017)

Human MutuI cells ( EBVpositive Burkitt lymphoma)

BRD2/3/4

Strong colocalization at the EBV lytic origins of
replication

BRD2/3/4

Colocalization of BRD3/4 at GATA1 and
BRD2/3 at CTCF

Stonestrom et al, Blood (2015)
& Hsu et al, Mol Cell (2017)

PMID: 28588024
Mouse G1E-ER4 erythroblast PMID: 25696920 &
cells
PMID: 28388437

Cheung et al, Mol Cell (2017)

Mouse CD4+ T cells (Th17
cells)

PMID: 28262505

BRD2/4

Colocalization with more BRD2 at CTCF

Piunti et al, Nat Med (2017)

Human SF8628 cells (diffuse
intrinsic pontine glioma)

PMID: 28263307

BRD2/4

Colocalization of BRD2/4

Fontanals-Cirera et al, Mol Cell
2018

Human melanoma cells

PMID: 29149598

BRD2/4

Similar metagene profiles at promoters and
enhancers, perhaps more BRD2 at promoters

Xu et al, PNAS (2018)

Human U87 gioblastoma cells PMID: 29764999

BRD2/3/4

Colocalization at E2F1 target genes

Chen et al, Nature Commun
(2019)

Human liposarcoma cell lines

PMID: 30903020

BRD2/3/4

Colocalization with more BRD2/3 at promoters
and more BRD4 at enhancers

Khoueiry et al, Epigenetics
Chromatin (2019)

Human K562 cells

PMID: 31266503

BRD2/3/4

Similar metagene profiles at promoters

Bevill et al, Mol Cancer Res
(2019)

Human breast cancer cells
(MDA-MB-231)

PMID: 31000582

BRD2/4

Similar metagene profiles at promoters

Federation et al, Cell Reports
(2020)

Human K562 cells

PMID: 32101728

BRD2/3/4

Similar gene track profiles

Gilan et al, Science (2020)

Human THP-1 cells

PMID: 32193360

BRD2/3/4

Similar gene track profiles

Table 1.2. Studies comparing chromatin distribution of two or more BET
proteins. PubMed IDs (PMID) listed for reference.
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BET proteins tend be highly enriched at promoters and enhancers,
consistent with their role in regulating transcription. There is some indication that
BRD2 and BRD3 are slightly more enriched at promoters in comparison to
enhancers, whereas BRD4 is more enriched at enhancers102,117,129. This is
consistent with BRD2 and BRD3 binding more strongly to the promoter-associated
histone variant H2A.Z57–59. Interestingly, whereas BD1-specific bromodomains
inhibitors displace BRD2, BRD3, and BRD4 relatively equally from chromatin,
BD2-specific inhibitors affect BRD2 and BRD3 while leaving BRD4 occupancy
largely intact110. This indicates that BRD2 and BRD3 may bind chromatin using
mechanisms inherently differently than BRD4. Nevertheless, all three BET proteins
bind promoters where they exhibit similar binding profiles55,118. BET proteins may
also bind within gene bodies potentially reflecting a role in transcriptional
elongation40,41,55. However, in comparison to promoter-proximal binding, the
degree BET protein binding over gene bodies is not as defined as that of POL2 or
other components of the elongating POL2 complex130. This indicates that BET
proteins may not travel as part of the elongating POL2 complex directly, but the
exact details of BET protein function over gene bodies remains unclear. Consistent
with the observation that the transcriptional elongation promoting activity is shared
by all three BET proteins, no obvious differences in their distributions at promoters
or within genes can be appreciated40,41,55. In addition to enrichment of BET proteins
at promoters, enhancers and gene bodies, we and others have noted some degree
of overlap between BRD2 (and BRD3) and the architectural protein CTCF122,129,131.
This suggests a role for BRD2 and possibly BRD3 in higher order chromatin
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organization via the maintenance of topologically associating domains (TADs)
and/or transcriptional boundaries. However, the degree of colocalization and the
specificity of overlap between CTCF and BRD2 versus BRD4 varies between study
and technical replicate. In summary, BET proteins tend to bind similar regions of
the genome. Though some distinctions have been identified, a thorough metaanalysis of publicly available data is required to confidently state which differences
are robust to experimental parameters and thus reflect true functional specificity.
Insights revealed by protein interaction studies

BET proteins may carry out distinct functions or bind unique regions of the
genome by associating with different protein complexes. However, as with the
chromatin occupancy profiles described above, the interactomes of BRD2, BRD3
and BRD4 are also largely similar30,31. This may be due to the tendency of BET
proteins to associate with one another through direct dimerization, their mutual
association with active chromatin, or their shared possession of the highly
conserved ET protein-protein interaction domain. Nevertheless, one clear
difference that is observed is that BRD4 tends to associate more strongly with the
PTEFb than does BRD2 or BRD330,31. BRDT also binds to PTEFb31, which is
consistent with both BRD4 and BRDT containing the PTEFb-interacting CTM
domain on their extended tail. This is in contrast to interactions with casein kinase
II (CK2) which are predominated by BRD2, BRD3 and BRDT31 and to interactions
with the RNA polymerase II associated factor (PAF) complex which occur to some
degree between all BET proteins30. Immunoprecipitation of ectopically expressed
BRD3 was shown to enrich PTEFb, PAF, and CK2 among many other chromatin33

associated proteins71. Unlike for PTEFb, BET protein domains that interact with
PAF and CK2 are not known, though CK2 has been shown to phosphorylate
regions of BRD4 that are conserved with the other BET proteins85. Several
additional interactions known to be mediated by the ET domain (JMJD6, ATAD5,
WHSC1L1/NSD3) are also found in interactome datasets.
In summary, BET proteins are highly enriched at active chromatin where they bind
acetylated residues and interact with multiple chromatin regulators, but the mechanisms
underlying BET-specific functions in transcription remain unresolved. It has been
proposed that BET-specific functions are conveyed in part via selectivity of the
bromodomains for distinct acetylated substrates44,55. Specificity may also be mediated in
a bromodomain-independent manner by protein-interaction domains such as the ET

domain that influence co-factor recruitment and perhaps chromatin binding30,31.
Nevertheless, the chromatin distributions and protein interaction networks of BET
proteins are largely similar though with some exceptions. Additional work is
required to determine whether these exceptions reflect biologically significant
differences in BET protein function.
Functions of BET proteins in GATA1-mediated transcription
Our laboratory has used GATA1-mediated erythroid cell differentiation as a

model system to further dissect the functions of BET proteins in transcription132.
Interestingly, anemia is one of the predominant side effects observed in patients
treated with clinical BET inhibitors133–135. Thrombocytopenia (reduced platelet
count) is another common toxicity. GATA1 drives the differentiation of both
erythrocytes and megakaryocytes (the cells that give rise to platelets) from a
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common precursor136. This clinical picture is highly indicative of deficient GATA1
activity in patients treated with anti-BET therapy. GATA1-mediate transcription in
erythroid cells is thus a physiological and clinically relevant model for the study of
BET protein function.
GATA1 is acetylated by the acetyltransferases EP300 and CBP137,138. The
BET protein bromodomain BD1 binds to a di-acetylated peptide within GATA1
using a mechanism reminiscent of acetylated histone peptide recognition50.
Though this was demonstrated in structural detail for BRD3-BD1, acetylated
GATA1 peptides also enrich BRD4139. Mutations of the acetylated GATA1 residues
recognized by BD1 prevent erythroid maturation and reduce occupancy of GATA1
on chromatin, indicating that GATA1 acetylation is critical for its function in vivo140.
GATA1-induced gene expression is also drastically reduced by BET bromodomain
inhibition, indicating that BET proteins are critical mediators of acetylated GATA1
activity113,139. In support of this model, BET proteins colocalize with GATA1
genome wide, are required for GATA1 recruitment, and mediate transcription
downstream of GATA1 binding113. Using GATA1-mediated erythroid maturation,
our laboratory has demonstrated that BRD2 and BRD4 are both uniquely required
for GATA1 activity (Figure 1.6)113. BRD3 appears dispensable, potentially due to
compensation by BRD2113. Thus, BRD2 and BRD3 may function independently of
BRD4 in these cells.
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Figure 1.6. BET protein requirements in erythropoiesis. Adapted from
Stonestrom et al132. BRD2 depletion partially inhibits erythroid maturation. BRD3
depletion has no apparent effect itself, but when combined with BRD2-deficiency,
completely blocks maturation. BRD4 depletion prevents maturation on its own.
The distinct functions of BRD2 and BRD4 may be reflected by their unique
distribution patterns on chromatin. Whereas BRD4 tightly colocalizes with GATA1
and binds chromatin in a GATA1-dependent manner, BRD2 exhibits a more
GATA1-independent occupancy pattern and is also enriched at CTCF-sites113,131.
It remains unclear whether these differences in chromatin occupancy patterns
reflect the distinct functions of BRD2 and BRD4. Moreover, the structural basis for
these distinct patterns remain unknown. Identifying the BET protein structural
domains that underlie the shared and distinct functions of BET proteins may offer
a window of insight into the mechanisms by which individual BET proteins function
distinctly or cooperatively in transcription. Moreover, identification of structural
features that differ between BRD2 and BRD4 could be exploited to design BET
inhibitors that target specific BET proteins. The goal of my dissertation is thus to
36

use GATA1-mediated differentiation to map the domains that distinguish BET
proteins functionally in order to identified BET-specific transcriptional mechanisms.
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CHAPTER 2: MATERIALS AND METHODS
Cell lines, cell culture, and GATA1-ER activation

G1E cells are erythroblasts derived from Gata1-null male mouse embryonic
cells141. G1E-ER4 cells are subcloned from G1E cells after expressing a retrovirally
inserted construct that encodes GATA1 fused to the ligand binding domain of the
estrogen receptor (GATA1-ER), which allows for conditional activation of GATA1
upon administration of estradiol142. Brd2-null G1E-ER4 cells (BRD2 KO1-KO4)
cells were derived by single cell cloning after nucleofection with vectors expressing
spCas9 and a gRNA targeting the first bromodomain of BRD2 as previously
described113. Clones KO1 and KO2 were previously described131. G1E-ER4 based
cells were grown in suspension flasks in a humidified incubator at 37C at 5%
carbon dioxide in G1E media. G1E media consists of the following reagents:
Iscove’s Modified Dulbecco’s Medium (Corning, 10-016-CV); 15% FBS (Gemini,
100-106), 2% Pen Strep (Gibco, 15140-122), 140µM 1-Thioglycerol, (Sigma,
M6145), 2U/mL Epoetin (Amgen) and conditioned medium (titered for optimal cell
growth) from a kit ligand producing CHO cell line. Cells were maintained in culture
at a cell density of 0.1-1.0e6 cells/mL. Erythroid maturation experiments were
performed by plating G1E-ER4 based cells at a cell density of 0.4-0.5e6 cells/mL
in fresh G1E media containing 100nM estradiol (Sigma, E2758) for 24 hours. For
the visualization of hemoglobin production, 40e6 cells were plated as above and
matured for 48 hours with estradiol. 293T cells used for retrovirus production were
grown on 100mM plasma-treated polystyrene plates in 293T media: Dulbecco’s
Modified Eagle Medium (Gibco, 11965084), 10% FBS (Gemini, 100-106), 2% Pen
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Strep (Gibco, 15140-122), 1% L:-Glutamine 200mM (Gibco, 25030-081) and 1%
100mM sterile-filtered sodium pyruvate. 293T cells were split every 2-3 days using
0.05% Trypsin-EDTA (Gibco, 25300-054).
RNA isolation and RTqPCR

For gene expression analysis, up to 1 million cells were resuspended in
1mL of TRIzol (Ambion, 15596018). 200µl of chloroform (Fisher, BP1145-1) was
added to each sample. Samples were vigorously inverted for 15 seconds, rested
for 3 minutes and spun at 10,000 rpm for 15 minutes at 4C in a microcentrifuge.
The aqueous phase (top layer) was applied to purification spin columns from the
RNeasy® Mini Kit (Qiagen, 74106). Subsequent purification steps, including an
on-column DNase treatment step (Qiagen, 79256), were followed according to the
manufacturer’s instructions. RNA was eluted from the column in 40µl RNAse-free
water from the kit, and the RNA concentration and purity were quantified using a
spectrophotometer (Thermo Scientific, Nanodrop 2000). Reverse transcription
was performed on 1µg of RNA using the iScript Reverse Transcription Supermix
for RTqPCR (Bio-Rad, 1708841). The cDNA samples were diluted 5x in sterile
0.2µM filtered MiliQ water. RTqPCR was performed using 2µl diluted cDNA,1µl of
9µM forward/reverse primers and 5µl Power SYBR™ Green PCR Master Mix
(Thermo Fisher Scientific, 4367660) on an ABI Vii7 real-time PCR machine. qPCR
primers were designed to target mature transcripts. RTqPCR primer sequences
are found in Table 2.1.
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Name
Brd2 5'
Brd2 3'
Brd3
Brd4 5'
Gata1-ER
GFP/YFP
Hbb-b1
Hba-a1
Alas2
Slc4a1
Spta1
Csf2rb
Csf2rb2
Kcnn4
Rhag
Actb
Gapdh
Pabpc1

Forward
Reverse
Note
TTAAACACCCCATGGACCTC
ATCAGCAGCAAACTCCTGTG
mouse RTqPCR
GCTCAACTCCACCAAAAAGC
AGAAGAGGAAGATGACGACGAG mouse RTqPCR
GGAGATGCTGTCCAAGAAGC
TGTGCATCTGGGTACTCTCG
mouse RTqPCR
TAAAGTGCTGCAGTGGCATC
TGGAGAACATCAATCGGACA
mouse RTqPCR
TATGGCAAGACGGCACTCTAC TGTTGTTGCTCTTCCCTTCC
mouse RTqPCR
AAGGGCATCGACTTCAAGG
ATGCCGTTCTTCTGCTTGTC
mouse RTqPCR
AACGATGGCCTGAATCACTTG AGCCTGAAGTTCTCAGGATCC
mouse RTqPCR
GTGGATCCCGTCAACTTCAAG CAAGGTCACCAGCAGGCAGT
mouse RTqPCR
TATGTGCAGGCCATCAACTACCCA
TTTCCATCATCTGAGGGCTGTGGT
mouse RTqPCR
TGGAGGCCTGATCCGTGATA
AGCGCATCGGTGATGTCA
mouse RTqPCR
AAAGAGTTCCGCTCTTGCCTGAGA
TTTCCTCCCTGGATCCACAGCATTmouse RTqPCR
AAGAGCCTGCAACTCACTGG
AGGGCTTGTGATTCTTCCCT
mouse RTqPCR
GAGCGAGTGGAGCAATGAGTA ATAAACACGGCCAAAGTGGA
mouse RTqPCR
TCTCTGGCTCACCACAGCTT
GGAATGTGATCGGAATCAGC
mouse RTqPCR
TTCTGGAAATTGCTGTATTTGCT CTCCAAAGGCATGGATTGTC
mouse RTqPCR
ACACCCGCCACCAGTTC
TACAGCCCGGGGAGCAT
mouse RTqPCR
AGGTTGTCTCCTGCGACTTCA CCAGGAAATGAGCTTGACAAAG mouse RTqPCR
CTACCAGCCAGCACCTCCTT
TGCAGCACGGTTCTGAGTCT
mouse RTqPCR

Table 2.1. RTqPCR primer sequences used in this study
Relative mRNA levels were quantified using the delta cycle of threshold (Ct)
method (Relative mRNA Level = 2^(Ctcontrol gene – Cttarget gene). All gene expression
analyses included at least two of the following housekeeping genes as controls for
normalization: Pabpc1, Actb and Gapdh. All RTqPCR experiments were
performed at least in triplicate (three independent GATA1-ER induction replicates).
Plots illustrating gene expression were generated in RStudio using ggplot2.
RNA sequencing

For the RNA sequencing experiment, parental G1E-ER4, BRD2 KO1 and
BRD2 KO2 cells were matured for 24 hours with estradiol prior to harvesting RNA.
The experiment was performed in three replicates yielding a total of 9 samples.
Library preparation and sequencing

RNA concentration was determined using the Agilent RNA 6000 Nano kit
(Agilent, 5067-1511) and 4µg of total RNA was enriched for mRNA by polyA
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selection with Dynabeads mRNA DIRECT Micro Kit (Life Technologies, 61021)
using the mRNA Isolation from Purified Total RNA protocol. Concentration of
mRNA enriched samples was measured using the Agilent RNA 6000 Pico kit
(Agilent, 5067-1513) before proceeding to library preparation with the remaining
sample volume using the Ion Total RNA-Seq Kit c2 and IonXpress RNA-Seq
Barcode 1-16 kit (Life Technologies, 4475936, 4475485). Final libraries were
assessed using the Agilent High Sensitivity DNA kit (Agilent, 5067-4626) before
pooling on an equimolar basis as determined by Bioanalyzer (Agilent) molarity
estimate of each library. The pool was subsequently sequenced three times on an
Ion Torrent Proton sequencer using Ion PI Hi-Q OT2 200 Kit, Ion PI Hi-Q
Sequencing 200 Kit and Ion PI Chip Kit v3 (Life Technologies, A26434, A26433,
A26771).
Computational analysis

Primary analysis of sequence data was performed by Ion Torrent Torrent
Suite software (v4.4.3) before being exported into FASTQ format. Mapping to the
mm10 genome (GCF_000001635.24_GRCm38.p4_genomic.gff) was performed
using the following STAR options: runThreadN 8, readFilesCommand zcat,
outSAMtype SAM,
chimSegmentMin

32,

outFilterType

BySJout,

outFilterMultimapNmax

20,

alignSJoverhangMin 8, alignSJDBoverhangMin 1, outFilterMismatchNmax 999,
outFilterMismatchNoverLmax 0.04, alignIntronMin 20, alignIntronMax 1000000,
alignMatesGapMax 1000000. The following analyses were performed using the
indicated R packages/functions: PCA (stats/prcomp), differential gene expression
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(DEGandMore/DeWrapper), heatmap visualization (stats/pheatmap). The top ten
gene sets enriched in the list of differentially expressed genes were identified from
the Molecular Signatures Database hallmark gene sets using the GSEA online tool
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) with FDR cutoff of
0.05. Plots illustrating gene expression and gene set enrichment were generated
with custom code in RStudio using ggplot2. For the comparison with the previous
microarray data set assessing the impact of JQ1 treatment on GATA1-ER activity,
we downloaded publicly available data from Gene Expression Omnibus
(GSE62709: samples G1E GATA-ER +E2 and G1E GATA-ER +E2 +JQ1
replicates 1-3). Genes were included in the merged data if they had an average
microarray measurement of 6 or higher in at least one of the groups and had an
average normalized RNA-seq read count of 6 or higher in at least one of the
groups. A correlation between the two datasets was tested by calculating a
Pearson correlation coefficient and a linear regression line was computed.
Differentially expressed genes were identified from the microarray based on an
average fold change > 2 and FDR < 0.01, which were then intersected with
differentially expressed genes from the RNAseq experiment (using same criteria)
as depicted by the Venn diagrams in Figure 3.2.G. Statistical significance for each
overlap was calculated using a Fisher’s Exact Test. For differential isoform
analysis, the Ensembl gene mode of mouse Brd4 that includes 7 known alternative
transcripts was used. All reads aligning to Brd4 by STAR (run with a 2-pass gap
alignment mode) were included. The Bioconductor package was used to tabulate
the sequencing depth at each Brd4 exon and the frequency of reads mapping to
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junction sites. The reads all three replicates in each group were summed and
DEseq2 was used to calculate statistical significances between groups.
Plasmids and cloning

All cloning was performed using standard molecular cloning techniques.
PCR was performed using Platinum® Pfx DNA Polymerase (Invitrogen, 11708).
All constructs were cloned into the MigR1 murine retroviral vector (with an IRESGFP selection marker) or a PK1-based N-terminal YFP fusion vector. For
constructs requiring assembly of multiple PCR fragments, Gibson Assembly®
Master Mix was used (NEB, E2611L). The vectors and inserts for each construct
are provided in Table 2.2.
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Plasmid Name
HA-Brd2
HA-Brd3
HA-Brd4S
HA-Brd4L
HA-Brd2-4S
HA-Brd4-2
HA-Brd2dET
HA-Brd2dCC
YFP-Brd2
YFP-Brd3
YFP-Brd4S
YFP-Brd2-4S
YFP-Brd4-2
YFP-Brd2-4mid
YFP-Brd2-4ET
YFP-Brd2-4end
YFP-Brd4S-2ET
YFP-Brd4S-2CC
YFP-Brd4S-2ETCC
YFP-Brd2dET
YFP-Brd2dCC
GST-BRD2-mB
GST-BRD2-ET
GST-BRD2-CC
GST-BRD2-CCp
GST-BRD2-CCd
GST-BRD2-ETCC
GST-BRD3-ET
GST-BRD3-ETCC
GST-BRDT-ET
GST-BRDT-ETCC

Vector
MigR1
MigR1
MigR1
MigR1
MigR1
MigR1
MigR1
MigR1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
PK1
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T
pGEX-2T

Insert
Brd2(1-798)
Brd3(1-726)
Brd4S(1-723)
Brd4L(1-1400)
Fusion of Brd2(1-456)-Brd4S(463-723)
Fusion of Brd4S(1-462)-Brd2(457-798)
Brd2 with Brd2(629-716) deleted
Brd2 with Brd2(717-762) deleted
Brd2(1-798)
Brd3(1-726)
Brd4S(1-723)
Fusion of Brd2(1-456)-Brd4S(463-723)
Fusion of Brd4S(1-462)-Brd2(457-798)
Fusion of Brd2(1-456)-Brd4S(463-599)-Brd2(629-798)
Fusion of Brd2(1-628)-Brd4S(600-687)-Brd2(717-798)
Fusion of Brd2(1-716)-Brd4S(688-723)
Fusion of Brd4S(1-599)-Brd2(629-716)-Brd4S(688-723)
Fusion of Brd4S(1-687)-Brd2(717-762)-Brd4S(688-723)
Fusion of Brd4S(1-599)-Brd2(629-762)-Brd4S(688-723)
Brd2 with Brd2(629-716) deleted
Brd2 with Brd2(717-762) deleted
Brd2(509-554)
Brd2(629-716)
Brd2(717-762)
Brd2(717-762, E725P+R732P+D740P)
Brd2(717-762, L726D+L734D+L738D)
Brd2(629-762)
Brd3(562-651)
Brd3(562-694)
BrdT(495-580)
BrdT(495-624)

Table 2.2. Mouse BET protein expression constructs used in this study.
Cell growth assay

Differences in cell growth upon transduction with retroviruses expressing
BET protein constructs were performed using viral titers that yield 30-40% GFP+
cells. GFP% was measured by flow cytometry and tracked over time while
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maintaining the cells at a cell density of 0.1-1.0e6 cells/mL. %GFP was normalized
by subtracting the starting %GFP (either day 1 or day 2). All cell growth assays
were performed in triplicate (three independent transduction experiments).
Retrovirus production and transduction

Retroviruses were produced using calcium phosphate co-transfection of
15µg construct and 15µg of pCL-Eco packaging plasmid into 293T cells. 293T cell
media was replaced with G1E media after 24 hours. Virus-containing G1E media
was then harvested after an additional 24 hours and passed through a 0.2µm filter.
Viral supernatants were diluted in G1E media to find titers that yield 30-40%
GFP/YFP+ cells. Retroviral transduction was performed by adding 250µl of titered
virus to one million G1E-ER4 (or BRD2 KO) cells in 1mL G1E media supplemented
with 4µl/mL polybrene and 10µl/mL 1M HEPES (Gibco, 15630080) in 12-well
plates and spinning at 2000rpm in an centrifuge for 90 minutes. The supernatant
was removed, and cells were resuspended in 5mL fresh G1E media. Fluorescence
was measured 24 hours later on a flow cytometer.
TER119 staining, flow cytometry, and cell sorting

Flow cytometry was performed using standard antibody staining protocols
and cytometry settings. Briefly, 105 to 106 cells were harvested and washed with
PBS. For TER119 expression experiments, cells were infected with low-titer YFPBET encoding (or empty vector control) virus to guarantee single copy gene
integration. After 24 hours of rest, estradiol was added to the mixed population of
infected/uninfected cells for an additional 24 hours. Cells were then resuspended
in a 100µl of staining buffer (PBS, 2% FBS) with a 1:200 dilution of anti-TER11945

APC (Biolegend, 116211) and incubated on ice for 30 minutes. Samples were
washed three times with PBS and resuspended in 200µl staining buffer and
analyzed by flow cytometry by gating on YFP- or YFP+ cells. Derivation of stable
YFP-BET expressing cell lines was achieved by iterative fluorescence activated
cell sorting with narrow sorting gates in order to achieve similar YFP mean
fluorescent intensity between cell lines.
Whole cell extracts

Whole cell extracts were prepared using standard laboratory techniques.
Briefly, 1-3e6 cells were harvested for each sample. After washing in ice-cold PBS,
cells were resuspended in 50-100µl RIPA buffer (150mM NaCl, 0.5% Na
Deoxycholate, 50mM Tris-HCl pH 8.0, 1% NP-40, 0.1% SDS and freshly added
500x

protease

inhibitor

cocktail

[Sigma,

P8340]

and

100x

100mM

phenylmethylsulfonyl fluoride [PMSF]) and incubated on ice for 30 minutes. Lysed
cells were sonicated in a Qsonica sonicator (model Q800R) for 3x 30 second on/off
cycles at maximum amplitude in a water bath chilled to 4C. Insoluble material was
pelleted by centrifugation at 15000 rpm for 5 minutes at 4C in a microcentrifuge.
The supernatant was transferred to fresh microcentrifuge tubes and used
immediately or snap frozen in liquid nitrogen and stored at -80C. Protein
concentration was determined using the BCA protein assay (Pierce, 23225) with
absorbance measured at 562nM compared to a BSA protein standard curve.
Western blotting

Western blots were performed using standard laboratory techniques.
Briefly, protein samples were resuspended in 4x sample buffer (500mM Tris-HCl
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pH 6.8, 8% sodium dodecyl sulfate, 20% 2-mercaptoethanol, 0.3% bromophenol
blue, 30% glycerol) and denatured at 95C for 10 minutes. Equal protein amounts
were loaded and separated on 4-15% or 4-20% gradient pre-cast gels (Bio-Rad,
4561084 or 4561096) and transferred to nitrocellulose membranes (Bio-Rad,
1620115). Primary antibodies include: Brd2 N-term (Cell Signaling, 5848S), Brd2
C-term (Bethyl, A302-583A), Brd3 (Active Motif, 61489), Brd4L (Bethyl, A301985A), Brd4 N-term (Abcam, ab128874), HA (monoclonal 12CA5, purified inhouse) or HA (Cell Signaling, C29F4), GFP/YFP (Abcam, ab290), PCNA (Santa
Cruz, sc-9857) and β-Actin−Peroxidase (Sigma, A3854). Secondary staining
reagents include goat anti-rabbit IgG-HRP (Abcam, ab6721), donkey anti-goat
IgG-HRP (Santa Cruz, sc-2020) and Protein A-HRP (Thermo Fisher Scientific,
101023). Stained membranes were imaged using enhanced chemiluminescent
substrate (Thermo Scientific, 34080 or 34095) and autoradiography film (Denville
Scientific, E3012). For fluorescent Western blots, fluorescent secondary
antibodies conjugated to IRDye-680 or IRDye-800 and the Odyssey imaging
system and buffers were used (LI-COR).
Coiled coil prediction

Coiled coil prediction was performed by inputting the UniProtKB amino acid
sequences for the following mouse BET proteins BRD2 (Q7JJ13-1), BRD3
(Q8K2F0-1), BRD4S (Q9ESU6-2) and BRD4L (Q9ESU6-1) into a Hidden Markov
Model

coiled

coil

prediction

algorithm

(https://toolkit.tuebingen.mpg.de/#/tools/marcoil)143. To generate the plots in
Figure 3.7.A, the output was graphed and scaled to the BET protein diagrams
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using ggplot in R. The sequence alignments of the regions surrounding and
containing the ET and CC domains in Figure 3.7.B was generated using Jalview
software144 for the indicated UniRef entry names and fragments. Sequences were
sorted by length and individual residues were labeled using Clustal X default
coloring and thresholding.
Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) was performed using the following
antibodies: GFP/YFP (Abcam, ab290), LEO1 (Bethyl, A300-175A), CSNK2A1
(Bethyl, A300-198A). Antibody specificity was verified by comparing to isotype
control IgG/sera as well as in the case of the GFP/YFP antibody to epitopenegative samples (data not shown).
For the LEO1_r1 sample, sonication-based ChIP was performed on G1EER4 cells as described131. For the YFP-BET, CSNK2A1, and LEO1_r2 samples,
the ChIP protocol was adapted for enzymatic fragmentation as follows. G1E-ER4
cells (≥10 million per sample) were fixed in 1% formaldehyde in PBS at room
temperature with agitation for 10 minutes, then quenched with 1M glycine for 5
minutes. Fixed cells were resuspended in 1mL cell lysis buffer (10mM Tris-HCl pH
8.0, 10mM NaCl, 0.2% NP-40/Igepal) prepared fresh with 500x protease inhibitors
(Sigma, P8340) and 1mM PMSF and incubated on ice for 10 minutes. Nuclei were
pelleted and digested with 10U/µl MNase in 400µl MNase buffer (NEB, M0247S)
at 37C for exactly 5 minutes. MNase activity was quenched with 10µl of EGTA.
Nuclei were pelleted and resuspended in 1mL nuclear lysis buffer (50mM Tris-HCl
pH 8.0, 10mM EDTA, 1% SDS, prepared fresh with protease inhibitors and PMSF).
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Samples were split into 500µl aliquots in 1.5mL polystyrene sonication tubes
(Active Motif, 53071) and sonicated for three 10 second intervals at 4C. After
sonication, samples were spun at 13000rpm in a microcentrifuge for 5 minutes at
4C to remove debris. Aliquots were combined and diluted with 4mL of IP dilution
buffer (20mM Tris-HCl pH 8.0, 2mM EDTA, 150mM NaCl, 1% Triton X-100, 0.01%
SDS prepared fresh with protease inhibitors and PMSF). To preclear, 50µg of
protein A/G agarose beads (agarose beads slurry was prepared by mixing Protein
A [Invitrogen 15918014] and Protein G [Invitrogen 15920010] agarose beads at
1:1 ratio) and 50µg of isotope-matched IgG were added. Samples were precleared
for ≥2 hours. Prior to setting up immunoprecipitation (“IP”) reactions, 200µl of
precleared chromatin was removed as “Input.” IP reactions were performed by
adding 35µl of protein A/G beads pre-bound with antibody (35µl protein A/G bead
slurry, 1mL PBS, 10µg antibody, incubated with rotation at 4C for ≥2 hours) and
rotated overnight at 4C.
Beads were washed once with IP wash buffer 1 (20mM Tris-HCl pH 8.0,
2mM EDTA, 50 mM NaCl, 1% Triton X-100, 0.1% SDS), twice with high salt buffer
(20 mM Tris-HCl pH 8.0, 2mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.01%
SDS), once with IP wash buffer 2 (10 mM Tris-HCl pH 8.0, 1mM EDTA, 0.25 M
LiCl, 1% NP-40/Igepal, 1% Nadeoxycholate), and twice with TE (10mM Tris-HCl
pH 8.0, 1mM EDTA pH 8). All washes were performed on ice. Following the final
wash, beads were moved to room temperature and eluted twice with 100µl of
elution buffer (100mM NaHCO3, 1%SDS, prepared fresh) for a final eluate volume
of 200µl. The following were added to each IP and input sample: 12µl of 5M NaCl,
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2µl RNaseA (10mg/ml, 10109169001 BMB) and samples were incubated at 65C
for ≥1 hour. 3µl of Proteinase K (20mg/ml, 3115879 BMB) was added and samples
were incubated at 65C overnight. Following overnight incubation, 10µl of 3M
sodium acetate pH 5.0 was added to each sample and DNA was purified using the
QIAquick PCR Purification kit (Qiagen 28106) per the manufacturer’s instructions.
IP samples were eluted with 60µl water, and input samples with 133.3µl water.
ChIP-qPCR was performed as described above. Standard curves were
constructed for each input sample and used to calculate the IP quantities for each
primer set.
ChIP sequencing
Library preparation and sequencing

Samples for ChIP sequencing (ChIP-seq) were prepared as above for ChIPqPCR. ChIP-seq libraries were processed using the TruSeq Sample Preparation
Kit (Illumina, IP-202-1012/IP-202-1024) per manufacturer’s instructions. Following
library preparation, SPRIselect beads (Beckman Coulter, B23318) were used at
0.9X and 0.5X for left and right-side size selection, respectively, for the MNasefragmented samples. For sample LEO1_r1, which was fragmented using
sonication, 0.6X right-side size selection was used yielding library sizes in the 300600 bp range with average sizes ~450 bp. Final library size and concentration was
measured using BioAnalyzer (Agilent). Single-end sequencing (1 x 75 bp) was
performed on the Illumina Nextseq 500 in high-output mode per manufacturer’s
instructions. Reads were converted to fastq using bclfastq2 v2.15.04 (default
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parameters). Fastq reads were aligned to the mm9 genome using bowtie (bowtie
--best --strata --chunkmbs 512 -S -q -l 40 -n 1 --phred33-quals -p 3 -m 1).
Computational analysis

After alignment, peaks were called and bedgraph files were generated using
MACS2 (callpeak -B -p 1e-5 --SPMR --nomodel --extsize 300 --local 100000 -g
mm). The bedGraphToBigWig tool from UCSC was used to convert into bigwig.
Enrichment

scores

in

peak

coordinates

were

calculated

using

multiBigwigSummary in deepTools. All enrichment scores and bigwig files are
library size normalized using reads per million. Merging of bigwig files for technical
replicates was performed using bigwigCompare in deepTools (bigwigCompare –
operation mean -bs 200). Pearson coefficients comparing correlations across
samples were calculated using plotCorrelation in deepTools. Metaprofile plots
across peaks were generated using computeMatrix (computeMatrix referencepoint –referencePoint center -b 1000 -a 1000) and plotProfile in deepTools.
Consensus peak sites were calculated from ChIPseq replicates using bedtools
intersect. Differential binding analysis was performed using DiffBind. Annotation of
genomic regions was performed using annotatePeaks.pl mm9 in Homer. Genome
browser views were generated using IGV. Transcription factor motif analysis was
performed using findMotifsGenome.pl mm9 -size 200 in Homer. A peak file
containing consensus peaks generated by DiffBind was used as background to
calculate motif enrichment. Scatter plots and volcano plots were generated using
ggplot2 in RStudio.
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Structural assessment of human BRD2/3-CC
Protein purification

The coiled coil domain of human BRD2 (715-757) and that of human BRD3
(641-688) were cloned into pGEX6p and expressed with a GST tag. BL21 (DE3)
colonies transformed with respective plasmids were inoculated into LB and after
overnight incubation, were used to inoculate 1-2L of culture. The culture was
induced at OD600 = 0.75 with 0.5mM isopropyl β- d-1-thiogalactopyranoside
(IPTG), followed by overnight expression at 25C.
The cell pellet was resuspended in 50 mM Tris pH 7.2, 500 mM NaCl, 0.1%
Triton X-100, 1 mM dithiothreitol (DTT), 10µg/ml DNase I, 10 µg/mL RNase A and
1× cOmplete EDTA-free protease inhibitor (Roche, 11873580001) at ~10 mL/g of
cells and then lysed via sonication. After clarification at 15,000× g for 30 min at 4C,
the clear lysate was incubated with pre-equilibrated glutathione-Sepharose 4B
beads (GE Healthcare, 17075601) for 1.5 hours at 4C with mixing. The beads were
washed with 3× 5 CV of GST wash buffer containing 10mM Tris pH 7.2, 100 mM
NaCl and 1 mM TCEP. The proteins were eluted with wash buffer containing 50
mM reduced glutathione. The GST tag was cleaved using HRV-3C protease by
incubating with the eluted protein overnight. On the next day, the cleavage protein
sample was concentrated and then injected onto a pre-equilibrated (in the GST
wash buffer) Superdex™ 75 16/600 column, and the gel-filtration chromatography
was run at 1 mL/min for 1.25× CV with 1-mL fractions collected. Fractions
containing desired bands were combined and concentrated to 700 µM for SECMALLS analysis.
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Size exclusion chromatography

Size exclusion chromatography with inline multi-angle light scattering (SECMALLS) analysis runs were performed on either a Superdex™ 75 10/300 GL
column or a Superdex™ peptide 10/30 GL column (GE Healthcare) with an in-line
MiniDawn MALLS detector with a laser source at 690 nm (Wyatt Technology,
Santa Barbara, CA, USA) and Wyatt refractometer. Proteins were eluted in 10 mM
Tris pH 7.2, 100 mM NaCl, 1mM TCEP using a flow rate of 0.5 mL/min. The weightaverage molecular weight was calculated using the intensity of scattered light at
90° in combination with the change in refractive index. Protein concentration at the
detector was determined by the change in refractive index. Allexperiments were
performed at room temperature (25C). Data collection and SEC-MALS analysis
were performed with ASTRA 6.1 software (Wyatt Technology).
Circular dichroism spectropolarimetry

Circular dichroism spectropolarimetry spectra were recorded on a Jasco J720 spectropolarimeter using a 1-mm quartz cuvette. In each case, spectra
comprised the sum of three successive spectra with a step size of 0.5 nm, a 1-s
response time and a 1-nm bandwidth. Data were acquired at 4C. Secondary
structure

content

was

estimated

using

Raussens’

method

(http://perry.freeshell.org/raussens.html).
GST pulldown and proteomic analysis
Protein purification

The sequences from mouse BRD2, BRD3 and BRDT (BRD2-mB, BRD2ET, BRD2-CC, BRD2-CCp, BRD2-CCd, BRD2-ETCC, BRD3-ET, BRD3-ETCC,
BRDT-ET, and BRDT-ETCC [Table 2.2]) were cloned into the pGEX-2T GST
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fusion vector. The GST fusion proteins were expressed and purified from bacteria
as above with the following changes: after BL21 transformation, a 5mL LB/Amp
culture grown at 37C overnight was used to inoculate 200mL LB/Amp, which was
then grown at 37C for 2.5 hours. Protein expression was induced with 0.25mM
IPTG and the culture incubated at 30C for an additional 2.5 hours. Cell pellets were
resuspended in 5mL BC500 (20mM Tris-HCl pH 8.0, 0.5mM EDTA, 50mM KCl,
20% glycerol, 1% NP-40, 1mM DTT, 500x protease inhibitor cocktail [Sigma,
P8340]). Prior to sonication, 50µl of 100mg/mL lysozyme and 0.5mL of 20% Triton
X-100 was added. Bacterial suspensions were sonicated (Misonix, Sonicator
3000) at 50% output with microtip limit for 1 second for three sets of 10 cycles,
keeping samples on ice. The bacterial lysates were cleared with 10,000rpm
centrifugation for 10 minutes at 4C. The cleared supernatant was harvested and
250µl of glutathione agarose beads (Pierce, 16100) were added with gentle
inversion overnight at 4C. After overnight incubation, the beads were centrifuged
at 1500rpm at 4C for 3 minutes. The beads were washed 4x in 5mL BC500 and
1x in a wash buffer (1x PBS, 20% glycerol, 1% NP-40, 1mM DTT, 500x protease
inhibitor cocktail [Sigma, P8340]). GST proteins were eluted from the beads using
3x washes in 0.833 mL reduced glutathione solution (50mM Tris-HCl pH 8.8,
100mM NaCl, 20mM reduced glutathione [Sigma, G4251], final pH adjusted to 8.0)
pooling each eluate yielding approximately 2.5mL of soluble protein. Protein
samples were concentrated using Amicon Ultra-4 conicals (Millipore-Sigma)
centrifuged at 4100rpm for 10-40 minutes per manufacturer’s instructions. The spin
was repeated twice after refilling to maximum volume with BC100 (20mM Tris-HCl
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pH 8.0, 100mM KCl, 0.5mM EDTA, 20% glycerol, 1mM, DTT, 500x protease
inhibitor cocktail [Sigma, P8340]). Protein concentration was estimated using BSA
standards on an SDS-PAGE gel and aliquots were stored at -80 °C.
Nuclear extract preparation

Nuclear extracts were prepared from murine erythroleukemia (MEL) cells.
Briefly, ~100e6 cells increments were washed in PBS and resuspended in 10x cell
pellet volume of Buffer A (10mM HEPES-KOH pH 7.9, 1.5mM MgCl2, 10mM KCl,
1mM DTT, 100mM PMSF, 500x protease inhibitor cocktail [Sigma, P8340]) and
incubated on ice for 30 minutes with intermittent vortexing to lyse the cell
membrane. Nuclear pellets were resuspended in 3x pellet volume of Buffer C
(20mM HEPES-KOH pH 7.9, 25% glycerol, 420mM NaCl, 1.5mM MgCl2, 0.2mM
EDTA, 1mM DTT, 100mM PMSF, 500x protease inhibitor cocktail [Sigma, P8340])
and incubated on ice for 30 minutes with intermittent vortexing. Nuclear extracts
were cleared by spinning in tabletop microcentrifuge at 13000rpm for 5 minutes at
4C. Concentrations for cleared extracts were determined using the A280
absorbance measurement on a spectrophotometer (Thermo Scientific, Nanodrop
2000). Samples were stored at -80C.
GST pulldown assay

GST pulldown assays were performed by diluting 500µg of nuclear extract
in dilution buffer (50mM Tris-HCl pH 7.5, 0.5% NP-40) to a final NaCl concentration
of 150mM and bringing to a final volume of 1mL using binding/wash buffer (150mM
NaCl, 50mM Tris-HCl pH 7.5, 0.5% NP-40). 2.5µg of respective GST fusion
proteins and 20µl of glutathione agarose beads (Pierce, 16100) were added and
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samples were incubated with rotation 4 hours to overnight at 4C. Beads were
washed 5x in 1mL binding/wash buffer and eluted in 50µl 4x sample buffer. Eluted
samples were run on SDS-PAGE gels and either submitted for mass spectrometry
or analyzed by Western blot (see above).
Mass spectrometry

Liquid chromatography coupled with tandem mass spectrometry (LC–
MS/MS) analysis was performed by the Proteomics and Metabolomics Facility at
the Wistar Institute using a Q Exactive Plus mass spectrometer (Thermo Fisher)
coupled with a Nano-ACQUITY UPLC system (Waters). Samples were digested
in-gel with trypsin and injected onto a UPLC Symmetry trap column (180 μm i.d. ×
2 cm packed with 5 μm C18 resin; Waters). Tryptic peptides were separated by
reversed-phase HPLC on a BEH C18 nanocapillary analytical column (75 μm i.d.
× 25 cm, 1.7 μm particle size; Waters) using a 95 min gradient formed by solvent
A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A 30
min blank gradient was run between sample injections to minimize carryover.
Eluted peptides were analyzed by the mass spectrometer set to repetitively
scan m/z from 400 to 2,000 in positive-ion mode. The full MS scan was collected
at 70,000 resolution followed by data-dependent MS/MS scans at 17,500
resolution on the 20 most abundant ions exceeding a minimum threshold of
20,000. Peptide match was set as preferred, exclude isotopes option and chargestate screening were enabled to reject singly and unassigned charged ions.
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Proteomic analysis

Peptide sequences were identified using MaxQuant 1.5.2.8. MS/MS spectra
were searched against a UniProt mouse protein database using full tryptic
specificity with up to two missed cleavages, static carboxamidomethylation of Cys,
and variable oxidation of Met and protein N-terminal acetylation. Protein
quantification was performed using razor +unique peptides. Razor peptides are
shared (non-unique) peptides assigned to the protein group with the most other
peptides (Occam's razor principle). False discovery rates for protein and peptide
identifications were set at 1%. Identified proteins required a minimum of 2 razor or
unique peptides in at least one of the samples. The list of proteins was further
filtered by dropping proteins not identified in 5/7 observed samples per replicate
and by dropping proteins observed in only one of three replicates per sample.
Intensity values were normalized to GST detected for each sample. Values for
proteins absent in one replicate were imputed by averaging the intensity values of
the flanking proteins in the other two replicates. If the flanking proteins are absent
in one of the two remaining replicates, the protein was discarded, and if one of the
flanking proteins was absent in both replicates, an average of the two remaining
flanking proteins (one from each replicate) was used. Finally, ComBat145 was
applied to reduce batch effect between replicates. Comparison between samples
was performed by calculating the mean of the log2 of the ratio between two
samples from each replicate and the log10 of the Q-value. STRING protein
interaction network analysis (https://string-db.org/) was performed on proteins
more strongly enriched in the ETCC sample than the ET sample (log2ratio > 1.2,
57

logQvalue > 4) using the highest confidence setting (0.900) labeled with
experimentally validated interactions and interactions from curated databases.
Data availability

The FASTQ files for the RNA sequencing data have been deposited in the
NCBI BioProject database with BioProject accession number PRJNA560407.
ChIP sequencing data will be made publicly available through the Gene
Expression Omnibus (GEO) pending publication.
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CHAPTER 3: DOMAIN MAPPING REVEALS A COILED COIL THAT FUNCTIONALLY
DISTINGUISHES BET PROTEINS

Chapter summary

Research described in this chapter forms the basis of a pending manuscript
currently in the review process title “Comparative structure-function analysis of
bromodomain

and

extraterminal

motif

(BET)

proteins

using

a

gene-

complementation system”. Many people contributed to this work. The initial cell
growth and hemoglobinization experiments were performed by Sarah Hsu and
Kristen Jahn while they were in the Blobel lab. Sarah Hsu also conducted the RNA
sequencing experiment in collaboration with Tapan Ganguly and Erik Toorens from
the Perelman School of Medicine Penn Genomics Analysis Core. Computational
analysis of the RNA sequencing data was performed by Zhe (Jim) Zhang from the
Children’s Hospital of Philadelphia (CHOP) Department of Biomedical and Health
Informatics. Analysis of proteomic data was carried out in collaboration with Perry
Evans of the CHOP Department of Biomedical and Health Informatics. Other
members of the Blobel lab contributed significantly to this work. Hongxin Wang
provided a substantial amount of technical support as did Nicole Hamagami and
Jennifer Yano.
Introduction

Bromodomain and extraterminal motif (BET) proteins mechanistically link
chromatin acetylation to gene transcription15,20. The BET family consists of BRD2,
BRD3 and BRD4, which are widely expressed across tissue types, and the testisspecific BRDT20. BET proteins share a general domain structure consisting of
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tandem N-terminal bromodomains and a C-terminal ET domain conserved across
species18. The bromodomains bind to acetylated lysine residues on histones and
transcription factors15. The ET domain is a protein-protein interaction motif that
recruits additional co-activators31,64,66,68,71,72. BET proteins thereby function as
molecular scaffolds for transcriptional regulators. Small molecules which target the
bromodomains partially displace BET proteins along with associated co-factors
from chromatin95,96. BET inhibitors are in clinical trials for the treatment of several
cancers and may have additional use in inflammatory, metabolic and cardiac
disorders20,45. Because the bromodomains are similar between BET proteins,
molecules targeting them do not strongly discriminate between individual BET
proteins95,96,117. The lack of specificity might underlie some of the unwanted side
effects of BET inhibitors and constrain their use. Moreover, clinical exploitation of
BET inhibition requires a better understanding of selective BET protein functions.
Structurally, the long-isoform of BRD4 (BRD4L) is the most distinct BET
protein in that it possesses a unique extended C-terminal tail that recruits factors
required for the transition of RNA polymerase 2 from transcriptional initiation into
productive elongation76,78,146. The short isoform of BRD4 (BRD4S) lacks this
domain and is thus structurally more similar to BRD2 and BRD3, but its expression
and function in most cell types remains poorly characterized70,82. Depletion of
BRD2 or BRD3 results in transcriptional and phenotypic outcomes that in some
settings are different from BRD4 depletion104,124, suggesting non-overlapping
functions among them. In fact, BRD2 deficient mice exhibit a phenotype distinct
from that of BRD4 deficient mice21–23,119. BRD3-null mice have not been reported.
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It has been proposed that BET-specific functions are conveyed in part via
selectivity of the bromodomains for acetylated substrates44,47,48,51–53. Specificity
might also be mediated by additional domains that influence chromatin
occupancy35,36 or by differences in protein interactions30,31. However, the ET
protein interaction domain is highly conserved across BET proteins, making its
contribution to BET-selective interactions unclear64,66,68,71,72. Thus, whereas all
BET proteins are enriched at acetylated chromatin, the mechanisms underlying
BET-specific functions remain unresolved.
GATA1-mediated erythroid cell differentiation has provided a useful model
for the dissection of BET protein biology132. GATA1 is a master erythroid
transcription factor that drives the terminal maturation of erythroid precursor
cells136. BRD3 and to a lesser extent BRD4 bind to GATA1 in an acetylation
dependent manner and co-localize with GATA1 on chromatin113,139. Point
mutations in the BET-binding motif of GATA1, or pan-BET inhibition, impair GATA1
occupancy on chromatin113,139,140. GATA1 transcriptional activity has been
extensively studied in G1E-ER4 cells, an erythroid progenitor line that stably
expresses a conditional form of GATA1 fused to the ligand binding domain of the
estrogen receptor (GATA1-ER)147. Using this system, GATA1-ER target genes can
be activated upon treatment with estradiol, which faithfully recapitulates terminal
erythroid maturation147. BRD2 and BRD4 are both necessary for GATA1-ERmediated gene expression113. In contrast, BRD3 appears to be dispensable, but
BRD3 loss exacerbates defects associated with BRD2 deficiency, suggesting
overlapping functions of these two proteins113. Accordingly, overexpression of
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BRD3 can partially compensate for BRD2 loss113. BRD3 is expressed
approximately four-fold less than BRD2 based on RNA-sequencing in G1E-ER4
cells, potentially explaining its lack of compensatory activity when not
overexpressed148. It is unclear whether BRD2 and BRD3 possess structural
features that could facilitate functions that are distinct from BRD4.
To better understand functional differences between BRD2, BRD3 and
BRD4, we took advantage of Brd2-null G1E-ER4 erythroblasts. These cells are
viable but fail to undergo GATA1-mediated terminal maturation. We asked whether
reconstitution of these cells with exogenous BET proteins rescues their growth
rate, maturation and gene expression. We found that the BRD4 isoforms are
functionally different from BRD2 and BRD3. Moreover, the bromodomains
contribute surprisingly little in terms of BET specific functions. We define a small
region adjacent to the ET domain that contains a predicted coiled coil structure in
BRD2 and BRD3 but not BRD4 that we show to contribute to BRD2 selective
activity.
BRD2 is essential for GATA1 dependent erythroid differentiation and gene
expression
A mechanistic explanation for specific functions of individual BET proteins remains
unresolved. We therefore took advantage of a cellular system in which BET proteins can
be directly compared. We generated four Brd2-null G1E-ER4 cell lines (KO clones, KO1
- KO4) using CRISPR-Cas9 (see “Materials and Methods”). The absence of BRD2 was
confirmed by Western blot with antibodies against BRD2 N- and C-terminal epitopes
(Figure 3.1.A). We measured BRD3 and BRD4L protein levels and found them to be
unchanged in the BRD2 KO cells (Figure 3.1.A), indicating that BRD2 is not necessary
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for BRD3 and BRD4L expression, and that any defects in the BRD2 KO cells cannot be
attributed to their loss. We were unable to detect endogenous BRD4S protein in

whole cell lysates using commercially available antibodies (Figure 3.1.B) but reads
mapping to the BRD4S-specific exon were detected by RNA sequencing. Exonexon junction analysis suggested that BRD4S is the minor isoform with
approximately ~33% of BRD4 transcripts corresponded to it in parental G1E-ER4
cells, ~24% in BRD2 KO1 cells and ~19% in KO2 cells, indicating that BRD2 does
not influence which isoform predominates. Thus, changes in BRD4 mRNA
alternative splicing likely do not account for any phenotypic differences observed
in BRD2 KO cells. To test whether GATA1-driven erythroid maturation depends on
BRD2, we exposed BRD2 KO clonal lines to estradiol for 24 hours147, a time point
sufficient for the maximal accumulation of GATA1-ER target genes. Consistent with our
previous studies113, all BRD2 KO clones failed to induce the expression of major erythroid
GATA1 target genes, including Hbb-b1, Alas2, Slc4a1 and Spta1 (Figure 3.1.C).
Importantly, BRD2 depletion did not appear to impact RNA levels of the Gata1-ER
transgene or housekeeping genes Actb and Gapdh. Consistent with the Western blots,
Brd3 and Brd4 RNA levels were unchanged in BRD2 KO cells.
Identification of a BRD2-specific transcriptional signature
To measure the global transcriptional changes associated with BRD2 loss, we
performed RNA-sequencing on parental G1E-ER4 and two BRD2 KO clones (KO1 and
KO2) after 24 hours of GATA1-ER induction. Pearson correlation coefficients
demonstrated strong reproducibility between the three replicates for each cell line and
higher similarity of KO1 and KO2 (Figure 3.2.A). The overall high correlations between
each of the samples indicate that a majority of genes are similarly expressed.
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Dimensionality reduction using principle component analysis showed separation of the
two KO clones from the parental G1E-ER4 cells on PC1 (37.3% of variance), revealing
the transcriptional impact of BRD2 depletion. Separation of the three cell lines on PC2
(18.9% of variance) suggested clonal variation between the cell lines (Figure 3.2.B). We
therefore classified differentially expressed genes as those that exhibit a ≥ 2-fold change
(false discovery rate [FDR] < 0.01) in both KO clones compared to parental G1E-ER4 cells
and that were unchanged between the two KO clones (Figure 3.2.C). This identified 158
downregulated genes (Table 3.1) and 261 upregulated genes (Table 3.2). A less
stringent cutoff of ≥ 1.5-fold change (FDR < 0.05) resulted in 433 and 626 genes that were
downregulated and upregulated, respectively (Figure 3.2.C). Expression of several highly
expressed maturation associated genes (Hbb-b1, Hbb-b2, Hba-a1, Hba-a2, Alas2, Slc4a1
and Spta1) was decreased in the BRD2 KO cells in comparison to the parental cells,
whereas many genes whose expression is high in immature cells and downregulated
during erythroid maturation (Gata2, Myc, Myb, Kit, Il2rg, Lyl1 and Vim) were elevated in
at least one of the BRD2 KO cell lines (Figure 3.2.D). This indicates a general failure of
BRD2 KO cells to fully mature upon GATA1-ER activation.
To determine what biological pathways could be affected by the observed
transcriptional changes, we queried the differentially expressed genes for enrichment of
hallmark gene sets in the Molecular Signatures Database. The gene sets most associated
with the downregulated genes were HEME_METABOLISM, MTORC1_SIGNALING and
CHOLESTEROL_HOMEOSTASIS (Figure 3.2.E, right). These pathways are consistent
with known biological processes important for erythroid maturation149–151. The gene sets
most associated with the upregulated genes include IL2_STAT5_SIGNALING,
TNFA_SIGNALING_VIA_NFKB and P53_PATHWAY. The relevance of these pathways
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is not immediately clear but could reflect a failure to downregulate genes important for cell
proliferation. An analysis using the less stringent list of differentially expressed genes (fold
change ≥ 1.5, FDR <0.05) yielded similar gene set enrichment results (not shown).
The pharmacologic BET inhibitor JQ1 targets all BET proteins with comparable
efficacy95. We assessed to what extent the cellular response to JQ1 can be attributed to
BRD2 inhibition by comparing the transcriptome analyses of BRD2 KO cells to our prior
data sets in which these cells were exposed to JQ1. Since the prior experiments employed
a microarray platform113, we first intersected genes detected by both methods, resulting
in 9132 genes (see “Materials and Methods”). Comparison of the gene expression
changes in the two datasets revealed a positive correlation between genes impacted by
BRD2 loss and JQ1 exposure (Pearson correlation coefficient of R=0.47 (p<2.2e-16))
(Figure 3.2.F). Of the 248 genes upregulated in BRD2 KO cells, 104 were also
upregulated (FC>2, FDR<0.01) upon JQ1 treatment (p<2.2e-16), and of the 137
downregulated genes, 54 were also downregulated upon JQ1 treatment (p<2.2e-16)
(Figure 3.2.G). A limitation to this comparison is that alterations in gene expression upon
chronic BRD2 loss are a composite of direct and indirect effects. In contrast, JQ1 treatment
enables detection of an immediate response to BET inhibition. Moreover, JQ1 does not
fully displace BET proteins from chromatin95,117, which might limit effect size. In spite of
these limitations, these results suggest that impaired BRD2 function accounts for at least
part of the effects of JQ1 treatment. In sum, BRD2 is critical for the regulation of a wide
array of erythroid genes involved in multiple aspects of GATA1-mediated differentiation,
and loss of BRD2 activity accounts for at least part of the JQ1 effects.
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BET specific functions during erythroid cell growth and differentiation
While BET proteins are structurally similar, few studies have directly examined
whether conserved protein domains contribute to BET selective functions or whether they
simply reflect functional overlap (Figure 1.4, Table 1.1)25,35,79,85,152. We previously
reported that BRD2 and BRD3 can partially compensate for each other in G1E-ER4
cells113. We next tested whether a similar functional overlap exists between BRD2 and
either BRD4S or BRD4L in these cells. Although BRD4S was not detected in G1E-ER4
cells, we included it in this functional comparison due to its structural resemblance to
BRD2 and BRD3. We used a murine retroviral expression vector to transduce HA-tagged
forms of BRD2, BRD3, BRD4S or BRD4L cDNA into parental G1E-ER4 cells or BRD2
KO1 cells. We used three assays to study the relative activities of these proteins: 1) a
reddening of the cells indicating activation of the hemoglobin synthesis pathways, 2)
expression of erythroid maturation associated genes upon GATA1-ER activation, and 3)
cell growth. To visualize hemoglobinization, we induced GATA1-ER activity for 48 hours
at which time the cells normally have turned red. As expected, BRD2 was required for
hemoglobin production (Figure 3.3.A). Expression of BRD2 restored the ability of BRD2
KO1 cells to produce hemoglobin. BRD3 was also able to rescue hemoglobinization, but
both BRD4S and BRD4L displayed much lower activity in this assay. We next measured
the mRNA levels of Hbb-b1, which was one the most differentially regulated genes in the
BRD2 KO cells based on the previous analysis. Activation of GATA1-ER failed to induce
expression of Hbb-b1 in the BRD2 KO1 cells. However, expression of BRD2 and BRD3
restored Hbb-b1 expression in BRD2 KO1 cells to similar levels while BRD4S and BRD4L
showed little activity (Figure 3.3.B). Note that overexpression of BET proteins in parental
cells did not overtly perturb Hbb-b1 expression or hemoglobin production, suggesting that
excess levels of a given BET protein is compatible with cell maturation.
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To further compare the activities of BET proteins, we assessed the impact of BET
expression on cell growth. The retroviral vector encoding the BET cDNAs contained an
IRES-GFP module to mark cells with stably integrated constructs. We designed a
competitive growth assay which monitors the fraction of GFP+ cells in a mixture of infected
and uninfected cells over time using flow cytometry. Restoration of BRD2 expression in
BRD2 KO1 cells increased the fraction of GFP+ cells by ~40% over the time course
(Figure 3.3.C). BRD3 expression augmented growth almost to the same extent as BRD2.
In contrast, BRD4S expression failed to rescue BRD2 KO1 cell growth and even lowered
cell numbers. We also measured growth rates in cells expressing BRD4L and found
BRD4L to be incapable of restoring BRD2 KO1 cell growth (Figure 3.3.D). In parental
cells, BRD2 overexpression had no impact on cell growth, whereas BRD3 resulted in a
~20% decrease, BRD4S in a ~40% decrease and BRD4L in a 10% decrease (Figure

3.3.C,D), suggesting that excess levels of these molecules can impair proliferation or
viability. In sum, both differentiation and growth assays point at overlapping functions
between BRD2 and BRD3, while BRD4S, which is overall structurally similar, and BRD4L
exert distinct functions in these cells.
The abundance of BRD2 and BRD4S is strongly influenced by their N-terminal
halves
Even though the BET constructs were expressed by the same vector, the resulting
protein amounts were markedly variable as determined by Western blot with anti-HA
antibodies (Figure 3.3.E). Specifically, BRD3 and BRD4S were readily detected, whereas
BRD2 was not detected unless a BRD2-specific antibody was used. Differences in
exogenous BET expression potentially confound interpretation of the results. However,
comparisons between the effects of BRD3 and BRD4S might still be instructive since
these proteins are expressed at similar levels and their effect on BRD2 comparable. For
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example, BRD3 and BRD4S exert opposite effects on BRD2 KO1 cell growth, with BRD3
restoring their expansion and BRD4S lowering cell numbers (Figure 3.3.C). Similarly,
whereas BRD3 rescued Hbb-b1 expression to levels comparable to that achieved by
BRD2, BRD4S failed to do so (Figure 3.3.B).
Variable production of BET proteins could be due to differences in mRNA stability,
translation and/or protein turnover. To address this, we measured mRNA levels of the
BRD2, BRD3, BRD4S and BRD4L transgenes in the above cells using primers common
to all constructs (specific to the GFP coding portion of the mRNAs). We found that mRNA
levels varied substantially less than protein levels. In fact, Brd2 transcripts were somewhat
higher than the others (Figure 3.3.F), indicating that the decreased BRD2 protein was due
to a post-transcriptional mechanism.
To identify which features may be dictating the contrasting nature of BRD2 and
BRD4S in terms of function and stability, we began to dissect their differences by
designing chimeric BET constructs consisting of the N-terminal and C-terminal halves of
BRD2 and BRD4S fused immediately downstream of the second bromodomain. These
chimeric BET proteins were termed BRD2-4S and BRD4-2, respectively (Figure 3.4.A).
This strategy preserved their overall modular domain structure, including the N- and Cterminal nuclear localization signals153,154. These constructs were introduced into the
same retroviral vector as described before. We infected parental and two BRD2 KO cell
lines expressing the chimeric and intact BET proteins and isolated stably expressing cell
lines. We measured mRNA levels produced by each construct and found them to be
similar (Figure 3.4.B). Strikingly, the protein levels of BRD2 and the chimeric BRD2-4S
were dramatically lower than those of BRD4S and chimeric BRD4-2 (Figure 3.4.C). To

quantify these differences in protein expression, we repeated the infection of BRD2
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KO1 cells with retroviruses encoding the intact BRD2, BRD3, BRD4S and BRD4L
HA-tagged proteins, as well as the chimeric BRD2-4S and BRD4-2 constructs and
performed a Western blot probing the HA epitope using fluorescently labeled
antibodies. This strategy allowed the visualization and quantification of all six BET
proteins (Figure 3.4.D). Consistent with our prior observations, BRD2 and BRD24S were expressed at equally low levels in comparison to BRD3, BRD4S and
BRD4-2. BRD4L was expressed at an intermediate level. This indicates that steady
state protein levels are determined by the N-terminal halves of the BET proteins.
Selective functions of BET proteins are determined by their C-terminal halves
To determine whether there are BET-selective functions that are conveyed by
domains that do not affect protein levels, we tested the ability of BRD2, BRD4S and the
chimeric BRD2-4S and BRD4-2 proteins to restore BRD2 KO cell growth and
differentiation-associated gene expression. BRD2-4S, which was expressed at similar
levels as BRD2, was impaired in its ability to restore cell growth compared to BRD2 (Figure

3.4.E), whereas BRD4-2, which was expressed similarly to BRD4S, had a positive effect
on BRD2 KO cell growth (Figure 3.4.F). Given that BRD2 but not BRD4S rescued the
expression of Hbb-b1 in BRD2 KO cells (Figure 3.3.B), we asked whether the C-terminal
halves of BRD2 and BRD4S were responsible for this differential activity. BRD4-2 rescued
Hbb-b1 expression comparably to wild type BRD2 whereas BRD2-4S had no measurable
effect (Figure 3.4.G). The same trends held true for the expression of the other major
globin chain gene Hba-a1, though compared to Hbb-b1, Hba-a1 expression was less
affected by BRD2 depletion (Figure 3.4.H). Together, these observations suggest that the
C-terminal half of BRD2 encodes its specific activity, which can be grafted onto the Nterminal half of BRD4S to substantially convert it into a BRD2-like molecule. This further
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suggests that the specific functions of BET proteins are not critically determined by
differences in the bromodomains, but rather by differences in the C-terminal halves of the
proteins.
So far, comparisons among proteins were largely limited to those that were
expressed at comparable levels, but the drastic differences in protein abundance
conferred by the N-terminal halves of BRD2, BRD3 and BRD4S confounded direct
functional comparison across all of the constructs. To overcome these limitations, all BET
constructs were fused to YFP and stably introduced into BRD2 KO1 cells via retroviral
transduction. Generation of cell lines with comparable expression of each construct
required careful titering of viruses and multiple rounds of fluorescence-activated cell
sorting using stringent gating on the YFP signal (Figure 3.5.A). In that manner we
eventually succeeded in isolating subpopulations of cells in which all proteins were
produced at nearly equal levels that in turn were similar to the amount of endogenous
BRD2 in parental G1E-ER4 cells (Figure 3.5.B). YFP-BET transgene mRNAs were
measured with qPCR primers that target the YFP sequence (YFP) and the 5’ and 3’ end
of Brd2 (Figure 3.5.C). These measurements indicate that the RNA levels corresponding
to the YFP-BRD2 and YFP-BRD2-4S proteins were slightly higher than the RNA levels for
the YFP-BRD3, YFP-BRD4S and YFP-BRD4-2 proteins. This is consistent with the lower
protein yields for BRD2 and BRD2-4S, requiring selection of cells with higher RNA
expression. These relative mRNA differences, however, were not as drastic as the original
protein differences. The YFP sequence may stabilize BRD2 mRNA or protein to some
extent resulting in a better correlation between its RNA and protein levels. Of note, levels
of Gata1-ER and Gapdh mRNA were similar in the cell lines (Figure 3.5.C).
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We next assessed whether the reconstituted BRD2 KO1 cells could activate eight
BRD2-dependent genes during erythroid maturation. As expected, expression of Hbb-b1,
Alas2, Slc4a1, Spta1, Csf2rb, Csf2rb2, Kcnn4 and Rhag were all reduced in the unreconstituted BRD2 KO1 cells compared to the parental G1E-ER4 cells (Figure 3.5.D).
Expression was rescued by YFP-BRD2 and to a lesser extent by YFP-BRD3, indicating
that the increased bulk added by the YFP fusion onto the N-terminus of BET proteins did
not impact their overall function. YFP-BRD4S had a marginal impact on the expression of
these BRD2-dependent genes and was clearly less potent than YFP-BRD3. We next
assessed the functions of the chimeric YFP-BRD2-4S and YFP-BRD4-2 BET proteins.
YFP-BRD2-4S was unable to restore expression of 7 of the 8 genes. In contrast, YFPBRD4-2 was able to restore expression of all 8 genes to levels comparable to YFP-BRD2
and parental G1E-ER4 cells.
To test for the global rescue of GATA1-induced erythroid maturation by the various
BET proteins, we examined the ability of the YFP-BRD2, YFP-BRD4S and the two
chimeric YFP-BRD2-4S and YFP-BRD4-2 proteins to rescue hemoglobinization in BRD2
KO1 and KO2 cells after sorting for equal YFP-BET levels, which was confirmed by postsorting flow cytometry revealing comparable YFP intensity for all of the YFP-BET proteins
(Figure 3.6.A). As previously observed, parental G1E-ER4 cells fully hemoglobinized
whereas the BRD2 KO1 and KO2 cells failed to turn red (Figure 3.6.B). YFP-BRD2
expression in both BRD2 KO cell lines rescued hemoglobin production to levels
comparable to the parental G1E-ER4 cells, whereas YFP-BRD4S expressing BRD2 KO
cells failed to turn red. Chimeric YFP-BRD2-4S failed to rescue BRD2 KO cells whereas
YFP-BRD4-2 restored hemoglobinization comparably to, if not better, than YFP-BRD2. To
further confirm that these phenotypic changes reflect underlying gene expression changes
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associated with rescued GATA1-ER activity, we measured mRNA levels of candidate
BRD2-dependent GATA1-activated genes in these cells after 24 hours of GATA1-ER
activation. These data indicate that the C-terminal but not the N-terminal half of BRD2
conveys BRD2’s functional specificity in BRD2-dependent cell growth, differentiation and
gene expression.
BRD2 and BRD3 contain a putative coiled coil domain that contributes to BRD2
activity
The previous experiments reveal that BRD2-like activity shared by BRD2 and
BRD3 maps to the C-terminal half of BRD2. We therefore examined the amino acid
sequences of the C-terminal halves of both BRD2 and BRD3 for shared features that may
distinguish them from BRD4S. Coil prediction of the mouse BET proteins using
MARCOIL143 reveals multiple putative coiled coils (Figure 3.7.A). We identified a region
immediately downstream of the ET domain that is predicted to harbor a coiled coil (that
we refer to as the CC domain) in BRD2 and BRD3 but not in BRD4. The CC domain is
conserved across the BRD2, BRD3 and BRDT paralogues in human, mouse and zebrafish
(Figure 3.7.B). It is also conserved in the Drosophila BET paralog FSH as well as one of
the yeast paralogs, BDF1 but not BDF2. We therefore asked whether this region could
account for some of the observed differences between BRD2/BRD3 and BRD4S.
To expedite analyses of several constructs testing the function of this region
without having to generate multiple independent cell lines for each, we developed a flow
cytometry-based version of the erythroid maturation gene complementation assay in G1EER4 cells. This approach quantifies the fluorescent tag on each construct as a proxy for
protein abundance and the erythroid-specific surface antigen TER119 as a measure of
GATA1-mediated differentiation (Figure 3.8.A). As expected, TER119 was only
expressed on G1E-ER4 cells upon GATA1-induced maturation (Figure 3.8.B)155. We
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validated the use of the TER119-based erythroid maturation assay by demonstrating that
YFP-BRD2, but not a YFP empty vector, restored GATA1-mediated TER119 expression
in BRD2 KO cells to levels observed in the parental G1E-ER4 cells (Figure 3.8.B, 3.8.C).
We also compared erythroid gene expression levels to TER119 surface staining after 24
hours of GATA1-ER activation in parental G1E-ER4 cells or BRD2 KO1 cells expressing
YFP-fused BRD2, BRD3, BRD4S, or chimeric BRD2-4S or BRD4-2 (Figure 3.8.D). There
was a strong correlation between the amount of TER119 expression on the surface of
these cells and the mRNA levels of the erythroid genes Alas2 (R=0.81, p=0.026), Hbb-b1
(R=0.84, p=0.017), Slc4a1 (R=0.82, p=0.024) and Spta1 (R=0.88, p=0.009). For example,
whereas the parental G1E-ER4 cells exhibited high levels of mRNA and TER119 staining,
the BRD2 KO1 cells without YFP-BET contained low mRNA levels of these genes and
exhibited minimal TER119 staining. However, the YFP-BRD2-rescued BRD2 KO1 cells
expressed mRNA and TER119 levels comparable to the parental G1E-ER4 cells. YFPBRD3 and YFP-BRD4-2 likewise rescued the BRD2 KO1 cells, albeit to varying degrees,
whereas YFP-BRD4S and YFP-BRD2-4S failed to rescue mRNA and TER119 expression.
These data indicate that the gene encoding the TER119 antigen is BRD2-dependent and
is representative of erythroid maturation.
The ET region is a protein-protein interaction domain that recruits transcriptional
co-activators to chromatin64. Given the proximity between the CC and ET domains, it is
possible that the CC contributes to the ET-mediated interactions or functions
independently. We therefore deleted both the ET (BRD2dET) and CC (BRD2dCC) regions
individually to determine if either region contributes to BRD2 activity in G1E-ER4 cells
using YFP-BET fusions (Figure 3.9.A, middle). YFP-BRD2dET and YFP-BRD2dCC were
expressed at levels similar to full length YFP-BRD2 based on YFP fluorescence (Figure
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3.9.A, left). Deletion of the ET domain completely abrogated TER119 expression in
comparison to full length YFP-BRD2 (Figure 3.9.A, right). Deletion of the CC domain also
reduced TER119 expression, albeit to a lesser extent. To measure the effect of the ET
and CC deletions on BRD2 protein expression and BRD2-mediated gene expression and
cell growth, we expressed HA-tagged versions of these proteins in BRD2 KO1 cell lines.
RNA levels of the constructs were similar based on qPCR primers targeting the 5’ end of
Brd2 and the GFP sequence (Figure 3.9.B). Levels of Gata1-ER, Brd3, and Brd4, as well
as the control genes Actb and Gapdh were similar across the cell lines. The protein levels
of the constructs were likewise similar, indicating that the ET and CC domains do not
significantly contribute to BRD2 stability (Figure 3.9.B, inset). As seen previously,
restoration of BRD2 rescued the expression of multiple BRD2-dependent genes (Hbb-b1,
Alas2, Slc4a1, Spta1, Csf2rb2, Kcnn4, Rhag) (Figure 3.9.C). Deletion of the ET domain
completely abrogated the ability of BRD2 to rescue these genes. Deletion of the CC
domain had a more partial, but uniform, effect on the expression of these genes. These
data indicate that whereas the ET domain is absolutely critical for proper BRD2 functioning
during erythroid maturation, the CC region contributes more partially to BRD2 function.
In addition to restoring erythroid gene expression, BRD2 also restores the cell
growth rate of BRD2 KO cells. We therefore tested whether the ET and CC regions
contributed to BRD2-mediated cell growth. As performed previously to measure the effect
of BET protein expression on cell growth, we infected parental G1E-ER4 as well as BRD2
KO1 and KO2 cells with viruses encoding HA-tagged BRD2, BRD2dET and BRD2dCC
and tracked the effect of BET expression on cell growth by measuring the fraction of the
GFP+ cells over time. Reconstitution of BRD2 in BRD2 KO1 and KO2 cells led to a ~45%
increase over the time course (Figure 3.9.D). Deletion of the ET domain drastically
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decreased BRD2 function in this assay. Interestingly, though the CC domain contributed
only partially to erythroid gene expression as seen above, its deletion had a significant
impact on BRD2 function in cell growth, indicating that the erythroid genes assayed may
not completely reflect the overall gene expression changes associated with loss of the
BRD2 CC region. In summary, whereas the ET domain is essential for BRD2 function, the
CC region may play a more variable role in the expression BRD2-dependent genes.
The combined ETCC region functionally distinguishes BRD2 and BRD4S
Like the bromodomains, the ET region is highly conserved between BET proteins.
The adjacent CC region, however, is present in BRD2 and BRD3 but not in BRD4. We
therefore asked whether either the ET, the CC, or the combined ETCC region functionally
specified BRD2 and BRD4S. To do this, we devised additional chimeric BET proteins
using BRD2 and BRD4S as the backbones onto which the sequences surrounding or
containing the ET and CC domains were interchanged (Figure 3.10.A). We can broadly
classify these constructs based on the whether they are composed of the BRD2 or BRD4S
N-terminal half. For the BRD2-based chimeric constructs, we tested which, if any, of the
C-terminal segments (the middle region between BD2 and ET, the ET, or the end
segment) resulted in a loss of BRD2 function when the corresponding region from BRD4S
was substituted. For the BRD4S-based chimeric constructs, we tested whether the BRD2
ET domain, the CC region or a segment containing both could impart BRD2 function to
BRD4S. As controls, we compared these new chimeric constructs to the original N- and
C-terminal-swapped chimeras BRD2-4S and BRD4-2. We also compare these constructs
to BRD2 and BRD3, which possess the CC region, and to BRD4S, which lacks the CC
region (Figure 3.10.B, center). We used a combination of TER119 marker expression
and erythroid gene activation to uncover any functional differences between these BET
constructs.
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We first examined TER119 expression by flow cytometry. Of note, we used low
titer viruses that statistically guarantee single-copy gene integration into the cells.
Therefore, any differences in protein expression detected by YFP fluorescence were not
due to gene copy number. YFP fluorescence revealed that BRD3 and BRD4S were
expressed approximately 2-3-fold higher than BRD2 (Figure 3.10.B, left). This difference
is less than that observed without the use of YFP fusion (Figure 3.3.E), indicating that the
YFP sequence stabilizes BRD2 mRNA or protein to some extent. Next, we examined
erythroid maturation based on TER119 surface phenotyping. As expected, a YFP empty
vector or no vector infection had no impact on TER119 expression in BRD2 KO cells
whereas virus encoding BRD2 restored TER119 close to parental G1E-ER4 levels (Figure

3.10.B, right). BRD3 also restored TER119 expression, although to a lesser extent than
BRD2. BRD4S had minimal impact on TER119 expression.
We next examined the relative abilities of the BRD2-based chimeric BET proteins
to restore TER119 and erythroid gene expression. All of the BRD2-based constructs are
expressed at levels similar to BRD2 based on YFP fluorescence (Figure 3.10.B, left).
Replacing the middle region (BRD2-4mid) or the ET domain (BRD2-4ET) from BRD2 with
the corresponding regions from BRD4S had no appreciable impact on TER119 expression

(Figure 3.10.B, right. However, replacing the end segment of BRD2 (BRD2-4end), which
contains the CC region, completely abrogated its activity to the same extent as replacing
the entire C-terminal half (BRD2-4S). To examine gene expression, we established stable
BRD2 KO1 cells expressing the above constructs at similar levels (Figure 3.11.A, left).
Expression of the Brd2-based transgenes and control genes (Actb and Gapdh) was similar
across the cell lines (Figure 3.11.A, right). Examination of erythroid gene expression
revealed differences in the ability of these constructs to rescue expression of Hbb-b1,
76

Csf2rb, Csf2rb2 and Rhag and to a lesser extent Alas2, Spta1 and Kcnn4 that largely
reflect the differences in TER119 expression (Figure 3.11.A, right). For some of these
genes, all of the chimeric constructs exhibited reduced activity. However, BRD2-4end had
the least activity and most resembled BRD2-4S for 7 of the 8 genes examined. In
summary, the activity of the BRD2-based chimeras indicates that the region that
functionally discriminates BRD2 and BRD4S is the C-terminal end segment containing the
CC domain. The middle segment and the ET domain appear interchangeable with minimal
disruption of BRD2 activity and therefore do not contain functionally specific elements.
We next assessed the activities of the BRD4S-based chimeras. The BRD4S-based
chimeric BET proteins were expressed at similar levels, about 2-fold higher than BRD2
based on YFP fluorescence (Figure 3.10.B, left). Replacing the BRD4 ET domain with
that of BRD2 (BRD4S-2ET) did not increase TER119 expression (Figure 3.10.B, right).
Adding the BRD2 CC domain adjacent to the BRD4 ET domain (BRD4S-2CC) likewise
did not impact TER119 expression. However, when both the ET and CC domains from
BRD2 were inserted into BRD4S (BRD4S-2ETCC), TER119 expression was restored to
BRD2-like levels. The BRD4-2 protein, containing the entire C-terminal half of BRD2, had
an even greater impact on TER119 expression, indicating that additional C-terminal
domains may contribute to BRD2 function. To examine gene expression, we established
BRD2 KO1 cell lines stably expressing the above constructs. Protein levels of the BRD4Sbased constructs were about two-fold higher than BRD2 protein levels but were similar
across the cell lines (Figure 3.11.B, left). Despite the lower protein level of YFP-BRD2,
its mRNA was slightly higher than that of the YFP-BRD4S-based BET proteins as
measured by qPCR primers targeting YFP or the 3’ end of Brd2, consistent with the
decreased protein:RNA ratio previously observed for BRD2 (Figure 3.11.B, right). Levels
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of mRNA for Gata1-ER, Actb and Gapdh were similar. As with TER119 staining, the ET
and CC domains were insufficient to confer BRD2-like activity to BRD4S based on the
inability of the BRD4S-2ET and BRD4S-2CC proteins to restore erythroid gene activation
(Figure 3.11.B, right). However, the combined ETCC domain (BRD4S-2ETCC) clearly
imparted BRD2-activity to BRD4S as Hbb-b1, Csf2rb, Csf2rb2 and Kcnn4 expression were
at least partially increased above the levels achieved by BRD4S. As with TER119 staining,
BRD4-2 construct had the most BRD2-activity at these genes.
To test whether the various BRD4S-based constructs were able to rescue BRD2dependent hemoglobinization, we visualized cell pellet color after 48 hours of GATA1-ER
activation. As seen previously, BRD2 KO1 cells failed to hemoglobinize in comparison to
parental G1E-ER4 cells, a defect which is largely rescued by the restoration of BRD2
expression in the BRD2 KO1 cells (Figure 3.11.C). Whereas BRD4S fails to rescue
hemoglobinization, substituting the ET and CC regions into the BRD4S backbone partially
converts BRD4S into a BRD2-like molecule, but the combined addition of the ETCC
region, or the entire BRD2 C-terminal half more fully restores hemoglobinization.
Lastly, we asked whether the ET, CC or combined ETCC domain from BRD2 could
confer BRD4S with the ability to promote cell growth. Note that in both parental G1E-ER4
cells and BRD2 KO cells, overexpression of BRD4S inhibits growth, but chimeric BRD42, which contains the entire C-terminal half of BRD2, promotes growth when expressed in
BRD2 KO cells. To test the role of the ETCC domains, we repeated the cell growth assay
after expressing the HA-tagged BRD4S-based chimeric BET constructs in parental and
BRD2 KO1 cells. Consistent with our previous experiments, expression of BRD2 promoted
cell growth in BRD2 KO1 cells but had no effect in parental G1E-ER4 cells which possess
endogenous BRD2 (Figure 3.11.D). BRD4S, on the other hand, repressed parental and
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BRD2 KO1 cell growth. Substitution of the BRD2 ET domain into BRD4S (BRD4S-2ET)
slightly reduced the growth inhibitory effect of BRD4S. Addition of the BRD2 CC domain
adjacent to the BRD4S ET domain (BRD4S-2CC) resulted in a minimal growth promoting
effect when expressed in BRD2 KO1 cells. Strikingly, addition of both the ET and CC
domains from BRD2 (BRD4S-2ETCC) had the same growth promoting effect as replacing
the entire C-terminus with that of BRD2, indicating that the combined ETCC region is the
module that functionally distinguishes BRD2 and BRD4S.
Overall, these gene expression, differentiation, and growth assays suggest that
neither the bromodomains, the ET domain nor the CC region are alone sufficient to convert
BRD4S into a BRD2-like molecule. Instead, the combined region containing the canonical
ET domain and the adjacent CC is the critical region encoding BRD2-specific function.
Discussion

We used BET dependent G1E-ER4 cell growth, maturation and gene
expression to define functional similarities and differences among BET proteins.
We exploited the fact that BRD2 is required for G1E-ER4 growth and GATA1-ER
activity. Overexpressed BRD3, but not BRD4S or BRD4L, could significantly
overcome defects associated with BRD2 deficiency, pointing to functional similarity
among BRD2 and BRD3. When comparing BRD2 and BRD4S, most of their
specific activities were determined not by the bromodomains but by the C-terminal
halves of the molecules. We identified a short sequence downstream of the ET
domain that contains a putative coiled coil (CC region) in BRD2 and BRD3 but not
in BRD4. Together with the ET domain, the CC region conferred BRD2-like activity
to BRD4S and deletion of the ET or CC domains diminished BRD2 function.
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G1E-ER4 cells are a powerful system for the study of BET proteins since
they are sensitive to pharmacologic BET inhibition and genetic perturbations of
BET proteins113,139. Acetylation of GATA1 promotes association with BET
proteins139 which in turn are thought to contribute to GATA1 activity. In this context
it is worth noting that the clinical side effects of BET inhibition include anemia and
thrombocytopenia133,134.

Since

GATA1

is

essential

for

erythrocyte

and

megakaryocyte lineage differentiation, it is likely that the detrimental effects of BET
inhibition are linked to GATA1 function.
Over the course of our study, we uncovered a discrepancy in the amount of
BRD2 protein compared to that of BRD3 and BRD4S when expressed from the
same retroviral vector. BRD2 protein was substantially lower even though
transcript levels of BRD2 were in fact higher than that of BRD4S, indicating that
the mechanism for the low BRD2 abundance is post-transcriptional. The Nterminal half of BRD2 was responsible for the low protein amounts, as the protein
levels of the chimeric construct BRD2-4S were similar to BRD2 whereas the
protein levels of the chimeric construct BRD4-2 were similar to BRD4S. By fusing
YFP to the N-terminus of BRD2, the discrepancy between BRD2 protein and
mRNA was reduced, though YFP-BRD2 protein was still lower than that of YFPBRD3 and YFP-BRD4S. The YFP portion might thus affect BRD2 protein
production or turnover. It is interesting to note that a similar discordance between
overexpressed BRD2 and BRD3 protein was observed in U2OS cells but not
HEK293T cells31. Cell-type specific mechanisms may exist to tightly regulate
BRD2 protein levels. SPOP-mediated proteasomal targeting has been implicating in
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regulating BET proteins in some models156–158. However, SPOP recognizes a degron
motif shared equally by each BET protein. Thus, this mechanism is unlikely to account
for the differences we observed between BRD2/3 and BRD4S in G1E-ER4 cells.

Additional studies are therefore required to elucidate what accounts for this
specificity.
Our unexpected finding that the BRD2 bromodomains can be exchanged
for those of BRD4 with no substantial loss of BRD2 function suggests that potential
differences in their affinities or specificities for acetylated substrates44,47,48,51–53 do
not seem to contribute much to their selective functions. Our results suggest that
the distinct functions of BRD2 and BRD4 are instead exerted by their C-terminal
halves, in which the extended ET region containing the CC in BRD2 but not BRD4
appears to be the critical element. Gene rescue experiments showed that ET
domain itself was essential for BRD2 function, which is consistent with previous
studies demonstrating that the ET domain recruits multiple chromatin regulators
including NSD3, CHD8, ATAD5 and JMJD631,64,66,68,71,72. However, in our study,
though the ET domain was essential, exchanging the BRD2 and BRD4S ET
domains did not change the activities of either protein. Instead, the BRD2 ET
domain appears to function in conjunction with the adjacent CC. Thus, when the
combined ETCC region was grafted into BRD4S, it imparted BRD2-like activity to
BRD4S.
Coiled coils are structural motifs present in a wide variety of proteins and
perform a multitude of functions including directly mediating protein-protein
interactions159. In this case, the ET proximal CC may be recruiting additional
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factors that are ultimately altering the function of BRD2 in comparison to BRD4.
Alternatively, the CC domain may be modulating the structure of the ET domain by
influencing its folding to create novel interaction surfaces at the junction. Protein
interaction and structural studies are therefore warranted to better understand how
this region contributes to BRD2 functional specificity.
The ETCC region may therefore allow individual BET proteins to incorporate
into different transcriptional complexes involved in discrete aspects of the
transcription cycle. This may at least in part reconcile how BET proteins can
function distinctly on chromatin while having relatively similar genome-wide
distribution patterns, as observed in many studies55,63,96,102,114,117,118,129,160. Protein
interactions mediated by the ET or ETCC regions may also account for
bromodomain-independent chromatin binding36. Thus, the complexes that each
BET protein associate with could also account for some of the differences in
chromatin occupancy exhibited by each BET protein, as is the case at enhancers
where there is a relative enrichment BRD4 and at promoters where there is a
relative enrichment of BRD2 and BRD3113,117,129. There is also evidence that the
conserved mB domain, which facilitates homo- and hetero-dimerization of BET
proteins, is required for chromatin binding35. Heterodimerization of BET proteins
might further explain their overlapping chromatin occupancy and may suggest that
BET proteins function coordinately to assemble multiple factors onto chromatin.
Together these considerations lead to a model in which BET proteins function both
independently and interdependently during transcription.
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At low doses of BET inhibitors, the expression of only a subset of genes is
affected in a manner that is not easily predictable based solely on local chromatin
features or levels of BET protein occupancy112,113. Predicting whether a gene
responds to pharmacologic BET inhibition remains a challenge in part because
cells express multiple BET proteins exhibiting mostly overlapping but partially
distinct chromatin occupancy patterns. Moreover, partial redundancy among BET
proteins, as exemplified by BRD2 and BRD3, might be rooted in structural and
functional similarities. Thus, overexpression of BRD3 at least partially
compensates for loss of BRD2113. This example illustrates that different BET
protein dependencies can also be a result of the expression levels of each protein.
These factors need to be taken into consideration when assessing the effects of
targeting BET proteins pharmacologically.
Hence, identifying BET protein specific mechanisms and predicting what
disease processes might be targeted by BET inhibitors remains an important goal.
Achieving this level of mechanistic understanding requires consideration of BET
protein expression levels, assessment of functional overlap among BET proteins,
and the identification of functional domains that are required for BET protein
activity in diverse contexts. Our work begins to address these criteria by identifying
the ETCC module, which may mechanistically differentiate BRD2, and given the
structural similarities also BRD3, from BRD4. In the next Chapter, we explore the
mechanisms by which this domain may contribute to transcription. We speculate
that targeting this region with a small-molecule inhibitor might provide a more
selective tool for therapeutic BET inhibition.
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Figure 3.1. Brd2-null G1E-ER4 cells fail to activate erythroid genes. A) Western blot
of endogenous BET protein levels in whole cell lysates from parental G1E-ER4 cells or
multiple Brd2-null clones (KO1-KO4). B) Western blot of endogenous and overexpressed
BRD4 isoforms using an N-terminal antibody that is predicted to detect both BRD4S and
BRD4L and a C-terminal antibody that only recognizes BRD4L. Whole cell lysates from
parental G1E-ER4 cells expressing no construct or HA-tagged BRD4S or BRD4L. C)
Gene expression levels normalized to Pabpc1 after 24 hours of GATA1-ER activity (+E2)
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in the indicated cell lines. Averages and standard deviation (error bars) are derived from
three independent replicates.
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Figure 3.2. BRD2-dependent gene expression. A) Heatmap depicting Pearson
coefficients of pairwise gene expression correlations in three independent RNAseq
replicates (r1-r3) after GATA1 activation. B) Principle component analysis (see text for
details). C) Summary of differentially expressed genes (FC=fold-change, FDR=false
discovery rate). Subsets used for subequent analysis shaded in red or gray. D) Normalized
read counts (FPKM) for indicated genes activated or repressed upon GATA1-ER
activation. Averages and standard deviation (error bars) are derived from three
independent replicates. E) Enrichment scores (log10Qvalue, left) and gene names (right)
in the top ten Hallmark gene sets from the Molecular Signatures Database enriched in the
up- and down-regulated genes. F-G) Correlation of all detected genes (F) and intersection
of most differentially expressed (FC>2, FDR<0.01) genes (G) after 24 hours of JQ1
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treatment or BRD2 depletion in GATA1-ER activated cells. P value (p), 95% confidence
interval (CI), and odds ratio (OR) of overlap calculated by Fisher’s Exact Test.
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Figure 3.3. Differential function and expression of BRD2, BRD3 and short and long
isoforms of BRD4 in G1E-ER4 cells. A) Visualization of hemoglobin production
(redness) with or without 48 hours of GATA1-ER activation (+E2) in parental (P) or Brd2null (KO1) G1E-ER4 cells stably expressing the indicated HA-tagged BET proteins after
retroviral transduction. B) Hbb-b1 mRNA levels normalized to Pabpc1 after 24 hours of
GATA1-ER activation. C-D) Competitive growth assay in which %GFP is tracked after
retroviral transduction with bicistronic vector encoding indicated BET protein and GFP
selection marker. Bars indicate consecutive days of GFP percentage measurement from
left to right starting with day 2 (d2) and ending with d8. Starting %GFP has been subtracted
to scale measurements to same axis. E) Western blots of HA-tagged BET protein
expression in whole cell lysates from BRD2 KO cells, representative of similar expression
patterns seen in lysates from parental G1E-ER4 cells. *NS = non-specific bands
associated with HA antibody. F) GFP mRNA levels (indicative of transgene expression)
normalized to Pabpc1. Averages and standard deviation (error bars) are derived from
three independent replicates.
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Figure 3.4. Structure, expression and function of chimeric BET proteins composed
of N- and C-terminal halves of BRD2 and BRD4S. A) Design of chimeric BET proteins
Location of epitope recognized by BRD2 antibody used in (C) is indicated. B) GFP mRNA
levels (indicative of transgene expression) normalized to Pabpc1 after 24 hours of GATA1ER activation (+E2). C) Western blot of HA-tagged BET protein expression in whole cell
lysates from BRD2 KO cells, representative of patterns also observed in lysates from
parental cells. NS = non-specific bands associated with HA antibody. D) Quantitative
western blot comparing protein expression levels of chimeric BET proteins with intact BET
proteins in BRD2 KO1 whole cell lysates, representative of expression patterns in parental
and BRD2 KO2 lysates. ACTB normalized signal plotted below. E-F) Competitive growth
assay in which %GFP is tracked after retroviral transduction with bicistronic vector
encoding indicated BET protein and GFP selection marker. Bars indicate consecutive
days of GFP percentage measurement from left to right starting with day 2 (d2) and ending
with d8. Starting %GFP has been subtracted to scale measurements to same axis. G-H)
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Hbb-b1 and Hba-a1 mRNA levels normalized to Pabpc1 after 24 hours of GATA1-ER
activation. Constructs grouped by expression levels. Averages and standard deviation
(error bars) are derived from at least three independent replicates.
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Figure 3.5. The C-terminal halves of BRD2 and BRD4S distinguish their function. A)
Schematic of YFP-fusion constructs utilized in this experiment. B) Western blot detection
of exogenous YFP-fused BET proteins in whole cell lysates after expression in BRD2 KO1
cells with detection of endogenous BRD2 in parental G1E-ER4 cell for comparison. C)
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Gene expression levels of BRD2-dependent and control genes normalized to Pabpc1 after
24 hours of GATA1-ER activity (+E2). 5’ and 3’ indicate the respective halves of the
mRNAs. Averages and standard deviation (error bars) are derived from three independent
replicates.
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Figure 3.6. Control gene expression and hemoglobin synthesis in BRD2 KO
cells expressing YFP-BET proteins. A) YFP-BET protein levels after iterative cell
sorting measured by flow cytometry. B) Visualization of hemoglobin production
(redness) after 48 hours of GATA1-ER activation.
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Figure 3.7. Identification of a conserved putative coiled coil (CC) domain
adjacent to the ET domain. A) MARCOIL coiled coil prediction across the mouse
BRD2, BRD3, BRD4S and BRD4L amino acid sequences. B) Conservation of the
ET and predicted coiled coil region between BET proteins and across species.
Color coding: blue (hydrophobic), red (positive charge), magenta (negative
charge), green (polar), pink (cysteines), orange (glycines), yellow (prolines), cyan
(aromatic) and white (not conserved).
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Figure 3.8. Validation of TER119 erythroid maturation assay. A) Schematic
depicting TER119 detection after 24 hours of GATA1-ER activation (+E2). B)
Representative flow cytometry data of parental G1E-ER4 cells or BRD2 KO1 cells
expressing an empty YFP vector or YFP-BRD2 with or without 24 hours of GATA1ER activation (+E2). C) Summary data quantifying mean fluorescence intensity
(mfi) of TER119 staining from three independent replicates. D) Scatter plots
depicting relationship between the amount of TER119 surface expression for
indicated cell lines and the amount of mRNA for the indicated erythroid genes upon
24 hours of GATA1-ER activity. R = Pearson coefficient. Averages and standard
deviation (error bars) are derived from three independent replicates.
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Figure 3.9. The ET and CC domains each contribute to BRD2 function. A)
Schematic of BRD2 constructs with the ET and CC domains deleted (middle) and
their resultant protein expression levels (left) and effect on TER119 surface
expression (right) when expressed in three independent BRD2 KO cell clones after
24 hours of GATA1-ER activation. Values are normalized to YFP-BRD2. B-C)
Gene expression levels of control genes (B) and BRD2-dependent genes (C)
normalized to Pabpc1 in cells stably expressing the indicated HA-tagged BET
proteins after 24 hours of GATA1-ER activation. Inset. Western blot of HA-tagged
BET protein levels. D) Competitive growth assay in which %GFP is tracked after
retroviral transduction with bicistronic vector encoding indicated BET protein and
GFP selection marker. Starting %GFP has been subtracted to scale
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measurements to same axis. Averages and standard deviation (error bars) are
derived from three independent replicates.
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Figure 3.10. THE ETCC region functionally distinguishes BRD2 and BRD4S.
A) Schematic of the YFP-BET fusion constructs in which C-terminal regions have
been interchanged. B) Protein expression levels (left) and TER119 surface levels
(right) of YFP-BET constructs after 24 hours of GATA1-ER activation. Values are
normalized to YFP-BRD2. C-D) Expression levels of mRNA normalized to Pabpc1
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after 24 hours of GATA1-ER activity (+E2). Averages and standard deviation (error
bars) are derived from three to four independent replicates.
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Figure 3.11. Protein levels, gene expression, hemoglobinization, and growth
associated with chimeric BET proteins. A-B) Left: western blots of YFP-BET
proteins in G1E-ER4 (P) or BRD2 KO1 lysates. Right: gene expression of BRD2dependent genes (top row) and control genes (bottom row) normalized to
Pabpc1.C) Hemoglobinization of BRD2 KO1 cells with total color signal intensity
averages across two replicates (error bars depict standard deviation). D)
Competitive growth assay in which %GFP is tracked after retroviral transduction
with bicistronic vector encoding indicated HA-tagged BET protein and GFP
selection marker. HA-BRD2-expressing cells have been grouped separately based
on lower protein expresson levels (data not shown). Bars indicate subsequent days
of GFP percentage measurement (days 1, 4, 7, 10, 13).
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Hs6st1
Cd177
Hemgn
Phf24
Tmem29
Csf2rb2
Rdh11
Slc25a13
Zg16
Hecw1
Oscp1
Fam205a1
Esd
Mif
St3gal6
Pdia2
Igflr1
Pla2g4c
Ccdc8
Foxh1
Ncf4
Higd1a
Slc52a3
Ttc41
Zfp939
Hbq1b
Fdft1
Nfe2
Ctsf
Ptrhd1
Tcrg-C1
Zfp599
Kalrn
Fkbp1b
Pctp
Mocs1
Tspo2
Scml2
Ttc12
Tubb1
Slc6a13
Pgk1
Dnajb2
Dlg5
Shmt2
Pcyt1b
Myh7b
Gch1
Rit1
Sult5a1
Gypc
Ston2
Zfp870
Hbb-bs
Arhgdig
Scd2
Slc43a3
Esco2
Ank2
Plekhm3
Galk1
Spi1
Arhgap23
Cyp2c55
Hyal3
Ypel4
Hba-x
Six4
Syne1
Uba7
Arrb1
C2cd4a

Table 3.1. Gene expression analysis of Brd2-null G1E-ER4 cells: down-

regulated genes. Differentially expressed genes in Brd2-null G1E-ER4 cells were
identified based on >2-fold change in expression compared to parental cells after
24 hours of GATA1-ER activation. Genes were only included if identified in both
BRD2 KO1 and KO2 cell lines.
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Genes up-regulated in Brd2-null G1E-ER4 compared to parental cells after 24 hours of
GATA1-ER activation
Abca2
Ier2
Rom1
Map3k14 Ydjc
Pag1
Znrf1
Snx33
Nckap5l
Agrn
Ier3
Pmel
Sept9
Bst2
Cnnm4
Il17rc
Gk5
Pdp1
Akap1
Itgb7
Slc19a1 Cdkl2
Mfsd3
Sfxn3
Fut10
Nbeal2
Zfp69
Akr1b3 Itpr1
Sms
Rfx5
Fastkd3 Fam102a Galnt10
Irf2bpl
Nxpe3
Alox5
Itpr2
Sntb2
Trim3
Cpne3
Tiparp
Mical1
Ccnb1ip1 Gnptab
Slc25a4 Itpr3
Serpinb9 Espn
Slc29a3 Tdrd7
Hexim1
Exd1
Acsl5
Anxa4
Jun
Sptan1
Sept6
Cotl1
Pafah2
Pla2g15
Usp35
Parp14
Aprt
Kcnu1
Srm
Rec8
Zfp661
Acacb
Grhl1
Peak1
Stard9
Rnd2
Khk
Srpk2
Bcam
Lrrc8e
Slc6a8
Gramd1c
Fam199x Fam129c
Cbfb
Kifc2
Stk10
Kcne3
Fgfbp3
Etv5
Ccdc62
Acsf3
Ccnd2 Arhgef2 Stx1a
Extl2
Mblac2
Sbk1
Thnsl1
Pkn3
Entpd6 Lcat
Tac2
Dip2a
Top1mt
Srl
Zfp710
Bahcc1
Plk3
Lgals9
Tep1
Dip2a
Tmem192 Ppcs
Tmem164
Xxylt1
Ctsl
Limk1
Tgif1
Ifi30
Ccdc103 Trip10
Suox
Znf512b
Dlx1
Man2b1 Klf10
Asph
Itpripl1
Tnfaip8
Fam46a
Irf2bp2
Dnmt3b Mfge8
Tle2
Lyrm9
Tubb2b
Osr2
Slc35e3
Maml2
Lefty1
Map4
Tnnc1
Ahnak
Iqce
Frs3
Ccdc92
Mbtps2
Nr2f6
Gadd45b Tnni3
Rnf128
Ppapdc2 Baiap2
Pdxk
Tango6
Fmo5
Myo5a
Tuft1
Bzw2
Pomk
Nabp1
Kctd11
Tmcc3
Fyn
Ncoa3
Ugdh
Pqlc1
Cklf
Fam212b Plekhh3
Ccdc171
Fzd7
Nnt
Xpc
Ptgr1
Exoc6b
Ssc4d
Cdca7l
Bcorl1
Gamt
Nnt
Ikzf2
Fam132a Lhpp
Pygb
Tmem184b Itpkb
Gata2
Oprl1
Zyx
Adck3
Ppp1r18 Ggct
Rnd1
Gchfr
Gata3
P2rx4
Mgll
Retsat
Klhl2
Amhr2
Camk1d
Soga1
Gip
Pdcd4
Spry4
Ppfibp1
Prss36
Nr3c2
Tnks1bp1
Nol4l
Hhex
Pik3r3
Homer2 Prpsap1 Eml4
Kiss1r
Cyb5rl
Adgrl1
Hk2
Prkce
Dlc1
Dynll2
Zfp623
Dok4
Zfp382
Piwil4
Hoxc8 Ppap2a
Galns
Mpzl1
Srd5a1
Tle6
Zfp764
Acad12
Icam1
Pros1
Hgsnat
Gpr155
Nfkbiz
Man2a2 Fhod1
Muc6
Id1
Psen2
Nucb2
Zfp707
Kremen1 Igf2bp1
Klhl36
Nefh

Table 3.2. Gene expression analysis of Brd2-null G1E-ER4 cells: upregulated genes. Differentially expressed genes in Brd2-null G1E-ER4 cells were
identified based on >2-fold change in expression compared to parental cells after
24 hours of GATA1-ER activation. Genes were only included if identified in both
BRD2 KO1 and KO2 cell lines.
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CHAPTER 4: THE COILED COIL CONTRIBUTES TO UNIQUE PROTEIN
INTERACTIONS

Chapter summary

Research described in this chapter is a combination of experiments that will
be included in a pending publication “Comparative structure-function analysis of
bromodomain

and

extraterminal

motif

(BET)

proteins

using

a

gene-

complementation system” and unpublished work. This chapter will include
unpublished chromatin immunoprecipitation (ChIP) sequencing data that was
generated in collaboration with Cheryl Keller and Belinda Giardine in Ross
Hardison’s laboratory at Pennsylvania State University. The analysis of this data
includes comparisons to previously published data generated by Aaron
Stonestrom and additionally analyzed by Sarah Hsu while they were in the Blobel
lab113,131. This chapter also includes proteomic data that will be published in the
above manuscript. Hongxin Wang was critical to the generation of the proteomic
data and subsequent validation experiments. The mass spectrometry data was
conducted in collaboration with Hsin-Yao Tang and Thomas Beer in the
Proteomics and Metabolomics Facility at the Wistar Institute. Perry Evans of the
CHOP Department of Biomedical and Health Informatics assisted with analysis of
this data. Structural characterization of the coiled coil region of BRD2 and BRD3
was performed by Yichen Zhong and Joel Mackay at the University of Sydney.
Experiments examining the interaction between BRD2 and PAF/CK2 in
more detail remain unpublished and will be the basis of future work to determine
the functional significance of these findings.
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Introduction

BET proteins are being investigated as therapeutic targets in a number of
solid and hematological cancers. However, treating these diseases with anti-BET
therapy will require an intimate knowledge of how BET proteins regulate
transcription. A simplistic model for BET protein function begins with the
observation that BET bromodomains form contacts with acetylated lysine residues
on active chromatin. Various chromatin regulators that influence POL2 activity are
then recruited through protein-protein interactions. Because BET inhibitors
typically disrupt the contact between the bromodomains and their acetylated
substrates, the mechanism of action of these drugs is thought to be the
displacement of POL2 regulators from chromatin.
The exact details of this model are more difficult to discern. For example,
though it is appreciated that some BET proteins (particularly BRD2 and BRD4) can
function distinctly in their roles as transcriptional regulators, it remains unclear how
this is achieved mechanistically. One hypothesis is that individual BET proteins
participate in distinct protein interactions. This is supported by immunoprecipitation
experiments demonstrating differential enrichment of protein complexes by each
BET protein. For example, interactions with the negative elongation factor (NELF)
and PTEFb are dominated by BRD4, whereas interactions with casein kinase II
(CK2) and TFIID, a subunit of the POL2 complex, are preferred by BRD2 and
BRD331. With the exception of the contacts made between BRD4 and PTEFb76, a
mechanistic basis for these preferential interactions remains unclear. For example,
CK2 is known to phosphorylate BET proteins at sequences that are well conserved
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across BET proteins85, which would suggest equivalent interaction frequencies,
not protein-specific ones. It is possible that BET proteins possess additional
interaction domains that specify some of these binding events. One potentially
significant domain is the ET domain. This domain has been well established as
protein-protein interaction region. Its crystal structure has been solved and a
consensus binding motif has been identified in many of its validated
substrates66,68,72. These substrates include many known chromatin regulators
such as ATAD5, JMJD6, GLTSCR1, WHSC1L1/NSD3, and NIPBL. Because the
ET domain is approximately 80% conserved across BET proteins, it remains to be
determined whether the remaining variation may confer some of the BET proteinspecific interactions that have been observed.
The interaction between BRD4 and PTEFb (composed of the CDK9 and
CCNT1) is perhaps one of the best studied molecular mechanisms involving BET
proteins. The specificity of PTEFb for BRD4 (and for BRDT in the testis) is
attributed to the CTM domain76. It is thought that BRD4 recruits PTEFb which
phosphorylates POL2 and releases it from its paused state. However, several
observations call into question the specificity and functional significance of this
mechanism. First, though this interaction is strongest for BRD4, BRD2122 and
BRD330 have also been shown to immunoprecipitate with CDK9. This may be
driven in part by the ability of the ET domain76 and the second bromodomain161 to
contribute to the PTEFb interaction. Second, regardless of which BET proteins
recruit PTEFb, rapid depletion of BET proteins inhibits POL2 elongation without
altering PTEFb levels on chromatin111, indicating an elongation role independent
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from PTEFb activity. Accordingly, BET inhibitors and CDK9 inhibitors impact
different subsets of genes112. In fact, in vitro transcriptional assays that do not
include PTEFb components reveal that all BET proteins exhibit histone chaperonelike activity (defined as the ability to facilitate passage of POL2 through
nucleosome templates)40,41. In the case of BRD4, this activity is independent of its
CTM domain. Whether this aspect of BET protein function accounts for all
transcriptional defects associated with BET inhibition remains unclear. It is also
unclear if BET proteins use similar or distinct mechanisms to carry out this activity.
Another hypothesis regarding distinct BET protein functions stems from the
observation that BET proteins can bind to unique regions of the genome. For
example, though there is a large degree of overlap, BRD2 and BRD3 bind more
predominately to gene promoters, whereas BRD4 favors enhancers. The basis for
these patterns is not known, but it is possible that the preference exhibited by
BRD2 and BRD3 for promoters is related to their interactions with the histone
variant H2A.Z57–59. We and others have reported additional BRD2 and BRD3
binding at CTCF sites, where they are thought to cooperate with CTCF to maintain
TAD boundaries131 and regulate enhancer-promoter looping122. Notably, BRD4
occupancy at these sites is minimal. This finding is consistent with previous work
from our laboratory demonstrating that BRD2 and BRD3 exhibit overlapping
functionality that is distinct from BRD4113. It is possible that these critical
differences in genomic occupancy also underpin the unique transcription
signatures apparent upon BRD2 and BRD4 depletion observed in other studies
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and perhaps even the different developmental phenotypes associated with Brd2and Brd4-null mice.
In Chapter 3, we sought to identify the domain that biologically distinguishes
BRD2 and BRD3 from BRD4. We found this domain to encompass the canonical
ET sequence shared by BRD2/3/4 and an adjacent coiled coil found in BRD2/3 but
not BRD4. We termed this BRD2/3-specific region the ETCC domain. In this
chapter, we examine the genomic distributions of YFP-tagged BRD2/3/4S and test
whether the C-terminal halves, either containing or missing the newly defined
ETCC region, control differential BET protein occupancy. Given the proximity to
the ET protein interaction domain, we then examine whether the ETCC mediates
different protein-protein interactions.
YFP-BET proteins share similar genome-wide binding profiles

BET proteins bind to similar regions of the genome – particularly promoters
and enhancers – and largely colocalize genome-wide. However, some exceptions
have been identified. For example, we and others observed BRD2/3-specific
binding at CTCF sites. To determine whether the distinct functions of YFP-tagged
BRD2, BRD3, BRD4S, and the chimeric BRD2/4S constructs are related to these
different binding profiles, we performed chromatin immunoprecipitation followed by
deep sequencing (ChIP sequencing) in the BRD2 KO1 cells expressing the YFPtagged BET proteins. Western blots detecting the levels of YFP-BET fusion
proteins in these cells are in Figure 2.5. Note that the levels of ectopic YFP-BET
protein are roughly similar to the level of endogenous BRD2 found in parental cells,
minimizing the risk of overexpression artifact. We use the YFP moiety shared by
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all of the ectopic BET proteins as the epitope for immunoprecipitation, allowing the
use of the same antibody to enrich chromatin associated with each BET isoform.
These technical considerations minimize biases related to protein expression and
antibody affinity/specificity.
We find strong reproducibility between replicates when assessing ChIP
sequencing signal at gene transcription start sites (TSS) and previously annotated
enhancer elements162 with Pearson correlation coefficients for each pair of
replicates ranging from 0.9036 to 0.9725 at TSSs and from 0.8572 to 0.9349 at
enhancers (Figure 4.1.A, Table 4.1). We therefore used the average of the binned
read counts for each technical replicate in subsequent analyses. We next asked
whether the YFP-tagged BET proteins were differentially bound at GATA1 and
CTCF sites using previously published GATA1 and CTCF peaks in activated
GATA1-ER4 cells113,131. All five YFP-BET proteins were enriched at GATA1 sites,
though the average levels of YFP-BRD4S and BRD2-4S were slightly lower than
those of YFP-BRD2, BRD3, and BRD4-2 (Figure 4.1B). Surprisingly, none of the
YFP-BET proteins were enriched at CTCF sites (Figure 4.1B). Because we had
previously observed colocalization of BRD2 and CTCF131, we repeated
endogenous BRD2 ChIP sequencing in G1E-ER4 cells. We observed strong BRD2
signal overall but found no BRD2 occupancy at CTCF sites (Marit Vermunt,
personal communication [data not shown]). This discrepancy could be due to
technical differences between the studies. For example, the previous BRD2
antibody manufacturer lot number was unavailable for the second study. To rule
out off-target binding for the new BRD2 antibody lot, antibody specificity was
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confirmed by ChIP sequencing in BRD2 knockout controls (Marit Vermunt,
personal communication [data not shown]). These data indicate that global
differences in BET protein binding at GATA1 or CTCF do not likely mediate the
differential activities of the YFP-tagged BET proteins.
To focus on differentiation-associated binding events, we next performed
our chromatin occupancy analysis on peaks that are gained or lost peaks upon
GATA1-ER activation. We hypothesized that changes in YFP-BRD2 binding would
be mimicked by YFP-tagged BRD3 and BRD4-2, which have BRD2-like activity,
but not by BRD4S or BRD2-4S. We thus centered our analysis on YFP-BRD2
peaks. We identified 4,218 YFP-BRD2 binding sites that are lost and 3,080 that
are gained upon GATA1-ER activation and measured the average levels of the
YFP-BET proteins across these sites. Before GATA1-ER activation, YFP-tagged
BRD3 and BRD2-4S levels are similar to those of BRD2 at both lost and gained
sites, whereas levels of BRD4S and BRD4-2 are slightly lower, indicating that
BRD3 largely mimics BRD2 and that differences in BRD2 and BRD4S levels are
determined by the bromodomain-containing halves of these proteins (Figure
4.1.C). Though these differences are maintained upon GATA1-ER activation, all
of the YFP-BET proteins follow the same pattern as YFP-BRD2 at sites that are
gained and lost. Together, these binding profiles suggest that though there may
be subtle binding differences determined by the bromodomain-containing halves
of these proteins, extrinsic factors that affect BET protein recruitment – likely
histone acetylation – appear to be affecting all of the YFP-BET proteins equally.
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However, careful interpretation requires additional testing to determine if histone
acetylation patterns differ across the cell lines.
To better understand the changes in occupancy that occur upon GATA1
induction, we identified gained and lost sites for each YFP-BET protein and
classified each region by genomic position (intronic, transcription start/termination
site [TSS/TTS], etc). This revealed that GATA1-ER activation results in an overall
redistribution of each YFP-BET protein towards TSS regions (Figure 4.1.D). For
example, TSS regions comprise only ~6% of sites lost by YFP-BRD2 but make up
over 30% of the gained sites, whereas the intergenic regions comprise ~50% of
lost sites and only ~16% of the gained sites indicating a general shift of YFP-BRD2
away from intergenic regions toward TSS regions. This dynamic is true for the
other YFP-BET proteins, though the enrichment at TSS upon GATA1-ER
activation is less apparent for YFP-BRD2-4S. To highlight the overall similarity of
the chromatin occupancy profiles of each YFP-BET protein, a genome browser
view of the Csf2rb locus is presented as Figure 4.1.E. The adjacent Csf2rb and
Csf2rb2 genes were chosen as BRD2-dependent genes in the mRNA expression
studies from Chapter 3. The genome browser view shows enrichment of all five
YFP-BET protein at the intergenic Csf2rb region upon GATA1-ER activation, with
levels of YFP-BET fairly similar and constant at the adjacent loci. In summary, our
global analysis of the genomic distributions of the YFP-BET proteins reveals
markedly similar binding at both stable and differentiation-associated loci.
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Identification of genomic sites differentially bound by YFP-BET proteins

Because our previous analyses did not identify clear differences in YFPBET binding patterns, we next looked specifically for regions that were occupied
by the BRD2-like BET proteins YFP-BRD2/3/4-2 but not by YFP-BRD4S/2-4S. Out
of 23,717 consensus regions prior to GATA1-ER activation, there were only 641
sites that were preferentially bound by YFP-BRD2/3/4-2 (FDR<0.05) and 194 sites
that were preferentially bound by YFP-BRD4S/2-4S (FDR<0.05) (Figure 4.2.A,
left). Likewise, out of 19,921 consensus regions after GATA1-ER activation, 1,207
were preferentially bound by YFP-BRD2/3/4-2 and only 6 were preferentially
bound by YFP-BRD4S/2-4S (Figure 4.2.A, right). These numbers indicate that the
vast majority of YFP-BET binding sites are shared by all five YFP-BET proteins,
which is consistent with our previous analyses. Differentially bound loci
exemplifying each condition, respectively, include the Dock2, Csmd3 and Txlnb
loci (Figure 4.2.B). The specificity of the differentially binding of YFP-BET proteins
at these sites in contrast to most other regions is highlighted by the relatively similar
levels of YFP-BET at the Spdl1 TSS adjacent to the differentially bound Dock2
TSS. Given that BET proteins are known to facilitate transcription factor
recruitment, we hypothesized that the differential binding of YFP-BET proteins to
this small percentage of regions may be due to the presence of transcription
factors unique to each subset of sites. We therefore assessed these regions for
transcription factor binding motifs. Interestingly, prior to GATA1-ER activation the
YFP-BRD2/3/4-2-specific peaks are enriched most predominantly for the ETS
factor motif whereas the YFP-BRD4S/2-4S-specific peaks are enriched only for
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the GATA factor motif (Figure 4.2.C, left and middle). These findings are consistent
with the role of ETS factors Fli1 and GABPa and GATA factors GATA1 and GATA2
in erythroid cell development and function163. Thus, individual BET proteins may
associate with these factors separately at some regulatory regions and these
interactions may be driven at least in part by the C-terminal halves of BET proteins.
After GATA1-ER activation, YFP-BRD2/3/4-2-specific peaks are enriched for
several GC-rich motifs (Figure 4.2.C, right). Of note, only the top five of these
motifs are shown, though 25 of these GC-rich sequences meet statistical
significance (not shown). Each of these GC-rich motifs comprises only a small
number of sites but collectively account for a more substantial proportion of the
YFP-BRD2/3/4-2-specific peaks. No consensus motifs were enriched in the YFPBRD4S/2-4S-specific peaks after GATA1-ER activation, perhaps due to the small
number of peaks detected. In summary, only a small number of YFP-BET peaks
are bound preferentially by either the BRD2-like YFP-BRD2/3/4-2 proteins or the
YFP-BRD4S/2-4S proteins. Of this small fraction, the BRD2-like proteins may be
binding preferentially at ETS-factor binding sites whereas the YFP-BET proteins
lacking BRD2-like activity may be binding at GATA1/2 binding sites prior to
differentiation.
The BRD2 and BRD3 CC domains are helical modules that do not dimerize

Our comparative YFP-BET chromatin occupancy data is consistent with
many other studies that demonstrate strongly overlapping binding profiles of
endogenous BET proteins55,63,96,102,114,117,118,129,160. We therefore hypothesized that
the ETCC domain, which we previously showed to control BRD2/3-like activity,
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may instead facilitate novel protein-protein interactions. We first characterized the
structural features of the CC domain to determine whether it possesses helical
structure or facilitates homo- or heterodimerization properties as seen with other
coiled coils, including motif B35. To assess the structure of human BRD2-CC (715757) and human BRD3-CC (641-688), we expressed and purified these regions
and recorded far-UV circular dichroism (CD) spectra of each protein (Figure 4.3.A).
The spectra show minima at 222 nm, indicative of the presence of some helical
structure. Raussens’ method estimates that each of the two peptides contains
~33% helical structure (http://perry.freeshell.org/raussens.html). Because coiled
coils often form dimers159, we assessed whether either the BRD2-CC or BRD3-CC
domains can form a homomeric coiled coil using size-exclusion chromatography
coupled to multiangle laser light scattering (MALLS). As shown in Figure 4.3.A,
both peptides run with molecular weights that are close to the monomeric weights
(5.3 kDa and 7.3 kDa, respectively), indicating that they do not significantly selfassociate in solution at a concentration of ~100 µM (accounting for dilution on the
column). We also assessed the ability of the peptides to associate with each other
using the same approach, but again no significant self-association was observed.
We conclude that if these sequences form coiled coils, then they must do this by
partnering with other proteins.
The ETCC region binds to the PAF and CK2 complexes

To identify partner proteins, we generated GST-fusion proteins and
exposed them to nuclear extracts from MEL cells (see Chapter 2: Materials and
Methods; Figure 4.4.A). We included the mB region, which is also a putative coiled
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coil. We also included two different sets of mutations in the CC predicted to
abrogate coiled structure (CCp and CCd). Given that the ET domain is a known
protein interaction domain and that the adjacent CC domain functions
cooperatively with the ET domain in the domain-mapping studies, we included
GST fusion proteins comprised of the ET domain alone or attached to the adjacent
CC (its native context) for comparison. Each sample was compared to a GST-only
control to determine signal above background. Mass spectrometry (see “Chapter
2: Materials and Methods”) revealed enrichment of a total of 392 proteins (log2ratio
> 1 over GST alone at FDR < 0.0001, Table 4.1). Several known BET binding
partners were among these, validating our approach. For example, ATAD5, CHD8,
SMARCA4/BRG1, WHSC1/NSD2, WHSC1L1/NSD3, and CDK9)64–66,71,76 were
enriched significantly by both the ET and ETCC domains (Figure 4.4.B). Likewise,
NIPBL, which has recently been shown to interact with the ET domain of BRD473,74,
was also enriched in these samples. Two other previously reported ET-mediated
interactions, CHD464,71 and CCNT176, did not meet the thresholds set in our
analysis but were nonetheless enriched in the ET and ETCC samples. Likewise,
mB interaction partner LYAR83,84 was elevated specifically in the mB sample. The
392 enriched proteins were distributed in the samples as follows: ET (165), ETCC
(179), mB (232), CC (0), CCp (2), and CCd (8). These data suggest that the CC
does not engage in protein interactions on its own (Table 4.1, Figure 4.4.B).
To identify the proteins that associate most strongly with the GST-fusion
proteins, we increased the threshold to log2ratio > 1.5. This identified interactions
that had not been previously reported. For example, the ET domain associated
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most strongly with AHNAK, AHNAK2, CBX4, ZMYND8 and ZNF592. Interestingly,
when combined with the CC domain, ETCC associated with several additional
proteins, including all five members of the RNA polymerase II-associated factor
(PAF) complex (PAF1, LEO1, CTR9, CDC73, WDR61) as well as the PAFassociated protein IWS1 (Figure 4.4.C, 4.4.D), which are involved in transcriptional
elongation130,164,165. The ETCC domain also enriched all three members
(CSNK2A1, CSNK2A2 and CSNK2B) of casein kinase II (CK2), which like PAF,
has been shown to occupy active chromatin166, associate with elongation
factors167, and contribute to POL2 regulation168. The CK2 complex also interacted
with mB (Figure 4.4.B). Of note, CK2 has been shown to phosphorylate BRD4 at
conserved region that partially overlaps with the mB sequence85, potentially
accounting for its association with BRD2 mB in this assay.
Western blots with antibodies against components of the PAF and CK2
complexes confirmed association with GST-ETCC but less so or not at all with
GST-ET or GST-CC (Figure 4.4.E). The ETCC-mediated interactions with PAF and
CK2 were also observed when using the ETCC regions from BRD3 and BRDT, but
not their ET domains alone (Figure 4.4.F). These results suggest that the BRD2
and BRD3 CC domains augment the ability of the ET domains to engage in specific
protein contacts.
Binding patterns of PAF and CK2 on chromatin

The ETCC domain does not appear to alter BET protein binding but may
facilitate PAF and CK2 recruitment to chromatin. To assess the feasibility of this
mechanism, we measured the genome-wide distributions of the PAF complex
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member LEO1 and the CK2 member CSNK2A1 in parental G1E-ER4 cells using
ChIP sequencing and compared them to the distributions of YFP-BRD2. We limited
our comparison of PAF and CK2 occupancy to that of YFP-BRD2 as the other
YFP-BET proteins strongly resemble YFP-BRD2. Technical replicates for
CSNK2A1 were highly correlated (Figure 4.5.A). The replicates for LEO1 were also
correlated but to a lesser degree, likely due to the use of different chromatin
fragmentation methods (see “Chapter 2: Materials and Methods” for details). Thus,
in the following analysis, the CSNK2A1 signal from each replicate was merged,
whereas for LEO1 each replicate was analyzed separately.
We first assessed the overall binding of CSNK2A1 and LEO1 to various
genomic positions to see if either resembled the overall distribution of YFP-BRD2.
The distribution of CSNK2A1 more closely resembled that of YFP-BRD2 with
>20% of peaks mapping to TSS regions, whereas both LEO1 samples had lower
enrichment at TSS regions and greater enrichment at TTS and 3’ UTR regions
(Figure 4.5.B). The distribution of LEO1 is consistent with the chromatin
distributions of other PAF members130 and with PAF involvement in the elongating
POL2 complex as it travels through genes164. To visualize these differences in
more detail, we generated heatmaps and meta-profiles for each factor across
genes. This reveals an accumulation of YFP-BRD2 and CSNK2A1 proximal to the
TSS with some extension into the gene bodies (Figure 4.5.C). This distribution of
CSNK2A1 is consistent with that of a previous study implicating CK2 directly in
transcriptional elongation168. In contrast, LEO1 is most notably found in gene
bodies toward the end of genes and in the 3’ UTR region downstream of the TTS.
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Of note, the different profiles of LEO1_r1 and LEO1_r2, particular near the TSS,
are consistent with previous reports of LEO1 occupancy using the different
fragmentation methods used to prepare these samples. Sonication-based
methods (as used for LEO1_r1) yield stronger LEO1 signal near the TSS130,169,
whereas enzyme-based methods (using endo/exo-nucleases, as used for
LEO1_r2) yield a relative absence of LEO1 at the TSS170. This may be due to
digestion of nucleosome-depleted chromatin at the TSS using enzymatic
fragmentation. Though the distributions may differ, the cumulative intensity of each
factor (both LEO1 replicates, CSNK2A1, and YFP-BRD2) over these regions is
positively correlated suggesting co-involvement in gene transcription. The similar
distributions of CSNK2A1 and YFP-BRD2 on chromatin support the notion of a
stable interaction in vivo, though it can’t be ruled out that these factors are recruited
independently to genes. The different patterns of YFP-BRD2 and LEO1 suggest
that any bona fide interaction may occur transiently or perhaps before both factors
assemble on chromatin.
Because CK2 colocalizes with BET proteins on chromatin and has also
been shown to phosphorylate PAF, we hypothesized that phosphorylation may at
least partially regulate the stability of the ETCC domain bound to PAF. We
therefore repeated GST-ETCC pulldown assays using nuclear extracts generated
from parental G1E-ER4 cells in the presence of phosphatase inhibitors, which
preserve the overall phosphorylated state of the protein lysate. Strikingly, addition
of phosphatase inhibitors dramatically hindered the interaction between the ETCC
domain and all five members of the PAF complex (Figure 4.5.D). This finding
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suggests that CK2, or perhaps one of the other promoter-proximal kinase, may
regulate the affinity of the BRD2/3-PAF interaction on chromatin via
phosphorylation. This mechanism may account for the reduced TSS-proximal
localization of LEO1 on chromatin. Based on our findings, we propose a model by
which BRD2/3 contributes to transcriptional regulation distinctly from BRD4 (Figure
4.5.E). We speculate that BRD2/3 functions to recruit PAF to the TSS and that
subsequent phosphorylation of the PAF complex by CK2 causes its disassociation
from BRD2/3 into the elongating POL2 complex, allowing transcription to proceed.
Discussion

BET proteins are transcriptional regulators that share a conserved domain
structure. In the previous chapter, we found that despite this shared structure,
BRD2 and BRD3 contribute to transcription independently of BRD4. We traced this
unique BRD2/3 function to the ETCC region, which BRD4 lacks. In this chapter,
we explored whether the ETCC region may affect BRD2/3 function by influencing
where BRD2 and BRD3 bind the genome in comparison to BRD4S. Surprisingly,
we found this not to be the case. All three BET proteins bind the genome at GATA1
sites but not CTCF sites and undergo similar changes in occupancy upon erythroid
differentiation. Though BRD4S signal is lower at these sites, exchanging the
bromodomain-containing segment with that of BRD2, but not the ET/ETCCcontaining segment, restores binding to BRD2 levels during erythroid maturation.
Together, these data indicate that distinct BET protein functions are not related to
differences in genomic localization. Instead, we found that the ETCC domain forms
contacts with the PAF and CK2 complexes, both of which have been implicated in
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transcription. Though PAF and CK2 colocalize with BET proteins at promoters, the
majority of PAF is found over gene bodies and its interaction with the ETCC domain
is phosphorylation-dependent, suggesting that it may transiently engage with
BRD2/3 in a regulated manner. In summary, we conclude that the ETCC region
functionally distinguishes BRD2/3 from BRD4 via the recruitment of distinct partner
proteins that regulate transcription.
The lack of colocalization between BRD2 and CTCF in this study is not
consistent with our previous observation131. Technical differences may have
contributed to the discrepancy. For example, our current study used MNase
digestion rather than sonication to fragment DNA and used an antibody targeting
ectopically expressed YFP-BRD2 instead of endogenous BRD2. These
parameters were chosen after several rounds of optimization to yield strong and
reproducible ChIP signal. It is conceivable that MNase preferentially degrades
CTCF-associated DNA (though unlikely based on preliminary experiments).
Likewise, it is possible that the YFP epitope blocks BRD2 binding at CTCF sites.
However, more elusive technical differences are likely to blame, as we were unable
to re-demonstrate endogenous BRD2 binding at CTCF sites using sonicationbased fragmentation and a newer lot number of the initial BRD2 antibody. It is
important to note that several other studies have observed some degree of BRD2CTCF colocalization122,129. However, these experiments were performed using the
same BRD2 antibody and were published in the same time frame as our previous
study, suggesting that this finding may be specific to a particular batch of the BRD2
antibody. Several BRD2 ChIP sequencing studies have been published in the
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meantime using various antibodies and experimental approaches56,102,110,118,171.
Future studies should perform CTCF ChIP sequencing in these models to
thoroughly address the robustness of the overlap between BRD2 and CTCF
across experimental systems and approaches.
Several studies have reported the distributions of BRD2, BRD3, and BRD4
on chromatin63,96,102,110,114,117,118,129,160,171. These studies use antibodies targeting
the endogenous BET proteins. Therefore, the signal intensity is dependent on the
amount of protein expression and the affinity of the antibody. These biological and
technical differences may account for the partially different binding patterns when
comparing BRD2, BRD3, and BRD4. Our study overcomes these limitations by
using a tightly controlled ectopic system in which each BET protein is expressed
at levels comparable to endogenous BRD2 and shares the same epitope tag for
immunoprecipitation. Using this approach, we report strikingly similar genomic
binding profiles of BRD2, BRD3, and BRD4S. This indicates that when BET
proteins are expressed at equal levels and immunoprecipitated with the same
antibody, they yield nearly identical chromatin binding patterns. This finding has
several implications. First, differences in the affinities of the BET protein
bromodomains for various acetylated substrates are unlikely to drive global
differences in BET protein localization. Second, differences in BET protein function
observed by us and others are not likely due to differential binding. Instead, BET
proteins appear to co-congregate at highly acetylated chromatin near promoters
and enhancers after which they then exert their unique influences on transcription.
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Our study used BRD4S rather than BRD4L for our comparisons to BRD2
and BRD3 because BRD4S structurally resembles these proteins in size.
Therefore, our YFP-BRD4S ChIP sequencing data may not be representative of
BRD4L, which is the dominant isoform expressed in G1E-ER4 cells and the
isoform assayed in virtually all previously published BRD4 ChIP sequencing
studies. Because previous studies suggest that BRD2 prefers promoters and
BRD4L prefer enhancers, future studies should test whether this holds true when
BRD2 and BRD4L are expressed at equal levels and precipitated with the same
antibody. If so, our data would suggest that these predilections for genomic regions
are driven not by bromodomain interactions but by protein-protein associations
mediated by the C-terminal domains. In particular, BRD2 may associate more
tightly with PAF and/or CK2 at promoters, whereas BRD4L may associate
preferentially with PTEFb at more distal elements67,172. Future studies should also
address how the ratio of BRD4S to BRD4L is regulated, as BRD4S appears to be
the dominant isoform in some cell types70, and whether this stoichiometry has an
effect on transcription.
To investigate how the ETCC domain contributes to BRD2/3-selective
function, we identified partner proteins using a proteomic approach. This revealed
PAF and CK2 as the dominate ETCC-specific interactions. Because BRD4 does
not possess the ET-proximal CC, BRD4 is not predicted to interact with PAF and
CK2 by this mechanism. However, CK2 is known to phosphorylate BET proteinsat
a conserved serine-rich region that partially overlaps with the mB segment used in
this study85. Thus, mB-mediated enrichment of CK2 (Figure 4.4.B) likely relates to
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this enzyme-substrate binding event and applies to BRD2, BRD3, and BRD4
equally. It is plausible that CK2 phosphorylates serine-rich regions in the ETCC
domain of BRD2 and BRD3 in a similar manner, but this is unlikely given that
neither the ET nor CC domains alone enrich CK2 and no predicted CK2 substrates
span the ET-CC junction (NetPhos 3.1). Thus, whereas CK2 may engage BRD2
and BRD3 via multiple contacts, it likely only binds BRD4 via phosphorylation near
the mB region. This is supported by immunoprecipitation data which revealed CK2
is more highly enriched with the CC-containing BRD2/3/T proteins compared to
BRD4, and that these interactions are enhanced upon bromodomain inhibition,
indicating that they are mediated by C-terminal protein-interaction domains such
the ETCC rather than by the bromodomains31. Future studies should address
which subunit of CK2 directly contacts the ETCC and whether it does so in a
manner similar to PAF.
Like CK2, PAF has been found in previous BET protein interaction
studies30,71, but it is notably absent in others31. These differences may be due to
biological and technical variability between studies and the relatively weak nature
of the interaction. For example, immunoprecipitation-based studies are limited by
protein abundance, antibody quality, and protein extraction conditions. Even under
ideal conditions, such as our GST pulldown assay in which large amounts of bait
protein encompassing the interaction surface are used, we find the PAF
association to be subject to the presence or absence of phosphatase inhibitors in
solution. We also find that in vivo crosslinking (ChIP sequencing) only captures a
minority of PAF co-localized with BET proteins on chromatin. Together, these
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observations suggest that the BRD2-PAF interaction is transient and highly
regulated by phosphorylation and/or other post-translational modifications.
Future studies should confirm that full-length BRD2 and BRD3, but not
BRD4, use the ETCC domain to associate with PAF and CK2. Based on the
limitations of immunoprecipitation described above, approaches that use highly
expressed or purified proteins, such as baculovirus-insect cell expression or in vitro
transcription/translation, should be leveraged for this line of investigation. Once the
individual partner proteins are identified from these multi-unit complexes, structural
studies will be required to fully elucidate the details by which the ETCC binds to
PAF and CK2. The role of phosphorylation in regulating the strength of these
interaction must be considered through the use of phosphatase inhibitors and
exogenous phosphatase. Ultimately, the exact residues that are phosphorylated
and the kinases and phosphatases implicated in this regulatory mechanism should
be identified and their role in transcription described.
In addition to identifying PAF and CK2 as ETCC-specific interactions, we
also identified ZMYND8 as the strongest ET-only interaction. ZMYND8 has been
shown to form a highly abundant trimeric complex with ZNF592 and ZNF687 (Z3
complex)173,174, both of which were also present in our proteomic data (though not
as highly enriched). Previous studies have shown ZMYND8 to associate with BET
proteins, including the BRD4-NUT fusion protein30,31,92. As in our study, this
interaction appears to occur via the ET domain31. Interestingly, ZMYND8 can function
both as a transcriptional activator and as repressor, depending on whether it is in its
monomeric or dimeric state175. In its dimeric state, ZMYND8 interacts with PTEFb
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whereas as a monomer ZMYND8 interacts with the CHD4 component of the nucleosome
remodeling and deacetylase (NuRD) complex175,176, both of which also associate with

the ET domain. Further investigation into the role of the ET domain in mediating the
various conformations of ZMYND8 and the impact of this on transcription is required. A

direct fusion between BRD4 and ZNF592 (a component of the Z3 complex with
ZMYND8) mimics BRD4-NUT in the molecular pathogenesis of NUT midline
carcinoma177 indicating that the Z3 complex may be a major mediator of BET
protein function. In addition to transcription, ZMYND8 may also coordinate with
BET proteins and NuRD to facilitate double-strand break (DSB) repair127,178,179.
These data support a multifunctional role for BET proteins via the recruitment of
diverse chromatin regulators.
The presence or absence of the CC domain may influence the strength of
ET-mediated

interactions

with

other

protein

complexes.

For

example,

ZMYND8/ZNF592, TBLX1, and AHNAK/AHNAK2 are strong ET-only interactions,
but their signal is reduced when the CC is included in the ETCC sample. In
contrast, PAF and CK2 proteins are more enriched in the ETCC sample compared
to the ET-only sample (Figure 4.4.B/C). As mentioned above, ZMYND8 and
ZNF592 are components of the Z3 complex. TBL1X is a component of the nuclear
receptor co-repressor (NCoR) complex180. Several other NCoR members
(TBL1X1R1, NCOR1, NCOR2, HDAC2, and HDAC3) are enriched in the ET
sample (Table 4.1). Together, these data suggest that whereas PAF and CK2
preferentially associate with BRD2 and BRD3, Z3 and NCoR may preferentially
bind to BRD4 which lacks the CC. This differential recruitment of transcriptional
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regulators may have functional consequences. For example, preferential
recruitment of NCoR, a repressive complex, may explain the growth restriction and
reduced gene expression observed when BRD4S is over-expressed in G1E-ER4
cells. The ETCC module may therefore control the major transcriptional
mechanisms directed by each BET protein.
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Figure 4.1. YFP-BET proteins bind to similar regions of the genome. A) Left:

Representative scatter plot comparing chromatin binding signal at transcription
start sites (500 bp windows) between two technical replicates with the Pearson
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correlation coefficient indicated. Right: Summary table of all of the Pearson
correlation coefficients at transcription start sites and annotated enhancers
between technical replicates. B) Average YFP-BET chromatin binding signal
across 2kb regions spanning all CTCF and GATA1 binding sites113,131. C) YFPBET binding at 2kb regions spanning YFP-BRD2 binding sites that are gained or
lost upon GATA1-ER activation. D) Percent/frequency of gained or lost binding
sites upon GATA1-ER activation for each YFP-BET protein categorized based on
proximity to known genes. E) Genome browser view of the Csf2rb locus,
representing a region all YFP-BET proteins are recruited upon GATA1-ER
activation despite some (YFP-BRD2/3/4-2) having more activity than others in the
expression of the Csf2rb and Csf2rb2 genes.
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Figure 4.2. Identification of differential YFP-BET binding sites. A) Volcano plots

depicting the mean YFP-BET binding signal for YFP-BRD2/3/4-2 in comparison to
YFP-BRD4S/2-4S before or after 24 hours of GATA1-ER activation (+/- E2). Each
dot represents a differentially bound peak. Red dots are differentially bound peaks
at an FDR ≤ 0.05. The number of such peaks is indicated. B) Genome browser
views of representative differentially bound peaks. The peaks of interest are in a
dashed box. C) Top 5 de novo motif analysis results with motif logos, best matched
transcription factors and P-values indicated of the indicated sets of differentially
bound peaks in comparison to all identified peaks.
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Figure 4.3. The CC has helical structure but does not homo- or hetero-dimerize in solution.
A) Far-UV circular dichroism spectra of hBRD2-CC (20 µM) and hBRD3 (45 µM). Spectra were
obtained in 10 mM Tris pH 7.2, 100 mM NaCl and 1 mM TCEP at 4 ºC. B) SEC-MALLS data
showing that hBRD2 and hBRD3 CC regions are monomers in solution. hBRD2 CC, hBRD3 CC or
an equimolar mixture of the two proteins (total protein concentration = 700 µM in each case) was
injected onto a Superdex 75 10/300 GL (for hBRD2 CC and h BRD3 CC) or Superdex peptide
10/300 GL (for the hBRD2+hBRD3 CC mixture). The calculated molecular weight is shown together
with an estimate of the standard deviation.
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Figure 4.4. The combined ETCC module binds to the RNA polymerase IIassociated factor (PAF) and casein kinase 2 (CK2) complexes. A)
Experimental schematic of GST pulldown assay. B) Volcano plots depicting
enrichment of bait proteins in each sample in comparison to GST alone controls.
Prey proteins that exceed a log2ratio of 1.5 and -log10Qvalue of 4 (dashed lines)
are labeled in red. Blue and green dots represent proteins known to interact with
the ET domain (blue) or mB domain (green) as described in the text. C) Volcano
plot comparing prey proteins enriched by the ET domain alone or the combined
ETCC. Prey proteins exceeding log2ratio of 1.2 and -log10Qvalue of 4 are labeled
in blue if higher in the ET sample and red if higher in the ETCC sample. Members
of the PAF complex are colored green and members of CK2 are colored purple.
D) Protein interactions (from STRING) of ETCC-high proteins. Purple lines indicate
experimental determined protein interactions. Blue lines indicate interactions from
curated databases. E) Western blot validation of PAF and CK2 complex members.
F) Western blot validation of PAF and CK2 interactions with the ETCC domains
from BRD3 and BRDT.
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Figure 4.5. Comparison of YFP-BRD2, CK2 and PAF localization across the
genome. A) Scatter plot comparing technical replicates of CSNK2A1 and LEO1
chromatin occupancy consensus peaks for each factor labeled with Pearson
coefficients and p values for the correlation. See text for technical differences
between replicates LEO1_r1 and LEO1_r2. B) Percent/frequency of binding sites
for YFP-BRD2, CSNK2A1 and each LEO1 replicate categorized based on
proximity to known genes. C) Meta-profiles and heatmap matrix illustrating
average and individual chromatin binding distributions of YFP-BRD2, CSNK2A1
and LEO1 across all known genes including the flanking 3kb regions. Gene lengths
are normalized to 100 bins. D) Western blot detection of PAF members pulled
down by GST-ETCC with or without the presence of phosphatase inhibitors. ACTB
and GST are included as a negative and positive pulldown controls. E) A
speculative model of BRD2/3-based transcription based on the data presented in
this dissertation.
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Prey proteins detected by each GST-fusion bait protein
ET
ETCC
Myb
Rpl35a
Phf8
Tceb1
Rpl6
Grwd1
Prrc2c
Cbx4
Ppp1r10 Xrn1
Rplp1
Mphosph10
Ints3
Hdac3
Med23
Lims1
Rpl5
Smndc1
Lims1
Rpl7
Cwf19l2
Rpl23a
Rpl13
Cggbp1
Hdac2
Srp54
Tbl1xr1
Wdr61
Rpl26
Gltscr2
Polr2a
Rpl13a
Znf592
Rpl19
Rpl27
Rcc2
Smarca4 Hspa5
Mtbp
Zmym4
Rpl37a
Rpl24
Med25
Tln1
Rcc2
Mllt3
Rps7
Rsl1d1
Wdr61
Pik3r1
Ticrr
Mrto4
Rps8
Iws1
Gpatch8 Pura
Lrch3
Tpx2
Rps14
Rbm14
Cdc27
Cct8
Chd9
Ythdc2
Rps23
Utp15
Med14
Hist1h1e Anapc2
Actb
Rps11
Tceb3
Mllt3
Rpl6
Med19
Rbm34
Rps13
Rbm28
Tpx2
Rplp1
Tbl3
Llph
Rps4x
Gnl3
Raly
Rfx1
Bcor
Aff3
Rpl18a
Kdm1b
Mga
Cit
Ago1
Whsc1
Rps6
Cdc73
Actb
Anapc1
Cdc73
Bre
Tceb2
N4bp2l2
Twistnb Wdr5
Bclaf1
Mki67
Rpl31
Polr1e
Kif7
Ybx1
Taf10
Rplp0
Rpl32
Pop1
Cep57
Rps27a
Pop1
Nolc1
Rpl8
Pacs1
Mbd3
Ywhah
Paf1
Kif23
Ybx1
Paf1
Anapc7
Erh
Mepce
Rnf169
Actg1
Mepce
Aff3
Smarcc1 Tada3
Ankrd17
Rps17
Ccdc137
Thoc6
Hnrnpul2 Luzp1
Ddx55
Csnk2b
Nop14
Whsc1
Prpf4
Nol6
Rpl15
Erh
Luzp1
Urb1
Larp7
Taf9
Inf2
Bop1
Nol6
Mki67
Tfdp1
Traip
Nop2
Rplp2
Imp4
Gm8730 Chd8
Med28
Rpl29
Sap30bp Traip
Kif14
Vrk3
Smc6
Rps18
Larp7
Ddx1
Ankrd11 Rfc3
Med1
Taf5
Eif5b
Znf622
Kif23
Gtf3c3
Cdk9
Ddx24
Ect2
Taf5l
Ahnak
Zmynd8
Med24
Zc3h18
Chd8
Arrb2
Ercc2
Mta3
Yaf2
Rpf2
Gpatch4
Ppan
Rnf169
Rfc4
Med30
Tcof1
Mybbp1a Ddx27
Ddx55
Lsg1
Rnf2
Rpl10
Utp18
Prpf3
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Hjurp
Gatad2a
Med16
Rpl29
Ahnak2
Pcnt
Taf5
Ncor2
Ddx24
Ppp2r1b
Brf1
Rnf219
Rpf2
Tcof1
Opa1
Dnmt1
Hdac1
Rpl21
Pold2
Slk

Eef1g
Atad5
Actl6a
Orc2
Thrap3
Ttf2
Kat7
Leo1
Setd5
Pml
Rbbp4
Rbbp7
Hcfc1
Smarcd1
Taf6
Zcchc2
Arhgap21
Nipbl
Whsc1l1
Tubb2a

Med31
Mau2
Haus5
Ccdc101
Ftsj3
Ipo7
Mllt1
Aff4
Hic2
Tbl1x
Exo1
Med20
Prpf40a
Racgap1
Nup160
Adnp
Ik
Orc1
Mbd3
Mbd2

Dnmt1
Rpl21
Dhx15
Csnk2a2
Eif6
Rpl35a
Cbx4
Ncl
Rpl7a
Dnmt1
Rpl27a
Rpl7
Rplp0
Hist1h1c
Rpl13a
Rps2
Tln1
Rpl3
Pabpc1
Rpl12
Chd1
Rpl28
Pura
Hist1h1e
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Rrp12
Sf3b2
Lsg1
Rpl4
Nufip2
Npm1
Leo1
Rpl10a
Csnk2a1
Khdrbs1
Kpna1
Ctr9
Top2b
Zcchc2
FAM120A
Nop58
Ddx31
Bms1
Rps9
Rpl36
Rpl17
Cd3eap
Ppp1r10
Clspn

Cdk9
Gnl2
Mmtag2
Gtpbp4
Npm3
Nop16
Rpl14
Hnrnpa0
Med31
Rpl11
Rpl34
Mau2
Ebna1bp2
Pelp1
Ftsj3
Brix1
Mllt1
Aff4
Tmod3
Utp3
Rcl1
Exo1
Racgap1
Mbd2

Prey proteins detected by each GST-fusion bait protein
(continued)
mB
CCd
CCp
Msh3
Pnn
Rps10
Rbm28
Gpatch8 Mov10
Dhx30
Bysl
Ppp2ca
Sltm
Hnrnpl
Abcf1
Rbpj
Csnk2a2 Csnk2b
Gnl3
Actg1
Rpl23a
Smarce1 Polr1b
N4bp2l2
Ywhah
Wdr61
Eif6
Rpl36a
Polr1e
Khdrbs1
Rpl19
Rpl35a
Erh
Pop1
Cyfip1
Gemin5 Gtf2h4
Polr1d
Nat10
Rbm14
Mrto4
Ncl
Rps3a1
Paf1
Ipo7
Tpx2
Rpl7a
Smn1
Wdr33
Ubtf
Dnmt1
Rplp2
Sf3b4
Casc5
Rpl27a
Hnrnpul2 Ccdc137
Rps16
Rpl7
Cdk7
Pspc1
Slfn8
Rpsa
Top1
Nop14
Lrrc47
Hist1h1c Akap8
Nol6
Ythdc2
Srp14
Larp7
Znf385a
Actb
Rpl13a
Eif5b
Hnrnpr
Twistnb Rps2
Gpatch4
Traip
Ddx18
Rpl3
Srsf10
Rbmxl1
Rbm34
Rpl12
Fam98a
Ddx1
Gfi1b
Chd1
Mybbp1a Znf622
Cbfa2t3 Rpl28
Dazap1
Arrb2
Cep57
Hist1h1e Rrp12
Gtf2h2
Ylpm1
Hist1h1a Eif2s2
Sf3b3
Llph
Rpl6
Lsg1
Ddx27
Rps5
Rplp1
Serbp1
Smc6
Sf1
Rpl5
Polr2e
Eif3m
Urb1
Rpl13
Nmnat1
Gnl2
Msto1
Cit
Ddx47
Mmtag2
Ankhd1 Ercc3
Rpl4
Gtpbp4
Farsa
Polr1c
Nufip2
Npm3
Gm8730 Snrpa1
Npm1
Nop16
Nolc1
Fam207a Leo1
Nop10
Kif23
Rpl26
Rpl10a
Rpl14
Ercc2
Rpl27
Csnk2a1 Nhp2
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Rnf169
Rpl37a
Fxr1
Rpl11
Ankrd17 Rps8
Srsf2
Ilf2
Ddx55
Rps15a
Snrnp70
Skiv2l2
Fmr1
Rps14
FAM120A Rps19
Rpl15
Rps23
Ncapg2
Ndc80
Gtf2h1
Rps29
Nop58
Rpl34
Nop2
Rps11
Pdcd11
Nop56
Dhx9
Rps13
Ddx31
Ebna1bp2
Rpl29
Rps4x
Rps9
Ftsj3
Rps18
Rpl18a
Rpl35
Brix1
Srbd1
Rps6
Rpl36
Aff4
Cdc45
Rps15
Rps12
Utp3
Ddx24
Rps24
Rpl17
Ddx21
Zc3h18 Rps25
Cd3eap
Rcl1
Rpf2
Tceb2
Znrd1
Ddx20
Trip12
Rpl30
Safb2
Hic2
Tcof1
Rpl39
Smndc1
Plec
Knop1
Rpl31
Noc4l
Uchl5
Rpl10
Rps3
Gltscr2
Racgap1
Dnmt1
Rpl32
Rcc2
Ik
Rpl21
Rpl8
Rpl24
Orc1
Polr1a
Rps27a
Naa25
Ilf3
Srsf5
Actg1
Utp15
Kpna6
Rps17
Smc5
Table 4.1. GST protein pulldown assay results. Target/bait proteins from
nuclear extracts pulled down by each GST-fused prey proteins (GST-ET, GSTETCC, GST-mB, GST-CCd, GST-CCp are listed. No proteins were detected in the
GST-CC sample. Protein enrichment was measured using standard mass
spectrometry label-free quantification (See “Chapter 2: Materials and Methods”).
Only proteins with enrichments exceeding a log2ratio>1 over GST-alone controls
at FDR<0.0001 were included.
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CHAPTER 5: CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS

Chapter summary

BET proteins are transcriptional regulators implicated in multiple
developmental and pathological pathways. As such, they have emerged as
attractive therapeutic targets for many diseases, but their pharmacological
inhibition can impair normal processes. Because the current inhibitors typically
target the highly conserved BET bromodomains, many of these drugs cannot
discriminate between individual BET proteins. Fundamentally, it remains unclear
how individual BET proteins contribute distinctly to transcription and whether
targeting single BET protein family members would be of therapeutic value. In this
study, we set out to better understand the extent to which BET proteins BRD2,
BRD3, and BRD4 differ functionally and to discover the domains and mechanisms
by which they do so. We used the G1E-ER4 erythroid cell line, a model system
where BET proteins are critical to cell growth and GATA1-mediated differentiation
and found a key functional domain that may mechanistically distinguish BRD2 and
BRD3 from BRD4. We posit that targeting this region, termed the ETCC, may
provide a BRD2/3-specific drug that prevents the recruitment of certain
transcriptional regulators. In this chapter, we expound upon this concept, discuss
limitations of this work, and propose future studies to examine the mechanistic
detail and broader applicability of these findings.
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Distinct BET protein functions revealed by gene rescue and domain mapping

Previous studies have shown that depletion of individual BET proteins
results in distinct phenotypes (see “Chapter 1, Evidence for distinct BET protein
functions”). In support of BET protein family members functioning distinctly, our
work in G1E-ER4 cells suggests that BRD2 and BRD4 have independent roles in
GATA1-mediated erythroid maturation. BRD3 behaves more similar to BRD2 in
this context. We draw this conclusion based on gene rescue studies performed by
ectopically expressing BET proteins in BRD2 knockout cells. An important
limitation to this work is the lack of reciprocal experiments performed in BRD4depleted cells. We have been unable to generate BRD4 knockout G1E-ER4 cells,
perhaps because BRD4 is required for cell survival. However, decreased BRD4
expression and reduce erythroid maturation using RNA interference (RNAi) can be
achieved113. Future experiments should be designed to test whether ectopic BRD2
and BRD3 expression can protect cells against defects associated with BRD4
depletion using this method. Based on our hypothesis, we would expect that
neither BRD2 nor BRD3 can compensate for BRD4 function.
It will be interesting to note whether ectopic BRD4S or BRD4L in isolation
will protect against RNAi-related defects. To the best of our knowledge, BRD4L is
the dominantly expressed isoform in this cell type, but BRD4S transcripts are
expressed and BRD4S has been implicated in transcription in other cell types. For
example, in CD4+ T cells, BRD4S is abundantly expressed and recruits SWI/SNF
remodelers70. In cancer cells, BRD4S levels vary but correlate with nuclear puncta
formation and exert BRD4L-independent effects on gene expression181. In some
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cancers, BRD4S may oppose BRD4L or function independently to promote tumor
growth and metastasis81,182. Thus, it is conceivable that both isoforms are
necessary for erythroid maturation, which can be teased apart using a combination
of isoform-targeted RNAi and ectopic BRD4S/L expression.
Identifying the structural basis for overlapping BRD2 and BRD3 function

In the absence of a distinct structural domain, it remained unclear prior to
our study how BRD2 and BRD3 could function separately from BRD4, especially
given that the bromodomains and ET domains are well-conserved across the
family. Our domain mapping approach revealed that the extended ET domain,
containing a coiled coil (ETCC) in BRD2 and BRD3 but not in BRD4S, is the critical
region distinguishing these proteins. This finding contributes to a mechanistic
model of how BRD2 and BRD3 can function distinctly from BRD4. For example,
BRD4-specific activity is generally attributed to the CTM on the extended Cterminal tail of BRD4L. Based on our domain mapping, we can now attribute
BRD2/3-specific activity to the ETCC domain. Whereas it is thought that the CTM
enables BRD4 to strongly associate with PTEFb, we propose that the ETCC
domain enables BRD2 and BRD3 to more strongly associate with PAF and CK2.
These distinct functions are likely in addition to shared functions, such as binding
acetylated chromatin via the conserved bromodomains and recruiting NSD365 and
JMJD667 by the conserved ET domains. We therefore suggest a model in which
individual BET proteins function distinctly but interdependently to coordinate the
recruitment of multiple transcriptional regulators to chromatin.
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Several additional gene rescue studies are needed to bolster this model.
First, additional chimeric BET proteins should be designed to test the ETCC
domains from BRD3 and BRDT. Based on their ability to bind PAF and CK2, we
hypothesize that the ETCC from these proteins should function similarly to the
BRD2 ETCC in their ability to impart activity to BRD4S in gene rescue assays.
Chimeric BET proteins possessing the BRD4L tail containing the CTM should also
be constructed. We might expect that addition of the BRD4L tail to BRD2 would
impart BRD4L-like activity to BRD2. In effect, this construct would resemble BRDT,
which has the key structural features of both BRD2 (the ETCC) and BRD4 (the
CTM). We did not include BRDT in our gene rescue assays, but it’s potential panBET functionality in G1E-ER4 cells based on possession of both the ETCC and
CTM domains may be a useful comparison in future experiments. BRDT is not
expressed in G1E-ER4 cells, but we hypothesize that its ectopic expression might
compensate for both BRD2 and BRD4 loss.
Structure-function considerations related to BRDT

As noted above, BRDT possesses both the ETCC domain shared by BRD2
and BRD3 and the CTM domain of BRD4. The function of BRDT in comparison to
the other BET proteins warrants further exploration. In the testis, where it is
exclusively expressed19, BRDT is required for proper spermiogenesis24 likely due
to an ATP-independent structural role it plays in large scale chromatin reorganization involving histone compaction and protamine replacement183–186.
Though the pronounced nuclear reorganization that occurs during spermatid
formation highlights the role of BRDT in chromatin structure, other BET proteins
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have been also been implicated in chromatin organization. For example, the yeast
homologue BDF1 maintains euchromatin by preventing heterochromatin spread at
transcriptional boundaries187, and mammalian BRD4 regulates nucleosome
density79,188. Moreover, BRD2, BRD3, and BRD4 all exhibit in vitro histone
chaperone activity that is independent of the CTM (in the case of BRD4) and
specific for acetylated histones40,41. Thus, though it is tempting to ascribe a unique
role for BRDT in this process, the other BET proteins may contribute to structural
changes during spermiogenesis and may mediate similar acetylation-dependent
nucleosomal dynamics in other cell types.
In addition to its structural function, BRDT also mediates testis-specific gene
activation via CTM-recruitment of PTEFb to gene promoters, akin to canonical
BRD4-related transcriptional regulation186. Thus, BRDT likely contributes to
spermiogenesis in two fundamental ways: 1) activation of genes required for
meiosis and 2) nuclear compaction and histone removal. Interestingly, other BET
proteins are expressed in the testis and contribute to spermiogenesis. In fact, Brd4
heterozygous null mice have reduced spermiogenesis23, and BRD4 was shown to
co-bind BRDT-bound promoter of active genes in spermatids189. Not unexpectedly,
BET bromodomain inhibition using small molecule JQ1 results in meiotic arrest
and reduced fertility in male mice190. The fact that BRDT and BRD4 are both
required in the testis suggests that they have undergone some level of functional
specification. For example, comparison of BRD4 and BRDT genome occupancy in
post-meiotic spermatids revealed that only a small percentage of BRDT was found
at gene promoters in comparison to BRD4189. And whereas BRD2 and BRDT
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localize diffusely throughout the nucleus in the late stages of spermatid
development, BRD4 forms a distinct ring-like structure adjacent to the cytoskeletal
acrosome in a confined band around the nuclear periphery189. Of note, it is unclear
if these structures involve full length BRD4 or a smaller noncanonical, possibly
testes-specific isoform. This technical caveat may be meaningful given that the
canonical BRD4S isoform associates preferentially with the nuclear envelope
whereas BRD4L concentrates in the salt-extractable nuclear matrix82. Thus,
differences in BET protein localization, genome occupancy, and function due to
testes-specific regulation of endogenous proteins is unlikely. Instead, such
dramatic differences likely reflect intrinsic protein attributes such as the gain/loss
of entire domains. For example, the intranuclear compartmentalization of BRD2
and BRDT versus the acrosomal localization of BRD4 might be explained the
shared possession of the ETCC by BRD2 and BRDT but not BRD4. Thus, future
studies should compare these proteins head-to-head in G1E-ER4 cells using
equally expressed and epitope tagged constructs. This may lead to new insights
about how the CTD-containing proteins BRD4L and BRDT function distinctly from
one another in comparison to BRD2, BRD3, and BRD4S.
In the absence of a robust cell culture system for modeling spermiogenesis,
it may be difficult to tease apart the unique or overlapping roles of each BET protein
– and map these similarities/differences to certain domains – as we have in the
G1E-ER4 system which allows for gene rescue experiments. Nevertheless,
spermiogenesis provides a unique biological setting to track differences in
endogenous BRD2, BRD3, BRD4, and BRDT genomic distributions and protein
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interaction networks through each stage of sperm development. The importance
of BET protein function in sperm development is showcased in Drosophila, which
lack a testis-specific paralog. In this setting, two proteins critical for spermatocyte
development, tBRD-1 which lacks an ET domain and tBRD-2 which lacks a second
bromodomain, can dimerize to reconstitute a BRDT-like BET isoform191. Future
studies examining their individual and combined function can help isolate the
critical domains necessary for BRDT’s role and may provide a window of insight
into general BET protein function.
Mechanisms of PAF recruitment by BET proteins
Validation and further characterization of ETCC-mediated interactions with PAF
We found that the GST-ETCC fusion proteins from BRD2, BRD3, and BRDT
were able to precipitate the PAF complex from solution. This reproducibility across

conserved but not identical ETCC sequences reassures us that is not a spurious
finding. However, several experiments are required to fully validate the functional
significance of this interaction. First, point mutations in conserved residues
comprising the CC should be explored for their ability to reduce PAF binding
without interrupting ET only-interactions. We have preliminary identified a set of
proline insertions predicted to abrogate the coil (mutations depicted in Figure 4.4.A
as CCp but data not shown) that when placed into ETCC reduce PAF signal
without altering CDK9, an ET-only interaction. Interestingly, the leucine to aspartic
acid mutations (depicted in Figure 4.4.A as CCd but data not shown) are also
predicted to disrupt the coil but do not reduce PAF enrichment. Thus, the effect of
these mutations on the structure of the ETCC domain should be verified using
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circular dichroism to determine the role of the helical component on these
interactions. Second, after isolating point mutations that abrogate the PAF
interaction without compromising the ET domain, BRD2 constructs harboring
these mutations should be expressed in Brd2-null G1E-ER4 cells so that their
function in cell growth and GATA1-mediated differentiation can be assessed. Last,
PAF occupancy should be measured in these BRD2 ETCC mutant-reconstituted
cells to determine the impact of the ETCC mutations on PAF recruitment to BRD2bound genes.
The GST pulldown experiments used large, micromolar amounts of GST-fused
bait proteins to identify partners, in essence flooding the reaction with the interaction
surface of interest. One advantage of this strategy is that the domain of interest
has already been defined functionally and thus large amounts of it can be used to
uncover weaker but still meaningful protein interactions that are perhaps
overlooked when full-length BET proteins are used. A disadvantage, however, is
that the ETCC domain in this case has been taken out of the context of the properly
folded full-length protein, and thus interaction surfaces on the ETCC may be
exposed that do not normally occur. Further complicating the matter is that
transient interactions may be tightly regulated through post-translational
modifications that alter protein conformation to open and close an interaction
surface. For example, a phosphorylation-induced intramolecular switch was
proposed to toggle BET proteins between two different conformations, one of
which exposes the second bromodomain to form contacts with acetylated
chromatin85. These factors must be considered when interpreting the following
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observations: 1) despite robust interaction with the ETCC in our GST pulldown
assays, PAF members are inconsistently co-immunoprecipitated with BET
proteins30,31,71, 2) only a fraction of PAF co-localizes with BET proteins on
chromatin, and 3) the ETCC-PAF interaction is sensitive to phosphorylation. Future
studies using orthogonal approaches and not limited to a single modality192 are
required to identify the exact conditions under which these proteins associate and
the implication of these interaction on transcription.
Toward this goal, we recommend against co-immunoprecipitation as the
method of choice for further biochemical characterization. In our hands, these
assays have failed to yield consistent results despite multiple attempts optimizing
the antibody/epitope and buffer conditions. Moreover, immunoprecipitation
enriches all three BET proteins regardless of the target BET protein. This is likely
due to the tendency of BET proteins to agglomerate with shared protein
complexes30 or to polymerize directly via the motif B35 rendering it difficult to tease
apart which protein interactions are directly mediated by a given BET protein.
Immunoprecipitation is also limited by endogenous protein level and specificity of
available antibodies. Use of epitope-tagged protein could overcome both
limitations but may lead to overexpression artifact.
Instead, we propose using a baculovirus vector and insect cell expression
system to purify high yields of individual BET proteins and PAF members (including
IWS1). By selectively adding individual components to the reaction mixture, this
system can be leveraged to 1) validate that interactions with PAF are strongest
with full length BRD2/3/T in comparison to BRD4, 2) confirm that the ETCC domain
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is the critical BET protein interaction surface, 3) determine which PAF member
directly mediates this interaction, and 4) identify the reciprocal interaction surfaces
on PAF. Though the PAF complex can be reconstituted using proteins derived from
both bacterial and insect cell expression systems164,165,193, insect cells retain most
post-translational modification processes that may be critical for the interaction
with BET proteins.
In vitro transcription/translation-coupled reactions may provide an
alternative to the baculovirus system described above. These systems are
generally conducted in reticulocyte lysates and may mimic, at least to some extent,
the conditions of erythropoiesis. Moreover, these lysates should be devoid of
nuclear components and lack endogenous PAF proteins, an advantage over insect
cells where the insect PAF homologs may participate in the interactions. This
system was used to successfully reconstitute the NuRD complex194.
Given that coiled coil domains have a tendency to form dimers35,175, we
might target our search for the ETCC-interacting component of PAF to those
protein segments that possess putative coiled coil regions. Alternatively, it is also
conceivable that all of the ETCC interactions with PAF are in fact indirectly
mediated by mutual associations with CK2, though this is unlikely given that PAF
and CK2 associate via FACT167,195, whose components (SUPT16H and SSRP1)
are not found in our list of ETCC-enriched proteins.
Functional significance of the BET-PAF interaction

The PAF complex is a well-studied transcriptional regulator shown to affect
POL2 pause-release and elongation. During the transition from transcriptional
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pausing to elongation, PAF replaces NELF at a mutually exclusive region of POL2,
and thus PAF is a core component of the elongating but not paused POL2
structure164,196. Within the structure of elongating POL2, PAF induces a
conformational change that unwinds upstream DNA, permitting POL2 forward
passage164. Consistent with its role in elongation, PAF facilitates transcriptional
elongation through chromatin templates in vitro165 and is found enriched over gene
bodies on chromatin130,169. PAF1 depletion results in decreased elongation130,197,
though some studies show the opposite effect (depletion of PAF increases
elongation)198–200 so the exact role of PAF in transcription remains controversial.
PAF has also been implicated in post-transcriptional RNA processing169,201,202,
though studies in yeast show that almost all the effects of PAF depletion on
transcripts levels are related to primary transcription suggesting that this is the
ancestral function of PAF203.
Mechanistically, the intrinsic elongation activity of PAF in vitro depends on
histone acetylation165, indicating that PAF may cooperate with factors that possess
acetylation-dependent histone chaperone activity. Intriguingly, this type of activity
has been observed for BET proteins40,41. As the elongating POL2 complex
approaches a nucleosome comprised of acetylated histones, BET proteins may be
influenced by PAF via the ETCC on BRD2 and BRD3 to help disassemble and
reassemble the nucleosome as POL2 passes through. Future studies will need to
test whether addition of both PAF and BET proteins to these in vitro transcriptional
assays yields synergistic effects. It is important to note that unlike serine-2phosphorylated POL2 (which demarks the elongating fraction of POL2) and the
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associated PAF proteins130, BET proteins are not found highly enriched in gene
bodies on chromatin, indicating that they likely do not travel with POL2 through
genes as part of this complex. Instead, only a small fraction of the total BET
proteins, which are mostly found near the TSS in promoters or at distal regulatory
enhancer elements55,129, may be bound to nucleosomes within gene bodies.
Nevertheless, the density of BRD4 in the gene bodies correlates better with gene
expression than does the density of BRD4 at the promoter, indicating that this pool
of BRD4 in the gene bodies, albeit the minority of BRD4, may be more directly
involved in transcription41. A comprehensive correlation of BRD2, BRD3, and
BRD4 levels in various genomic regions with gene expression in additional cell
types is needed to better establish this paradigm.
In addition to cooperating with the PAF complex to facilitate POL2
processivity through nucleosomes, BET proteins may also recruit PAF to gene
promoters. This is where the majority of BET proteins reside on chromatin. A
similar mechanism has been proposed for PTEFb recruitment by BRD4 via its
CTM-containing tail. But unlike PTEFb, which contributes to elongation but does
not incorporate into the elongating POL2 complex, PAF binds to the elongating
POL2 complex and leaves the promoter as it travels with POL2. In fact,
phosphorylation of POL2 by PTEFb in the promoter dismisses NELF from the
paused POL2 complex which allows PAF to takes its place in the elongating POL2
complex164,196. These differences in PTEFb and PAF functions are reflected in their
genomic

distributions.

PTEFb

sits

at

the

promoters

colocalized

with

unphosphorylated POL2 (marking the paused fraction of POL2), whereas PAF is
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split between a population colocalized with PTEFb and paused POL2 at the
promoter, a fraction traveling with serine-2-phosphorylated POL2 over gene
bodies (marking the elongating fraction of POL2), and a third pool enriched over
the TES130,169. Given that PTEFb is required for the proper loading of PAF onto
POL2, it may be difficult to disentangle the functions of BRD4 (which presumably
recruits PTEFb) and BRD2/3 (which we propose to recruit PAF) based on gene
expression signatures after depletion of a target BET protein. Instead, changes in
the PTEFb and PAF chromatin occupancy patterns described above may be more
informative. For example, we would expect that depletion of BRD2 may reduce
PAF signal over gene bodies without altering PTEFb, whereas depletion of BRD4
may reduce both PTEFb signal at the promoter and PAF signal throughout gene
bodies.
It has also been reported that PTEFb exists in multiple discrete
complexes204, some of which are recruited by BRD4 and others of which are
directly recruited by PAF via a mutual interaction with the elongation factor ENL205.
Thus, rather than BRD2/3 and BRD4 functioning coordinately to promote POL2
pause-release, it is also possible that BRD2/3 is responsible for PAF-dependent
PTEFb recruitment whereas BRD4 is responsible for PAF-independent PTEFb
recruitment. We would therefore predict BRD2/3-dependent genes to have
stronger levels of ENL at promoters whereas BRD4-dependent genes may not, but
this remains to be tested. Ultimately, these pathways may be more intertwined
then these models suggest. In fact, mutations in either ENL206 or CTR9207 (a PAF
component) predispose patients to Wilms tumors of the kidney. Given the rarity of
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this cancer, this coincidence suggests very similar molecular pathways involving
both proteins.
Phenotypic studies exploring the functions of PAF and PTEFb argue in favor
of more distinct functions. For example, PTEFb- or PAF-targeted depletion reveals
their antagonistic roles in maintaining multipotent neural crest progenitors208 as
well as the pluripotent state of embryonic stem cells209,210. Similar opposition
between PAF and PTEFb has also been reported in zebrafish for genes controlling
oligodendrocyte differentiation211 and perhaps most relevant to our study, for
erythropoiesis198. These studies suggest a model in which PAF represses PTEFbmediated pause-release (preventing expressing of differentiation-related genes)
as proposed by Chen et al199,200. PAF may therefore have two distinct and
seemingly paradoxical functions in transcription. It may poise POL2 in its paused
state, and then upon PTEFb phosphorylation of paused POL2, incorporate into the
elongating POL2 complex to help facilitate POL2 progression through chromatin.
This then allows another paused PAF/POL2 unit to take its place. These
dichotomous functions, further complicated by potential auto-feedback loops
regulating PAF and PTEFb recruitment and POL2 processivity, may explain the
discrepant effects of PAF-depletion on elongation observed by different groups. In
summary, the molecular mechanisms underpinning PAF and PTEFb coordination
versus opposition are not clear but BET proteins may contribute to these regulatory
pathways via BRD2/3 recruitment of PAF and BRD4 recruitment of PTEFb. This
may explain why targeted depletion of single BET proteins can elicit unique gene
expression changes and cellular phenotypes. Further biochemical characterization
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of the BRD2/3-PAF interaction may allow for the development of molecular tools
to purposefully and specifically disrupt this pathway to better identify their unique
role in transcription.
In addition to its roles regulating POL2 pause-release and elongation, PAF
has also been strongly implicated in various histone modifications, particularly
ubiquitylation of H2B (H2Bub) and subsequent H2Bub-dependent methylation of
H3K4 and H3K79202. Mechanistically, H2Bub deposition may occur directly via
PAF-mediated recruitment of ubiquitin ligases or indirectly through transcriptionmediated recruitment of the ubiquitylation machinery202.

Regardless, PAF-

regulated ubiquitylation H2B presents an intriguing parallel with BRD2 function.
Ubiquitylation of H2A.Z is reported to directly antagonize BRD2 binding to
acetylated H2A.Z at gene promoters59. Given that acetylated H2BK34 and
H2BK120, the same residues targeted by H2B ubiquitylation, can bind some of the
BET bromodomains44, it is possible that a similar antagonism between acetylation
and ubiquitylation on BRD2 recruitment occurs on H2B, though further studies are
required to clarify this. H2Bub may also directly regulate PTEFb recruitment212,
further intertwining the functions of PAF, PTEFb, and individual BET proteins.
Mechanisms of CK2 recruitment by BET proteins
Validation and further characterization of ETCC-mediated interactions with CK2

Interactions between BET proteins and CK2 are well supported by other
studies. Dawson et al. found that CK2 (included as part of the NOLC1 complex
with UBTF, NOLC and NHP2) co-immunoprecipitated with BRD2, BRD3, and
BRD430. Wai et al. likewise identified CK2 among many other transcription-related
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complexes associated with BRD3 (BRD2 and BRD4 were not included in the
study)71. Intriguingly, Lambert et al. identified CK2 as a major interaction partner
of BRD2, BRD3, and BRDT but not BRD431. This is consistent with BRD2/3/T but
not BRD4 containing the ETCC segment which we propose to at least in part
mediate the CK2 interaction. Moreover, inhibition of the BET bromodomains
actually enhanced the CK2 interactions with BRD2/3/T, supporting our hypothesis
that these interactions are bromodomain-independent. Importantly, CK2 is a
serine-threonine kinase and CK2 has been previously shown to phosphorylate
mammalian BET proteins as well as the yeast paralogs BDF1/2 at two conserved
serine-rich regions85,213,214. BRD2 is also one of about 60 candidate CK2-target
proteins identified in a large-scale meta-analysis of interlaboratory data215.
Conservation of the residues phosphorylated by CK2 in BET proteins strongly
suggests that these post-translational modifications are of functional significance.
One of the conserved CK2 substrates overlaps partly with the motif B (mB) domain
used in our GST-pulldown assay. This enzyme-substrate binding event appears to
have been captured by the GST-mB sample in our GST pulldown experiment
(Figure 4.4.B). The other conserved CK2 substrate occurs immediately 3’ to the
ET domain in BRD4 and the ETCC domain in BRD2/3/T and in the last 26 residues
of yeast BDF1, beyond the coiled coil region. Deletion of either the mB-proximal or
ET/ETCC-proximal phosphorylated region impairs the ability of BDF1 to rescue the
viability of bdf1/bdf2-null strains but does not impair its ability to rescue
temperature sensitivity of bdf1-null strains, indicating that though both regions are
required for full BDF1 activity, some redundancy exists between BDF1 and BDF2
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in regard to phosphorylation-specific function214. In BRD4, the mB-proximal CK2substrate functions as phospho-switch regulating bromodomain-dependent
chromatin contacts. The purpose of the ET-proximal substrate remains untested
in mammalian BET proteins85,213.
Though putative CK2 phosphorylation sites also occur in the ETCC, we do
not believe the ETCC domain itself to be a true CK2 substrate. For example,
neither the ET nor the CC domains alone precipitate CK2, indicating that the
mechanism of CK2 interaction with the adjoined ETCC is likely to be more related
to structural characteristics of the surface created by the ETCC than to enzymesubstrate binding. However, in vitro phosphorylation and in vivo mutagenesis
assays are required to verify this. Enzyme-substrate interactions may be transient
and thus difficult to capture in proteomic analyses that are biased toward stable
interactions, such as co-immunoprecipitation assays. The ability of the ETCC
domain to form a more stable interaction with CK2 than otherwise allowed by the
CK2 substrate regions may explain the BRD2/3/T-predominant CK2 associations
described in the Lambert et al study31. However, as with PAF, the preference of
CK2 for BRD2/3/T and the exact interacting fragments needs to be confirmed using
purified proteins.
Potential roles for CK2 in regulating BET and PAF transcriptional pathways

CK2 is a ubiquitously expressed kinase complex with a vast array of targets,
implicating it in numerous cellular functions and biological processes216. Given that
it associates with many chromatin-bound proteins in yeast167,217,218, it is not
surprising that deletions of CK2 subunits result in global gene expression
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changes219. In mammals, CK2 is preferentially bound to transcriptionally active
nucleosomes220, where it is thought to phosphorylate other nucleosome-bound
proteins221. Candidate screens of potential CK2 phosphorylation targets have
routinely yielded several chromatin-associated proteins, including members of the
PAF complex and BRD2215,222. A screen for proteins bound to various chromatin
fractions revealed that CK2 was associated with H3K9me3-marked chromatin166,
which may play a role in gene expression and chromatin organization223. In fact,
the chromatin-bound fraction of CK2 is distributed maximally at gene promoters
with extensions into gene bodies, particular at highly expressed genes, and with
accumulation at enhancers, all of which suggest a role in transcription168. In yeast,
CK2 was found to be associated with several transcription elongation factors
including the PAF complex and IWS1167. In mammals, multiple CK2 target
substrates were identified within PAF including 13 phosphorylation sites on the
LEO1 component alone222. Interestingly, the physical association between CK2
and PAF is bridged by mutual interactions with the FACT complex167,195, which is
a histone chaperone that facilitates removal and replacement of the H2A/H2B
dimer upon POL2 passage through the nucleosome224. Given that both FACT and
PAF are required for optimal POL2 elongation, it is thought they may function in a
coordinated and interdependent fashion225. Mechanistically, by recruiting CK2 to
PAF, FACT promotes the phosphorylation of PAF, which is required for PAFmediated H2B ubiquitylation195. Mutagenesis and structural studies are required to
better understand how phosphorylation moderates PAF’s function in transcription.
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It will be particularly interesting to note how phosphorylation of PAF by CK2 affects
PAF’s ability to complex with elongating POL2.
The exact role of BRD2 (and potentially BRD3 and BRDT) in this picture
remains elusive. Given that the biochemical studies identifying PAF, CK2, and
FACT interactions were performed in yeast, it is possible that in mammals BRD2
replaces FACT as the mediator of PAF-CK2 contacts. Like FACT, BRD2 also
possesses histone chaperone activity, though unlike FACT this activity is specific
for hyperacetylated nucleosomes40. The shared functionality of BRD2 and FACT
in these assays suggests common downstream mechanisms which may involve
PAF and CK2. To clarify whether BRD2 recruits PAF and CK2 into close proximity,
in vitro protein interactions studies should be performed using purified
components. To assess in vivo, each factor should be targeted for depletion
individually to reveal their roles on the others’ ability to bind chromatin. For
example, if BRD2 is playing a central role that governs CK2 phosphorylation of
PAF and subsequent PAF-mediated POL2 elongation, depletion of BRD2 should
result in reduced CK2 occupancy at the promoter and reduced levels of PAF and
serine-2-phosphorylated POL2 throughout gene bodies. Development of phosphoPAF-specific antibodies would further help characterize distribution of the
phosphorylated PAF in relation to total PAF on chromatin and the role of BRD2
and CK2 in this modification.
It is also possible that BRD2 interacts with PAF and CK2 separately,
perhaps recruiting PAF to promoters (or facilitating its progression through
nucleosomes) independently from any involvement in CK2-specific processes. For
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example, CK2 has been implicated directly in transcriptional elongation via its
ability to phosphorylate histone H2A at a conserved residue, which prevents
H2B deubiquitylation by the SAGA complex168. It is therefore thought that CK2
regulates the opposing actions of PAF (H2B ubiquitylation) and SAGA (H2B
deubiquitylation) to ultimately promote elongation via H2Bub. In this setting, BRD2
may separately recruit PAF and CK2 to active chromatin such that some BRD2
molecules help load PAF onto chromatin and into the elongating POL2 while others
simultaneously give CK2 access to H2A substrates on acetylated nucleosomes. In
this way, BRD2 may be functioning as a docking site for various elongation factors
involved in different (or perhaps interdependent) aspects of transcriptional
elongation. Additional structural characterization of the ETCC interactions will
elucidate whether BRD2, PAF, and CK2 form a single complex or separate entities.
Identification of a common binding motif recognized by the ETCC domain in
subunits of both PAF and CK2 would support the notion of independent
interactions.
In vivo, a large fraction of the chromatin bound CK2 is located at the
promoter, and depending on the level of gene expression, CK2 signal is also
detected throughout the gene body. PAF on the other hand has some signal at the
promoter with stronger signal throughout the gene body and maximal signal at the
termination site, largely paralleling that of elongating POL2 fraction marked by
serine-2-phophorylation. BRD2 and the other BET proteins are mostly found at
promoters. All three can be found distally at enhancers. The different distribution
patterns of these three factors suggests that they do not form a single stable
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complex on chromatin. Instead, the interactions we detect between the BRD2
ETCC domain and PAF and CK2 likely reflect momentary contacts that take place
in vivo during transcription. For example, the bulk of BRD2 may be engaged with CK2
at the site of paused POL2. A smaller fraction of BRD2 may be present along the gene
body and associate with PAF as it comes into contact with acetylated nucleosomes.
Given that CK2 can phosphorylate BET proteins and various PAF subunits, we

asked whether phosphorylation may be regulating the strength of the ETCC-PAF
interaction. We found that in our pulldown assay the ETCC-PAF interaction was
destabilized when phosphorylation was preserved through the use of phosphatase

inhibitors. We therefore hypothesize that CK2 kinase activity regulates POL2
pause-release by releasing PAF from promoter-proximal BRD2 allowing it to
incorporate into elongating POL2 (Figure 4.5.E).
However, much more work is needed to elaborate the details of this
mechanism. First, as described in the prior section, the interface between the
ETCC and the interacting PAF subunits needs to be identified. This structural
characterization can then inform the search for the relevant residues that are
phosphorylated by CK2. We expect that these amino acids will occur at an
interface with the ETCC, but they could occur elsewhere and still exert
intramolecular effects that modulate the ETCC interaction, akin to the phosphoswitch mechanism that occurs at the motif-B proximal CK2 phosphorylation site in
BET proteins85. It is also possible that the structurally relevant phosphorylated
residues are not in fact CK2 substrates. CK2 is a strong candidate based on its
physical association with PAF and the identification of CK2 targets therein, but
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other promoter-proximal kinases may contribute. These candidates can be
screened using kinase-specific small molecule inhibitors. The druggable kinases
which are known to phosphorylate various transcription cofactors include CDK7226–
228

, CDK9 (component of PTEFb, as described in previous sections)229,

CDK8/19230, and CDK12/13231. Drugs targeting these kinases can be tested in
parallel with CK2 inhibitors to identify the relevant factor that phosphorylates PAF
and reduces its ability to bind the ETCC domain. In addition to confirming the
correct kinase, we must also consider the opposing function of phosphatases. For
example, the phosphatase PP2A has been shown to counter CK2-mediated
phosphorylation of BRD4 such that the balance of CK2 and PP2A activity on BRD4
phosphorylation controls transcription and cell proliferation86. Chemical inhibition or
activation of PP2A or other phosphatases can be tested to determine their role in

controlling the ETCC-PAF interaction. Together, these studies will shed light on the
molecular regulation of ETCC interactions.

Chemical or genetic perturbation of promoter-proximal kinases, CK2, and
phosphatases may also be useful for studying the in vivo function of these factors
in BET-mediated transcription. For example, it is well known that PTEFb inhibition
(targeting CDK9 kinase catalytic activity) blocks POL2 pause-release resulting in
reduced POL2 elongation and transcription229. Inhibition of BET proteins has
largely the same effect as PTEFb blockade. Though this similarity is often
attributed to BRD4’s ability to recruit PTEFb67,232, BET proteins can promote
elongation independently from PTEFb40,41,111,112. Therefore, definitive molecular
mechanisms implicating BET proteins in elongation remain to be identified. We
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propose that BRD2/3 recruitment of PAF and CK2 may be one such mechanism.
In support of this, the effect of CK2 inhibition on elongation largely reflects that of
BET or PTEFb inhibition168. However, more detailed studies are required to
examine how CK2 inhibition effects BET protein recruitment. For example, we can
test whether CK2 activity is prerequisite for BET protein binding and more
specifically whether BRD2/3 occupancy is more sensitive than BRD4 occupancy.
It will also be interesting to note if CK2 activity is required for PAF recruitment to
promoters or its release into gene bodies. In the latter case, CK2 inhibition may
cause a pileup of PAF at the promoter. If so, we can then test if this promoterproximal PAF is BRD2-dependent using BRD2 KO cells. This may reveal a role
for BRD2 in recruiting PAF to chromatin before PAF is incorporated into elongating
POL2 and relocated into gene bodies.
Unlike CK2 and PTEFb, the exact effect of PAF on POL2 pause-release
and elongation remains controversial. However, it is possible that the contributions
of BET proteins and CK2 could help reconcile these differences and reveal
mechanistic insight into transcriptional regulation. For example, some studies
show that PAF depletion mimics BET or CK2 perturbation by causing reduced
elongation130,197. Other studies instead show an increase in elongation, suggesting
that PAF actually promotes pausing by somehow tethering POL2 to the promoter
perhaps in an enhancer-dependent fashion198–200. Interestingly, PAF and CK2
associate with FACT, which also has been found to exhibit dichotomous functions
in transcription. FACT maintains POL2 in a promoter-proximal paused state on
chromatin233, even repressing the expression of genes where it sits at the
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promoter234,235, yet it also clearly functions as an elongation factor in transcription
assays224,236. The distribution of FACT on chromatin resembles a blend of CK2
and PAF occupancy with a significant portion of FACT found at promoters as well
as within gene bodies233–235. This enrichment over gene bodies is consistent with
FACT’s interactions with PAF as part of the elongating POL2 complex164. PAF and
FACT may each have dual roles in pause-release and in elongation. Though BET
proteins do not likely interact directly with FACT, they resemble FACT in
transcription elongation assays and may associate together via PAF and CK2.
Therefore, it is possible that BET proteins, alone or in conjunction with CK2, help
to regulate or toggle between the various functions of PAF, potentially explaining
some of the paradoxical effects when these factors are depleted.
The overlap between BET proteins, CK2, and PAF in various functional
studies, protein interaction networks, and chromatin distribution profiles suggests
a common transcriptional pathway that may be independent from or in conjunction
with PTEFb-related elongation mechanisms. However, whereas PTEFb has a
relatively straightforward role in pause-release, the BET-PAF-CK2 pathway may
involve both pause-release and elongation. To test the role BRD2 in these
pathways, the chromatin distributions of PAF and CK2 can be measured in BRD2
KO cells. To avoid the confounding effects of altered gene expression in the BRD2

KO cells, a rapid depletion system targeting BRD2 can be developed to better define the
causal relationship between loss of BRD2 and the direct impact on the recruitment and

distribution of the other factors. We have preliminary data that the auxin-inducible
system can be used to promptly and reversibly degrade BRD2 (data not shown),
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as has been done for BRD4112. Similar systems have been used to target PAF for
depletion200 and could be used in conjunction with CK2 kinase inhibition to
elucidate the mechanics of this transcriptional pathway. Analysis of PAF and CK2
occupancy in BRD2 KO cells expressing BRD2 proteins with mutations in the ETCC
regions will help determine the extent to which this domain is directly involved in PAF
and CK2 recruitment.

In summary, we propose that BRD2 and BRD3 function independently from
BRD4 through protein contacts with PAF and CK2. Though the mechanistic details
remain unresolved, our data indicate that different elongation factors associate
preferentially with individual BET proteins. These pathways are unique enough that
BRD2 and BRD4 cannot genetically compensate for each other and thus operate
within distinct functional niches on chromatin.
Implications for BET inhibitor studies and therapies
In this study we identified a transcriptional mechanism that may involve

BRD2 and BRD3 but not BRD4. Classic BET inhibitors like the small molecules
JQ1 or I-BET targeting the bromodomains typically lack specificity for individual
BET proteins. Their impact on transcription is thus an aggregate effect. Based on
our findings we expect that at least part of their effect can be attributed to impeding
BRD2/3-dependent PAF and CK2 recruitment. Mechanistically, recruitment of
PTEFb and subsequent POL2 pause-release is often considered the downstream
effector of BET protein function. This activity is generally attributed to BRD4. Yet
when BET proteins are perturbed pharmaceutically, POL2 elongation is impacted
without disrupting PTEFb occupancy111. A BRD2/3-dependent elongation
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mechanism involving CK2 and PAF may thus partly explain this PTEFbindependent elongation defect. It may also account for the different transcriptional
signatures observed when comparing pan-BET and CDK9 (PTEFb) inhibitor
treatment112. Furthermore, defective PAF and CK2 activity could account for the
discrepancy between the effect of BRD4-specific depletion versus pan-BET
bromodomain inhibition on gene expression110. In the future, careful comparison
of genes affected by CK2 inhibition can help establish CK2 as a downstream
mediator of BET proteins. Depletion studies can be performed to likewise identify
common or distinct pathways involving PAF.
Though BD2-specific inhibitors target all of the BET proteins, they seem to
affect BRD2 and BRD3 chromatin occupancy more so than BRD4 occupancy.
Thus, BD2 inhibitors are functionally more specific for BRD2 and BRD3. In this
setting, it was found that BD2 inhibition has greater specificity for inflammationinduced gene expression while leaving baseline gene expression alone110. This
finding suggests that an intentionally targeted BRD2/3-based therapeutic may be
better tolerated in patients. Toward this goal, our study proposes that the ETCC
domain may offer a drug target that hits BRD2 and BRD3 while leaving BRD4
intact.
Concluding remarks

The results presented here provide a mechanistic rationale for distinct BET
protein functions. Our study highlights the value of combining a powerful gene
function assay with simple domain mapping experiments to drive discovery. Using
this strategy, we demonstrate a framework for the development of BET-specific
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inhibitors. And by identifying cofactors implicated in BET function, our study points
toward new avenues of investigation to better understand how chromatin
acetylation is linked to transcription.
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